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Cannabis and its derivatives have been used for medicinal purpose for thousand of 
years. More recently, the main cannabis constituents, cannabinoids, have been found 
to act and target at cannabinoid as well as other receptors. This brought particular 
interest around the pharmacology of phytocannabinoids and their possible clinical 
applications. The research object of this study focused on two phytocannabinoids, ∆9-
tetrahydrocannabivarin (∆9-THCV) and cannabidiol (CBD), and it has been divided in 
three individual investigations: 
   
In the first study, we investigated the pharmacology of ∆9-THCV at cannabinoid type 
1 (CB1) and type 2 (CB2) receptors. We found and confirmed that ∆9-THCV acts as 
antagonist at CB1 receptors in experiments of [35S]GTPγS binding assay on human 
CB1-CHO (Chinese hamster ovary) cell membranes. Also, in the same set of 
experiments, ∆9-THCV displayed a slight inverse agonism at CB1 receptors, which 
was confirmed in experiments of cyclic AMP assay in hCB1-CHO cells. At CB2 
receptors, we found that ∆9-THCV can behave as a partial agonist when the measured 
response is inhibition of forskolin-induced stimulation of cyclic AMP production in 
hCB2-CHO cells or stimulation of [35S]GTPγS binding to membranes obtained either 
from hCB2-CHO cells or from mouse spleen membranes. No such effect was 
displayed by ∆9-THCV in untransfected CHO cells, pertussis toxin (PTX)-treated 
hCB2-CHO cells or CB2-/- mouse spleen membranes.  
In collaboration with Dr. Barbara Costa and Dr. Dino Maione, we also showed that 
∆9-THCV shares the ability of established selective CB2 receptor agonist to reduce 
signs of inflammation and inflammatory pain (Guindon, Hohmann 2008). These 
experiments were performed on in vivo models of λ-carrageenan-induced oedema and 
thermal hyperalgesia, and formalin-induced nociception. 
 
In the second investigation we brought further evidences that ∆9-THCV is a partial 
agonist at CB2 receptors. In detail, we applied a protocol to hCB2-CHO cells in order 
to convert the selective CB2 receptor antagonist/inverse agonist, AM630, into an 
apparent neutral antagonist. In these experimental conditions, we found that ∆9-THCV 
still behaves as a CB2 receptor agonist and is antagonized by AM630 in experiments 
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of cyclic AMP assay. Additional tests were also conducted to better understand the 
pharmacology of the ligand, AM630, at CB2 receptors. 
 
In the third study, we investigated the effect of CBD at serotonin type 1A (5-HT1A) 
autoreceptors. This research was based on previous in vivo findings showing that 
CBD-induced anti-emetic and anti-nausea effects were mediated by somatodendritic 
5-HT1A autoreceptors located in the raphe nuclei (Rock et al. 2009, Parker et al. 
2010). Experiments of [35S]GTPγS binding conducted in rat brainstem membranes 
revealed that CBD, in a bell-shaped manner, is able to enhance the dose-response 
curve of the selective 5-HT1A receptor agonist, DPAT. In addition, our results suggest 
that CBD does not interact directly with 5-HT1A receptors, and that CBD-mediated 













































Cannabis is believed to be one of humanity’s oldest cultivated crops, providing a 
source of fibre, food, oil, medicine, and recreational drug since Neolithic times 
(Chopra et al. 1957, Li 1974, Fleming, Clarke 1998). 
 
 
TAXONOMY OF CANNABIS 
 
Cannabis is a genus of the dioecious annual plant, generally placed in the Hemp 
family Cannabaceae along with hops, Humulus species (spp). Recent phylogenetic 
studies, based on Chloroplast restriction site maps and gene sequencing, strongly 
suggest that the Cannabaceae should belong to the Celtidaceae clade, and that the two 
families should be merged to form a single monophyletic group (Song et al. 2001, 
Sytsma et al. 2002). 
Based on morphological attributes and on systematic chemotaxonomy, cannabis was 
found to comprise of three different species: sativa, indica and ruderalis (Figure 1). 
All of these taxa were indigenous from Central and South Asia, and were spread all 
over the world by different means and at different times by human beings (Figure 2) 
(Hillig 2005, Russo 2007). 
Morphologically, Cannabis sativa is a tall and thin plant, with narrow and light green 
coloured leaves; it grows quickly, up to 20 feet in height in some cases. Cannabis 
indica is a short thick plant, with broad and darker green leaves, flowering in 8 to 10 
weeks with thick dense flower tops. Cannabis ruderalis is a short and unbranched 
roadside plant, usually weak in cannabinoids (Figure 1). 
 
 
HISTORY OF CANNABIS 
 
The use of cannabis finds its roots in Asia (China in particular), where archaeological 
and historical findings indicate that the plant was cultivated for fibres since 4000 B.C. 
Several references reported cannabis usage for the treatment of several disorders like 
rheumatic pain, intestinal constipation, disorders of the female reproductive system, 
malaria and others; and  seeds, which are devoid of ∆9-tetrahydrocannabinol (∆9-
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THC), were usually reported as mainly being used for this purpose. In China, the 
medicinal use of cannabis never reached the heights it did in India. Here, the use of 
cannabis was widely disseminated, both as a medicine and recreational drug, which 
probably began together in around 1000 B.C. (Li 1974, Zuardi 2006). 
From Asia, cannabis spread to the Western World (Figure 2) where several references 
reported the use of this plant in Ancient Egypt; as well as the scarce references to the 
use of cannabis by the Greeks and Romans, suggesting that it was little-used by these 
populations. 
In Africa the use of cannabis began around the 15th century where it was reported 
useful for snake bite, to facilitate childbirth, malaria, fever, blood poisoning, anthrax, 
asthma and dysentery.  
In the 16th Century, cannabis reached the Americas, where probably African slaves 
brought the plant’s seeds to South America (Brazil). Here, cannabis was above all 
used in popular religious rituals.  
The effective introduction of cannabis in Western medicine occurred in the middle of 
19th century through the work of William B. O’Shaughnessy, an Irish physician, and 
by the book of Jacques-Joseph Moreau, a French psychiatrist. Their contributions had 
a deep impact on Western medicine, especially due to the scarcity of therapeutic 
options for infectious diseases, such as rabies, cholera and tetanus. The climax was 
reached in the late 19th century and the early 20th century, when various laboratories 
marketed cannabis extracts or tinctures, such as Merk (Germany), Burroughs-
Wellcome (England), Bristol-Meyers Squibb (USA), Parke-Davis (USA) and Eli Lilly 
(USA) (Fankhauser 2002). During this period, the medical indications of cannabis, as 
reported in Sajous’s Analytic Cyclopaedia of Practical Medicine (1924)                              
(Aldrich 1997), were summarized in three areas: sedative or hypnotic, analgesic and 
in appetite and digestion dysfunctions. 
Soon after this period, the use of cannabis significantly decreased, because of the 
difficulty to obtain replicable effects, due to the varying efficacy of different samples 
of the plant. Moreover, the introduction of many legal restrictions (e.g. Marihuana 
Tax Act in 1937 in the USA) limited the medicinal use and experimentation with 
cannabis. 
In the second half of 20th century, cannabis reached great social importance as a drug 
for recreational use by intellectuals groups, and later spread among the younger 
generation throughout the Western World. 
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In 1964, the isolation and characterization of the active constituent of cannabis, ∆9-
THC by Gaoni and Mechoulam (Gaoni 1964), contributed to a proliferation of studies 


















Figure 2. Map showing the countries of origin of Cannabis indica and sativa. The arrows suggest 
human-vectored dispersal from the presumed origin of cannabis in Central Asia. Figure taken from 
Hallig 2005. 
 
So far, three different drugs have been developed in the last 30 years from cannabis or 
on the basis of active components derived from cannabis (Table 1):  
1) Nabilone (Cesamet®, VALEANT Pharmaceuticals International), which is a 
synthetic analogue of Δ9-THC and it is used for suppression of nausea and vomiting 
produced by chemotherapy. 
2) Dronabinol (Marinol®, Solvay Pharmaceuticals), which is the synthetic (-)-trans-
Δ9-tetrahydrocannabinol; this drug finds applications as an anti-emetic and appetite 
stimulant, for example in Acquired Immune Deficiency Syndrome (AIDS) patients 
experiencing excessive loss of body weight. 
3) Sativex® (GW Pharmaceuticals), which contains approximately equal amounts of 
Δ9-THC and the non-psychoactive plant cannabinoid, cannabidiol (CBD), and is 
prescribed for the symptomatic relief of neuropathic pain in adults with multiple 
sclerosis, and as an adjunctive analgesic treatment for adult patients with advanced 
cancer (Pertwee 2009).  
These three drugs have been licensed in all or some of following countries:  UK,  




Table 1. Summary of plant constituents or synthetic cannabinoids licensed so far. In Canada, Sativex 
has been approved for the treatment of spasticity in 2010. In Spain, the final approval process is 





Cannabis is composed by a vast number of compounds (approximately 538), 
including mono- and sesquiterpenes, sugars, hydrocarbons, steroids, flavonoids, 
nitrogenous compounds and amino acids, among others. The best-known and the most 
specific class of cannabis constituents is represented by cannabinoids, which are 
characterized by a C21 terpenophenolic constituent’s structure (ElSohly, Slade 2005). 
There are ten main types of cannabinoids and fourteen different cannabinoids 
subtypes, based on their chemical structure (Figure 3) 
 Nabilone ∆9-THC Sativex Sativex 
Therapeuthic indication UK, Canada, USA USA Canada UK, Spain 
Anti-emetic Yes Yes No No 
Appetite stimulant No Yes No No 
Neuropathic & cancer pain No No Yes No 
Spasticity due to Multiple 
Sclerosis (MS) No No Yes Yes 
First licensed 1982 1986 2005 2010 
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Figure 3. The phytocannabinoids can be sub-classified into 10 main groups depending on their 
chemical structure. Figure taken from Hanus, 2009. 
 
The first natural cannabinoid to be discovered was cannabinol (CBN), which was 
extracted in 1899 (Wood 1899) and chemically characterized in 1940 (Adams, Cain & 
Baker 1940, Ghosh 1940). In 1963, Mechoulam’s group isolated CBD, the main non-
psychoactive constituent of cannabis (Mechoulam, Shvo 1963), and one year later 
they isolated and characterized Δ9-THC, the main psychoactive component of 
cannabis (Gaoni 1964). In more recent years, other phytocannabinoids have been 
isolated and characterized, but it is possible that some of them may not have been 
discovered yet. 
Phytocannabinoids are synthesised in cannabis by glandular trichomes as carboxylic 
acids from geranyl pyrophosphate and olivetolic acid to yield the parent 
phytocannabinoid compound, cannabigerolic acid (CBGA). Subsequent reactions 
involving different enzymes catalyze the transformation of CBGA into other 
phytocannabinoids. The presence of these enzymes differs between various strains 





CANNABIS PHYSIOLOGICAL EFFECTS  
 
The acute physiological and psychological effects of cannabis as a single entity 
(usually in resin or dried leaf form) are well documented. Following inhalation or 
intravenous administration, maximal levels in the brain are reached in approximately 
15 minutes, and the effects persist for around 3 hours before steadily declining. If it is 
administered orally, it may take up to an hour to reach maximal levels in the brain, 
and effects typically persist for longer, up to 5 or 6 hours, due to continuing 
absorption from the gut (Hollister 1986). Cannabis is primarily sought out for 
recreational use due to the “high” it produces, a combination of effects including 
euphoria, relaxation, alteration of perception, distortion of time, and enhancement of 
sensory modalities. Some users experience anxiety and stress instead. Impairment of 
short term memory, perturbation of motor function, slowed reaction times and overall 
impaired cognition are other common phenomena experienced by users in varying 
combinations and to differing degrees. Physiologically, cannabis ingestion/inhalation 
can cause tachycardia, drops in systemic and intraocular blood pressure, alterations to 
breathing rate, peripheral vasodilatation, increased cerebral blood flow, suppression of 
nausea, and analgesia. The multiple physiological and psychological effects of 
cannabis are summarized in Table 2. While recreational users seek the psychological 
effects of cannabis, patients using it therapeutically generally report any 
psychological perturbations as unwanted and sometimes disturbing side effects 
(Hollister 1986).  
The active constituents of cannabis are highly soluble, able to cross membranes easily 
and can also be accumulated in fatty tissues from where they are slowly released back 
into the bloodstream. Hence, total elimination from the body occurs only after a 
considerable period of time, and certain effects may be relatively long-lasting. 
However, in comparison to the acute effects of cannabis use, its chronic effects are 
much lesser-studied, a situation no doubt partially attribuTable to the legal status of 
cannabis over the past 50 years, as well as the problems associated with studying 
users over several years or decades. Interpretation is also problematic as the majority 
of long-term recreational users smoke cannabis mixed with tobacco, and many of the 
reported changes associated with prolonged cannabis use are similar to those seen in 
tobacco smokers. Despite these difficulties, several studies have attempted to address 
possible effects of chronic cannabis use in both animals and humans. Reported 
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consequences include suppression of the immune system (both cell-mediated and 
humoral responses in rodents), increased risk of chronic bronchitis and respiratory 
carcinomas (Hollister 1986). Reproductive impairments are also thought to occur, 
including reduced testosterone secretion and sperm viability in males, and disruption 
of the ovarian cycle in females. Recent data about smoking cannabis during 
pregnancy show an impairment and alteration in the development of the offspring’s 
brain (Jutras-Aswad et al. 2009). Heavy users may be subject to tolerance-dependence 
syndrome, and subtle cognitive impairments have been reported, which are boosted 
with increasing frequency/length of use. Finally, in some subjects cannabis use may 
exacerbate schizophrenic tendencies, and/or produce confusion, delusions, 

























Central nervous system 
Psychological effects  Euphoria, dysphoria, anxiety, depersonalisation, aggravation 
of psychotic states 
Effects on perception  Heightened sensory perception, distorted sense of space and 
time, misperceptions, hallucinations 
Sedative effects  Generalised CNS depression, drowsiness, sleep, additive 
effect with other CNS depressants 
Effects on cognition and  Fragmentation of thoughts, mental clouding, memory 
psychomotor performance impairment, global impairment of performance 
Effects on motor function Increased motor activity followed by inertia and lack of 
coordination, ataxia, dysarthria, tremulousness, weakness, 
muscle twitching 
Analgesic effects    Similar efficacy to codeine 
Anti-emetic effects  In acute doses; effect reversed with larger doses or chronic 
use 
Increased appetite 
Tolerance  To most behavioural and somatic effects including the `high' 
with chronic use 
Dependence,   Rarely observed but has been produced experimentally  
abstinence syndrome   following prolonged intoxication 
 
Cardiorespiratory system 
Heart rate    Tachycardia with acute dosage; bradycardia with chronic use 
Peripheral circulation   Vasodilatation, conjunctival redness, postural hypotension 
Cardiac output    Increased output and myocardial oxygen demand 
Cerebral blood flow   Increased acutely, decreased with chronic use 
Ventilation    Small doses stimulate, larger doses depress 
Bronchodilation   Coughing, but tolerance develops 
Airways obstruction   Due to chronic smoking 
 
Eye     Decreased intraocular pressure 
 
Immune system  Impaired bactericidal activity of macrophages in lung and 
spleen 
 
Reproductive system   Decreased sperm count and sperm motility in males 
Suppression of ovulation, complex effects on prolactin 
secretion, increased obstetric risks 
 











THE ENDOCANNABINOID SYSTEM 
 
The endocannabinoid system refers to a group of endogenous lipids and their 
receptors that are involved in a variety of physiological processes including 
neurotransmitter release, motor learning, synaptic plasticity, pain-sensation, 
inflammation and appetite. Broadly speaking, the endocannabinoid system 
encompasses: 
• The cannabinoid receptor type 1 (CB1) and 2 (CB2), two G protein-coupled 
receptors (GPCRs) primarily located in the central nervous system and 
periphery, respectively, as well as orphan receptors.  
• The endogenous lipids (endocannabinoids), that are synthesized “on demand” 
as ligands for the cannabinoid receptors.  
• Enzymes involved in the synthesis and degradation of endocannabinoids. 
• Endocannabinoid membrane transporters (EMTs), which have been 
hypothesized to guide the endocannabinoids through the cellular membrane. 
However, these carriers have not been cloned yet.  
 
 
CANNABINOID RECEPTORS  
 
The first results suggesting the existence of membrane receptors for cannabinoids 
came from experiments performed by Howlett’s group. Here, they showed that ∆9-
THC was able to inhibit the production of adenylyl cyclase in neuroblastoma cells, 
suggesting the involvement of GPCRs (Howlett, Fleming 1984). Furthermore, the 
same group showed that this inhibition was blocked by pretreatment with pertussis 
toxin (Howlett, Qualy & Khachatrian 1986), a bacterial toxin which selectively 
inactivates G proteins of the Gi and Go families. These experiments strongly 
suggested that ∆9-THC produced its effects acting via Gi/o-coupled GPCRs (Howlett, 
Qualy & Khachatrian 1986). 
The synthesis of cannabinoid compounds (i.e. CP55940) by Pfizer, and the 
consequently development of specific binding assays with these compounds, provided 
additional validation for the existence of cannabinoid receptors as member of the 
GPCR family, and allowed the first preliminary map distribution of the receptor 
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(Howlett et al. 2002). The cannabinoid receptor was eventually cloned from the rat 
cerebral cortex in 1990 and named the CB1 receptor (Matsuda et al. 1990). 
The CB1 receptor is widely expressed throughout the brain, with particular emphasis 
to those brain regions that correlate well with the observed effects of cannabinoids, 
including impairment of cognition, memory, learning, motor coordination, analgesia 
and anti-emesis (Howlett et al. 2002). Hence, autoradiography studies show very 
dense receptor binding in the lateral part of the caudate nucleus and putamen, 
cerebellar molecular layer, innermost layers of the olfactory bulb, and the CA3 and 
molecular layers of the dentate gyrus of the hippocampus. The rest of the forebrain is 
moderately densely labelled, while the brainstem and spinal cord is sparsely labelled 
(Herkenham et al. 1990, Pettit et al. 1998). At the subcellular level, CB1 receptors are 
highly expressed on axon terminals and pre-terminal segments, where their activation 
inhibits presynaptic calcium channels, decreasing calcium entry during axonal 
depolarization, leading to decreased neurotransmitter release (Chevaleyre, Takahashi 
& Castillo 2006). Peripherally, CB1 receptors have been identified in the spleen, 
tonsils, intestine, bladder, vas deferens, sympathetic nerve terminals, smooth muscle 
cells, and at very low levels in adrenal glands, heart, prostate, uterus and ovary 
(Demuth, Molleman 2006). 
Regarding the receptor signalling, as above-mentioned, CB1 receptor is coupled to Gi 
and Go proteins, and its activation involves the inhibition of adenylyl cyclase with a 
consequent decrease in cyclic AMP production (Howlett et al. 2002). A CB1 receptor 
interaction with Gs has also been demonstrated in vitro in both striatal neurons and in 
Chinese Hamster Ovary (CHO) cells overexpressing CB1 receptors (Felder et al. 
1995, Bonhaus et al. 1998). Activation of the CB1 receptor is also associated with the 
activation of mitogen-activated protein (MAP) kinase, which regulates many cellular 
functions such as cell growth, transformation and apoptosis. The exact mechanism 
underlying cannabinoid-mediated MAP kinase activation has yet to be fully 
elucidated; however this effect is both PTX- and SR141716A-sensitive (Bouaboula et 
al. 1995), confirming the involvement of the CB1 receptor. 
The CB1 receptor has also been associated with the modulation of voltage-gated ion 
channels, in particular N-and P/Q-type calcium channels and inwardly rectifying A-
type potassium channels, which are thought underlie the cannabinoid-induced 
inhibition of neurotransmitter release at the presynaptic level (Howlett et al. 2002). 
The majority of these effects are mediated through the CB1 receptor, although there is 
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evidence to suggest that cannabinoids modulate ion channel function directly 
(Demuth, Molleman 2006). 
The second cannabinoid receptor to be discovered was the CB2 receptor in 1993 
(Munro, Thomas & Abushaar 1993). This receptor is located prevalently in the 
immune system, in particular in the spleen and tonsils. At the cellular level, B cells 
express high levels of CB2 receptors, while moderate levels are found in natural killer 
cells, and low levels are found in T cells (Galiegue et al. 1995). Other tissues and cells 
also express CB2 receptors including some neurons, enterocytes, osteoclasts and 
osteoblasts, and the liver (Mackie 2007). Interestingly, the CB2 receptor appears to be 
highly inducible (Rousseaux et al. 2007), which makes this receptor an interesting 
tool for the treatment of diseases such as inflammation, pain, atherosclerosis, hepatic 
fibrosis, and bone remodelling, where CB2 receptors have been shown to be involved 
(Mackie 2007). 
In contrast to CB1, the sequence of the CB2 receptor gene shows considerable 
divergences between human, mouse, and rat (Howlett et al. 2002), which complicates 
the study of CB2 receptor pharmacology. 
The CB2 receptor has been demonstrated to couple to Gi/o proteins, which implicates 
the inhibition of adenylyl cyclase activity and consequently the production of cyclic 
AMP (Felder et al. 1995, Bayewitch et al. 1995). Moreover this receptor is able to 
modulate the activity of MAP kinase, and cannabinoids have been shown to activate 
p42/44 MAP kinase in vitro, an effect which could be blocked by both PTX and the 
CB2 receptor antagonist SR144528 (Bouaboula et al. 1996, Kobayashi et al. 2001). 
Conversely to CB1, the CB2 receptor is not able to bind to Gs proteins (Glass, Felder 
1997) or modulate ion channel function. 
Recently, other orphan receptors have been classified as putative cannabinoid 
receptors. In particular GPR55 has been found to be modulated by several plant, 
synthetic and endogenous cannabinoids (Ryberg et al. 2007). The pharmacology of 
this new putative cannabinoid receptor is still controversial, and it seems that the 
activation of GPR55 downstream signalling occurs a ligand- and tissue-dependent 
manner (Ross 2009). A possible fourth novel cannabinoid receptor is GPR119, which 
is strongly implicated in the regulation of energy balance and body weight, and seems 






The discovery of the cannabinoid receptors suggested the existence of endogenous 
ligand(s), which could bind to these receptors and exert physiological effects. The 
first endocannabinoid to be isolated was anandamide (arachidonoyl ethanolamide, 
AEA), which is the amide between arachidonic acid and ethanolamine, and acts as a 
partial CB1 agonist, but only as a weak CB2 agonist (Devane et al. 1992). This finding 
was soon to be followed by the identification of 2-arachidonoylglicerol (2-AG), the 
arachidonate ester of glycerol, which activates both CB1 and CB2 receptors 
(Mechoulam et al. 1995, Sugiura et al. 1995). More recently came the discovery of 
other endocannabinoids, in chronological order, 2-arachidonyl-glycerol ether (noladin 
ether), N-arachidonoyl-dopamine (NADA)13,14, and virodhamine15 (Bisogno et al. 





Figure 4.  Chemical structure of endocannabinoids. Figure taken from (De Petrocellis, Di Marzo 
2009). 
 
Endocannabinoids are synthesized and released “on demand”, which implies a very 
fast degradation process through specific enzymes. 
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So far, anandamide and 2-AG remain the only endocannabinoids for which the 
pharmacological activity and metabolism have been thoroughly investigated.  
 
BIOSYNTHESIS AND DEGRADATION OF AEA AND 2-AG 
 
Several pathways might exist for both the formation and catabolism of anandamide 
and 2-AG. 
In particular, anandamide originates from a phospholipid precursor, N-arachidonoyl-
phosphatidyl-ethanolamine (NArPE), formed from the N-arachidonoylation of 
phopshatidylethanolamine via N-acyltransferases (NATs). The N-acyl-
phosphatidylethanolamine-selective phosphodiesterase (NAPE-PLD) was first 
identified as the enzyme responsible for NArPE catalysis of anandamide through a 
direct reaction which is dependent upon the concentration of Ca2+. More recently 
other enzymes and consequently alternative pathways have been identified in the 
biosynthesis of AEA, through NArPE catalysis (Figure 5) (De Petrocellis, Di Marzo 
2009).  
Regarding 2-AG, this endogenous lipid is produced almost exclusively via the 
hydrolysis of diacylglycerols (DAGs), via DAG lipases (DAGLs) α and β enzymes. 
In turn, DAG precursors are produced either from the phospholipase-C-catalysed 
hydrolysis of phosphatidylinositol, or from the hydrolysis of phosphatidic acid 
(Figure 5) (Bisogno et al. 1999). 
After their biosynthesis, endocannabinoids are released from cells through the 
putative endocannabinoid membrane transporter (EMT), about which there are some 
controversies surrounding its existence since it has been yet not cloned (Di Marzo 
2008). After their release, endocannabinoids can act on cannabinoid receptors through 
an autocrine or paracrine mechanism, and soon after they undergo uptake by the same 
above-mentioned transporter (Figure 5). In neurons, the actions of endocannabinoids 
are peculiar, and are called “retrograde signalling”, where endocannabinoids are 
synthesized and released at the presynaptic level and, following a retrograde way, act 
at postsynaptic level where cannabinoid receptors are localized on the cellular 
membrane (Katona, Freund 2008). 
Subsequent to their internalization, endocannabinoids are catabolised.  
FAAH (fatty acid amide hydrolase) is the major enzyme responsible for anandamide 
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degradation via hydrolysis of its amide bond (Cravatt et al. 1996). In turn, 2-AG 
catabolism involves an enzymatic hydrolysis reaction by the MAGL enzyme 
(monoacylglycerol lipase), that hydrolyzes the 2-AG ester bond (Dinh et al. 2002). 
However, other enzymes have been recently found to be involved in 2-AG 
degradation, i.e. ABH 6, 12 and FAAH, and their involvement might be tissue-
specific (Figure 5) (De Petrocellis, Di Marzo 2009). Other potential catabolic 
pathways the endocannabinoids employ are the enzymes of the arachidonate cascade, 
i.e. cyclooxygenase-2 and lipoxygenases, as well as cytochrome P450 enzymes 





Figure 5. Biosynthesis, action, and degradation of the two best-studied endocannabinoids, anandamide 
and 2-arachidonoylglycerol (2-AG). Several pathways have been reported for both the formation and 
catabolism of anandamide and 2-AG. Anandamide is formed from a phospholipid precursor, N-
arachidonoyl-phosphatidyl-ethanolamine (NArPE), originates from the N-arachidoylation of 
phosphatidylethanolamine via N-acyltransferases (NATs). In turn, NArPE is transformed into 
anandamide via four possible alternative pathways, the most direct of which is catalysed by an N-acyl-
phosphatidylethanolamine-selective phosphodiesterase (NAPE-PLD). The other three pathways imply 






















































glycerophospho-anandamide, through the activity of specific enzymes. 2-AG is produced almost 
exclusively via the hydrolysis of diacylglycerols (DAGs) via sn-1-selective DAG lipases (DAGLs) α 
and β. After cellular re-uptake via a specific and yet-to-be characterized mechanism (EMT), which 
appears to also mediate the release of de-novo biosynthesized endocannabinoids (DiMarzo, 2008), 
anandamide is metabolized via fatty acid amide hydrolase-1 (FAAH), and 2-AG via several 
monoacylglycerol lipases (MAGLs). 2-AG can also be degraded by FAAH. Both endocannabinoids 
activate CB1 and CB2 receptors with different affinities (anandamide being the one with highest affinity 
in both cases) and efficacies (2-AG being the one with highest efficacy in both cases). Anandamide can 
also activate transient receptor potential vanilloid type-1 (TRPV1) channels at an intracellular site 
(Zygmunt PM, 1999), whereas both compounds, at very high concentration, were recently reported to 
activate peroxisome proliferator activated receptors (PPAR)-α and γ (O'Sullivan SE, 2007). Both 
anandamide and 2-AG were also reported by some authors, but not by others, to interact with GPR55 
(Ryeberg E, 2007).. Abh4,6,12, α-β hydrolases 4, 6, 12; PLD, phospholipase D; PLA1/2, 
phospholipase A1/A2; PTPN22, protein tyrosine phosphatase N22. Biosynthetic pathways are shown in 
black, degradation ones in red. Thick arrows denote movement or action. Figure adapted from (De 






















PHARMACOLOGY OF SELECTED PHYTOCANNABINOIDS 
 
Since the isolation of phytocannabinoids, and later the discovery of cannabinoid 
receptors and endocannabinoids, research and consequently the number of 
publications about cannabis has tremendously increased in the last 20 years (Figure 
6). 
In particular, the research has been focused around some of the constituents of 
cannabis, among these ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), 
cannabinol (CBN), ∆9-tetrahydrocannabivarin (∆9-THCV), and cannabigerol (CBG). 
The pharmacology of these compounds has not yet been fully elucidated. However, 
data obtained so far suggest a very complex pharmacological profile which involves 
not only cannabinoid receptors, but in some cases also other receptors, channels or 
intracellular targets (Pertwee 2009). The complex pharmacological profile 
demonstrated for some cannabis constituents has opened the way to various possible 
therapeutic applications. Thus, in order to introduce some of the receptors involved in 
the pharmacology of phytocannabinoids and the diseases in which the cannabinoid 
system is mainly implied, here I will mainly focus on the best-known 
phytocannabinoid characterized to date, ∆9-THC. In particular, I will explain its 
pharmacological profiles and the disease states in which it has been mainly 
characterised. In the results section I will instead focus on other two 
phytocannabinoids, ∆9-THCV and CBD. 
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Figure 6.  Histogram showing the number of cannabis-related publications (y-axis) in the last 50 years 




∆9-THC is the main psychoactive constituent of cannabis and it was first isolated by 
Mechoulam and Gaoni in 1964 (Gaoni 1964). Chemically, ∆9-THC is a poorly water 
soluble, amorphous substance which is sticky, resin-like and highly viscous which 
makes it difficult to handle and process (Thumma et al. 2008). 
As a cannabis constituent, ∆9-THC is assumed to be involved in self-defence, perhaps 
against herbivores. Besides, ∆9-THC has been found to posses high UV-B (280-315 
nm) absorption properties, which have been speculated to protect the plant from 
harmful UV radiation exposure (Pate 1994).  
Dronabinol is the synthetic analogue of tetrahydrocannabinol, in particular the (-)-
trans-delta9-tetrahydrocannabinol isomer that is the main isomer of ∆9-THC in 
cannabis. Dronabinol is sold as Marinol (a registered trademark of Saolvay 
Pharmaceuticals). In this formulation, the drug has limited stability and has to be 
stored at low temperatures (4°C). Moreover, the oral bioavailability of the drug is low 
(circa 6%) and inconsistent which is mainly due to its first pass metabolism and poor 
solubility. Furthermore, tetrahydrocannabinol has been reported to be unsTable in 
acid solutions or when exposed to heat, air, and light. Hence, in the last few years 
researchers have been challenging the development of ∆9-THC as a prodrug, to avoid 
the pharmacokinetics and physico-chemical limitation properties of the pure drug 
(Thumma et al. 2008). 
Regarding the pharmacokinetics, ∆9-THC is metabolized mainly to 11-hydroxy-THC 
(11-OH-THC) by the human body. This metabolite is still psychoactive and is further 
oxidized to 11-nor-9-carboxy-THC (THC-COOH). In humans and animals, more than 
100 metabolites could be identified, but 11-OH-THC and THC-COOH are the 
predominant metabolites. Metabolism occurs mainly in the liver by cytochrome P450 
enzymes CYP2C9, CYP2C19, and CYP3A4. More than 55% of ∆9-THC is excreted 
in the feces and ~20% in the urine. The main metabolite in urine is the ester of 
glucuronic acid, THC-COOH, and free THC-COOH. In the feces, mainly 11-OH-






PHARMACOLOGY OF ∆9-THC AT CANNABINOID RECEPTORS 
 
Several studies have been conducted around the pharmacology of this compound, in 
particular on cannabinoid receptors. ∆9-THC has a high affinity for CB1 receptors 
(Pertwee 2008), in fact displacement binding assays performed with rat brain 
membranes or cell membranes transfected with rat CB1 receptors, show mean Ki 
values in the nanomolar range (Rinaldi-Carmona et al. 1994). Similar affinity has 
been shown by ∆9-THC on CB2 receptors in experiments performed in rat spleen 
membranes or cell membranes transfected with rat CB2 receptors (Rinaldi-Carmona et 
al. 1994, Bayewitch et al. 1996). [35S]GTPγS binding assays, performed in the 
aforementioned membranes, showed agonistic properties of ∆9-THC at both CB1 and 
CB2 receptors, indicating an ability of this compound to activate both these receptors 
and consequently to inhibit the production of cyclic AMP, as direct consequence of 
Gi/o-mediated cannabinoid receptor signalling. However, the efficacy displayed by ∆9-
THC in these assays is lower compared to well-known synthetic CB1/CB2 receptor 
agonists (e.g. HU-210, CP55940 and WIN55212-2), indicating it to be a partial 
agonist for both of these receptors (Pertwee 2008).  
In vivo, the pharmacology of ∆9-THC on CB1 receptors has been proved by a typical 
bioassay: the “tetrad test”. This test represents a series of behavioral paradigms in 
which rodents treated with CB1 agonists show effects (Little et al. 1988). The four 
behavioral components of the tetrad are spontaneous activity, catalepsy, hypothermia, 
and analgesia. In particular, these bioassays are evaluated in the following way: 
1. Spontaneous activity (or hypomotility) is determined by an open field test, in 
which a mouse is placed in a cage with perpendicular grid lines, usually spaced by 
approximately 1 inch. An experimenter counts the number of line crossings by the 
mouse in a given amount of time.  
2. Catalepsy is determined by the bar test. The mouse is placed on a bar oriented 
parallel to and approximately 1 inch off of the ground. If the mouse remains 
immobile on the bar for typically > 20 seconds, it is considered cataleptic.  
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3. Hypothermia is determined by using a rectal probe to measure the rectal 
temperature.  
4. Analgesia is usually determined by the hot plate or tail immersion test. In the hot 
plate test, the mouse is placed on a heated plate, typically between 54 and 58°C. 
An experimenter measures the time it takes for the mouse to jump off of the hot 
plate. In the tail immersion test, the mouse is immobilized and its tail is placed 
into a warm water bath, typically also between 54 and 58°C. An experimenter 
measures the time it takes for the mouse to remove its tail from the water bath.  
∆9-THC and other CB1 agonists are able to induce suppression of locomotor activity, 
hypothermia, immobility in the ring test and antinociception in the tail immersion test 
or hot-plate test (Howlett et al. 2002). Tetrahydrocannabinol produces these “tetrad 
effects” with a potency (half-maximal effective dose = 1-1.5 mg/kg intravenous) that 
is consistent with its CB1 receptor affinity. Moreover, the involvement of CB1 
receptors in all “tetrad effects” is supported by findings that these are readily 
antagonized by the selective CB1 receptor antagonist, SR141716A (Rimonabant®), 
and that most of these effects are not produced by ∆9-THC in mice from which the 
CB1 receptor has been genetically deleted (Pertwee 2008). 
There is evidence to suggest that the activity of a partial agonist on a receptor is 
particularly influenced by the density and the coupling efficiencies of this receptor 
(Newman-Tancredi et al. 2000, Kenakin 2001). In other words, a partial agonist can 
antagonize agonists that possess higher receptor efficacy when these are administered 
exogenously or released endogenously. Because ∆9-THC has low cannabinoid 
receptor efficacy, and since both the density and coupling efficiencies of CB1 
receptors vary widely within the brain and in different species, several studies show 
that ∆9-THC can behave as an antagonist both in vitro and in vivo at the CB1 receptor 
(Pertwee 2008). For example, it has been shown that ∆9-THC can oppose R-(+)-
WIN55212-induced stimulation of guanosine-5’-O-(3-thiotriphosphate) ([35S]GTPγS) 
binding to rat cerebellar membranes (Sim et al. 1996). In vivo, ∆9-THC shares the 
ability of the CB1 antagonists, SR141617A and AM251, to induce signs of anxiogenic 
activity in a mouse model in which CP55940 and R-(+)-WIN55212 displayed 
anxiolityc-like activity (Patel, Hillard 2006). Besides, it can attenuate inhibition of 
glutamatergic synaptic transmission induced in rat or mouse cultured hippocampal 
neurons by R-(+)-WIN55212 or 2-arachodonoylglycerol (Pertwee 2008). 
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∆9-THC can also produce antagonism at the CB2 receptor (Bayewitch et al. 1996). 
Thus, this compound (0.01-1μM) has been found to exhibit partial agonism in COS-7 
cells transfected with human CB2 (hCB2) receptors when the measured response was 
inhibition of cyclic AMP production stimulated by 1 µM forskolin. Instead, ∆9-THC 
behaved as a CB2 receptor antagonists in this bioassay when incubated in combination 
with the agonist, HU-210, displaying an apparent KB value of 25.6nM (Bayewitch et 
al. 1996). Another group have found that ∆9-THC (1 µM) shares the ability of the 
CB2-selective antagonist, SR144528, to abolish 2-arachidonoylglycerol-induced 
migration of human leukemic natural killer cells (Kishimoto et al. 2005). 
This dual partial agonism/antagonism exerted by ∆9-THC has a strong therapeutic 
impact for disorders in which the pathology increases the expression of the 
cannabinoid receptors, or the production and release of endogenous cannabinoids 
(Pertwee 2005). This potential therapeutic aspect will be evaluated with more 
emphasis in the next paragraphs. 
 
 
PHARMACOLOGY OF ∆9-THC AT NON-CB1, NON-CB2 RECEPTORS 
 
Some of the phytocannabinoids investigated so far have been found to interact with 
non-CB1 and non-CB2 receptor targets, amplifying the therapeutic potential of these 
natural compounds. 
As shown in Table 4, ∆9-THC has been found to interact with several non 
cannabinoid receptors, targeting the orthosteric or allosteric site of other GPCRs, 
transmitter-gated channels, ion channels or nuclear receptors (Pertwee 2010).  
For example, ∆9-THC has been found to bind the allosteric sites of opioid receptors. 
Thus, in equilibrium binding experiments with rat whole brain membranes 
tetrahydrocannabinol was found to interact in a non-competitive/allosteric manner 
with μ and δ opioid receptors (Vaysse, Gardner & Zukin 1987). In the same paper, 
∆9-THC was shown to inhibit binding to μ opioid receptors with an IC50 of 7 μM. 
Corroborating results came several years later when another group found that in rat 
brain cerebral cortical membranes, ∆9-THC could accelerate the dissociation of 
[3H]DAMGO and [3H]naltrindol, presumably from μ and δ opioid receptors, 
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respectively. This effect was induced by ∆9-THC only at high concentrations (Table 
3) and was no more than two-fold (Kathmann et al. 2006). 
GPR55 is an additional GPCR that has been found to be activated by ∆9-THC. The 
potency and the efficacy exerted by this compound versus GPR55 are very 
controversial and depend on the samples and the assays used to evaluate the receptor 
activity (Pertwee 2010). 
∆9-THC acts as quite a potent antagonist on the ionotropic receptor 5-HT3, which 
belongs to the serotoninergic receptor family. 5-HT3 receptors are located prevalently 
in the central and peripheral neurons, where they trigger rapid depolarization due to 
the opening of non-selective cation channels (Na+, Ca++ influx, K+ efflux) (Hannon, 
Hoyer 2008). In particular, ∆9-THC has been found to modulate the 3A subunit of the 
human 5-HT3 receptor. In HEK293 cells transfected with this receptor subunit, ∆9-
THC was able to inhibit 5-HT3A-mediated currents induced by 5-HT (serotonin), with 
an IC50 of 38 nM (Table 3) (Barann et al. 2002).  
Moderate potency has been shown by ∆9-THC versus glycine receptors, where this 
phytocannabinoid can potentiate receptor activation, possibly in an allosteric manner 
(Pertwee 2010). Glycine receptors are widely distributed in the central nervous 
system, where they mediate inhibitory transmission predominantly in the spinal cord 
and brain stem. Thus, it has been found that ∆9-THC can potentiate glycine-activated 
currents in both homomeric α1 and heteromeric α1β1subunits of human glycine 
receptors that had been transfected into Xenopus laevis, and in native glycine 
receptors expressed by neurons obtained from the ventral tegmental area of the rat 
brain (EC50 = 115 nM) (Table3) (Hejazi et al. 2006).  
∆9-THC has also been shown to interact with some ion channels, in particular T-type 
Calcium (Cav3) and Potassium Voltage (Kv1.2) channels. In both these channels ∆9-
THC exerts inhibition with an IC50 in the micromolar range (Table 3) (Pertwee 2010). 
Additional ∆9-THC-target receptors are Transient Receptor Potential (TRP) channels, 
which are a family of ion channels with relative non-selective permeability for 
cations, including sodium, calcium and magnesium. In particular, ∆9-THC has been 
found to activate both TRP Vanilloid-2 (TRPV2) and TRP Ankirin-1 (TRPA1) 
channels, with an EC50 in the micromolar range (Table 3) (Pertwee 2010). 
Finally, ∆9-THC has been shown to interact with PPARγ (O'Sullivan et al. 2005). In 
detail, Randal’s group found that ∆9-THC (10 μM) can cause slowly developing 
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vasorelaxation in rat isolated aorta in a manner that can be antagonized by the 
selective PPARγ antagonist, GW9662, but not by the cannabinoid CB1 receptor 
antagonist, AM251. They also found that GW9662 antagonizes ∆9-THC-induced 
relaxation in rat superior mesenteric arteries and that at concentrations of 100 nM and 
above, ∆9-THC activates PPARγ in HEK293 cells expressing this receptor (Pertwee 
2010, O'Sullivan et al. 2005). PPARγ, also known as the glitazone receptor, is a 
nuclear receptor which regulates fatty acid storage and glucose metabolism by 
controlling the expression of specific target genes involved in adipogenesis, 
inflammatory responses, and lipid metabolism. 
 
Receptor or Channel Effect Concentration 
μ opioid Displacement IC50  = 7 μΜ 
μ opioid Dissociation EC50  = 21.4 μΜ 
δ opioid Dissociation EC50  = 10 μΜ 
β -adrenoreceptor Potentiation 3 & 10 μΜ 
5-HT3A Antagonism IC50  = 38 nΜ 
glycine (α1) Potentiation EC50  = 86 nM 
glycine (α1 β1) Potentiation EC50  = 73 nM 
Glycine Potentiation EC50  = 115 nM 
T-type calcium (Cav3) channels Inhibition 1 μΜ 
Potassium Kv1.2 channels Inhibition IC50  = 2.4 μΜ 
TRPA1 Activation 20 μΜ 
TRPA1 Activation 400 μM 
TRPV2 Activation EC50  = 16 & 43 μΜ 
PPARγ Activation 300 nM 
 
Table 3.  List of G protein-coupled receptors, transmitter-gated channels, ion channels and nuclear 













REPORTED THERAPEUTIC EFFECTS OF ∆9-THC 
 
Since the emerging role of the endocannabinoids in a wide variety of physiological 
and pathophysiological processes, ∆9-THC has been tested so far in different 
disorders, demonstrating some therapeutic effects. 
 
Brain related disorders. Neuroprotection. ∆9-THC has been shown to exert 
protection in several models of excitotoxicity on neuronal cultures (Costa et al. 2007). 
Nowadays, excitotoxicity is known to be one of the main pathological processes 
which occurs during brain injury or diseases, such as spinal cord injury, stroke, 
traumatic brain injury and neurodegenerative diseases of the central nervous system 
(i.e. multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's 
disease, alcoholism or alcohol withdrawal, and Huntington's disease). This 
phenomenon is caused by an accumulation of glutamate neurotransmission with a 
consequent hyperstimulation of glutamatergic receptors on neurons, in particular 
NMDA receptors, whose activation causes a massive influx of Ca2+ ions. In turn, the 
accumulation of Ca2+, as consequence of NMDA over-activation, causes a series of 
intracellular events which lead to neuronal death by apoptosis (Manev et al. 1989). 
The presynaptic localization of CB1 receptors on glutamatergic neurons inhibits the 
excitatory transmission, suggesting a neuroprotective effect of this cannabinoid 
receptor against the excitotoxicity process. During this disease state, the potential 
neuroprotective properties of ∆9-THC have been tested in several neuronal models 
(Costa et al. 2007). In all of these assays a protective effect of ∆9-THC has been 
demonstrated, but unfortunately the results obtained with the ∆9-THC treatment, 
imply a scenario more complicated than that suggested. In fact, in some models, the 
neuroprotective effects of ∆9-THC were blocked by CB1 receptor antagonists, 
indicating a cannabinoid receptor-mediated effect; conversely, in other assays the 
protective action of ∆9-THC was not CB1 receptor mediated, suggesting an 
antioxidant role of this phytocannabinoid (Costa et al. 2007). Moreover, the 
efficacious concentration of this compound was very close to its toxic effects in some 
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models, possibly due to an over-activation or desensitization of CB1 receptors. In 
summary, the potential protective role and the exact mechanism of ∆9-THC action in 
this scenario have yet to be fully clarified, but open up the possibility of discovering 
potential new drugs with more selective activity. 
Multiple Sclerosis. This neurodegenerative disease is characterised by the 
demyelization of axons in the brain and spinal cord, with a consequently progressive 
deterioration of neurological and bodily functions. 
In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, ∆9-
THC showed efficacy in improving the signs of MS, notably causing delayed onset 
and survival greater than 95% (Lyman et al. 1989). In the same model, a more sTable 
and less psychoactive ∆9-THC analogue, ∆8-THC, was found to reduce the incidence 
and severity of the neurological deficit (Wirguin et al. 1994). These data suggested an 
efficacy of ∆9-THC and analogues in the treatment of EAE and encouraged 
researchers to test these ligands in patients affected by MS. 
In the last 10 years several systematic, placebo-controlled, clinical trials have been 
conducted with the cannabis extract, ∆9-THC as oral medication (dronabinol), 
nabilone or CBME (cannabis based medicinal extract, i.e. Sativex). The results 
obtained with the pure ∆9-THC or its analogue were controversial: in a few cases, 
patients reported an improvement in spasticity, muscles spasms, pain, sleep quality, 
tremors, and general condition; on the other hand, no improvements were reported by 
other patients treated with ∆9-THC. Conversely, clinical trials conducted with CBMEs 
produced a statistically and clinically significant reduction in spasticity (Costa et al. 
2007, Smith 2010). However, it is still not clear which therapeutic advantages 
CBMEs will offer over conventional medications. 
The exact mechanisms underlying the reduction in cannabinoid-induced spasticity 
remain to be fully understood. It has been suggested that an inhibition of the 
excitatory transmission (glutamatergic receptors and potassium channels) through 
activation of pre-synaptic CB1 receptors in the CNS, in particular the spinal cord, 
could be responsible for these effects (Fujiwara, Egashira 2004).  
Parkinson’s Disease. Parkinson’s disease is one of the most common progressive 
neurodegenerative disorders, and is characterise by the loss of dopaminergic neurons, 
particularly in the substantia nigra pars compacta. In 2005, Fernandez-Ruiz and co-
workers reported a beneficial effect of ∆9-THC in a Parkinson’s disease animal 
model. In this model, ∆9-THC treatment was shown to rescue the neurodegeneration 
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induced by injection of the toxin, 6-hydroxydopamine (Lastres-Becker et al. 2005). 
The same neuroprotective effect was exerted by the non-psychoactive 
phytocannabinoid, CBD, suggesting a more probable antioxidant effect, instead of a 
CB1 receptor-mediated mechanism. 
A clinical trial was conducted in United Kingdom using 19 patients suffering from 
Parkinson’s disease and levodopa-induced dyskinesia. In this trial the oral 
administration of a cannabis extract, composed of 2.5 mg of ∆9-THC and 1.25 mg of 
CBD, failed to show any objective or subjective improvement in parkinsonism or 
dyskinesia (Carroll et al. 2004). 
 
Cancer. Antitumoral effects. The first study showing the anti-cancer effects of 
tetrahydrocannabinol was conducted by Munson et al. in 1975. Both ∆9-THC and ∆8-
THC were able to inhibit the growth of Lewis lung carcinoma cells in vitro and in 
vivo after oral administration to mice (Munson et al. 1975). Since then, ∆9-THC and 
other phytocannabinoids have been tested in various cancer types (lung, glioma, 
thyroid, lymphoma, skin, pancreas, uterus, breast and prostate carcinoma) using both 
in vitro and in vivo models. The resulting anti-cancer properties of ∆9-THC in these 
models imply an anti-proliferative, anti-metastatic, anti-angiogenic and pro-apoptotic 
effect of this drug, suggesting the involvement of several pathways (Alexander, Smith 
& Rosengren 2009). 
Recently, the first clinical trial has been reported, where 9 patients affected by 
glioblastoma multiforme were administered an intratumoral injection of ∆9-THC. The 
results showed that the intracranial administration of ∆9-THC was safe and did not 
result in any obvious psychoactive effects. Moreover, ∆9-THC was reported to inhibit 
the proliferation of the tumours in vitro, and reduce the Ki-67 immunostaining in two 
of the treated patients, confirming the anti-proliferative effect of this drug in cancer 
cells (Guzman et al. 2006). 
Although promising anti-cancer effects of ∆9-THC and other cannabinoids have been 
reported, there are a few studies which have shown a biphasic effect of ∆9-THC in 
cancer cells, where lower concentrations result in an increase in proliferation of 
cancer cells and higher concentrations cause a decrease in cell proliferation 
(Alexander, Smith & Rosengren 2009). 
Together, these results highlight the importance of further studies to truly establish the 
anti-cancer effects of ∆9-THC.  
 33
Palliative care in cancer. One of the best established effects of ∆9-THC in the clinic is 
its anti-nausea and anti-emetic properties in cancer patients. Thus, the synthetic ∆9-
THC, dronabinol, and its synthetic analogue, nabilone, are approved in different 
countries for this purpose (Table 1). Two possible mechanisms have been suggested 
to explain the anti-emetic effects of ∆9-THC. In particular, the location of CB1 
receptors in cholinergic nerve terminals of the myenteric plexus of the stomach, 
duodenum, and colon are suggested to be responsible for the ∆9-THC -induced 
inhibition of digestive-tract motility. It has also been suggested that the presence of 
CB1 receptors in the brainstem might have a role in ∆9-THC -induced control of 
emesis (Di Carlo, Izzo 2003).  
Despite the encouraging results from clinical trials conducted in the early 1980’s, the 
usage of this drug has been eclipsed by the severe incidence of side effects and the 
development of more-effective anti-emetic drugs (Costa et al. 2007).  
Other ∆9-THC -palliative applications include the anti-anorexic properties of this 
drug. This effect is supported by the well-established role of endocannabinoids system 
in feeding behaviour in several animal models, where the expression of CB1 receptors, 
in particular brain regions, nerve terminals, and adipocytes, might have a crucial role 
in the feeding behaviour produced by ∆9-THC. 
∆9-THC finds application as anti-anorexic drug not only in cancer, but also in patients 
affected by AIDS. In fact, dronabinol has been licensed for use in the USA for this 
purpose (Costa et al. 2007). 
 
Analgesic Effects. ∆9-THC has been shown to have anti-nociceptive abilities in a 
wide range of assays, in particular in both acute (e.g. tail-flick and hot-plate tests) and 
tonic (e.g. stretching) nociceptive tests (Costa et al. 2007). The involvement of CB1 
receptors in ∆9-THC -induced antinociception is well established. In fact, CB1 
receptors are located in tissues associated with the transmission and processing of 
nociceptive information (spinal cord, thalamus, periaqueductal grey, rostro-
ventromedial medulla, dorsal-root ganglia, afferent-fiber terminals) (Tsou et al. 1998). 
Moreover, the CB1 receptor antagonist, SR141716A, was found to prevent the anti-
nociceptive effects of ∆9-THC. Additional evidence comes from CB1 knock-out mice, 
in which during the hot plate test, the antinociceptive effects of ∆9-THC were 
completely abolished. Furthermore, in the warm-water tail withdrawal test, the effects 
of ∆9-THC were strongly reduced. However, CB1 receptors are not the only target 
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involved in ∆9-THC -induced anti-nociception. In fact, in the tail flick test using CB1 
knock-out mice, ∆9-THC retained the ability to induce antinociception, indicating the 
involvement of other targets (Zimmer et al. 1999). 
Concerning neuropathic pain, only one study has been conducted in an animal model 
for this disease, showing an anti-hyperalgesic effect of ∆9-THC. Unfortunately when 
∆9-THC was orally administered to patients suffering from neuropathic pain, no 
improvements in pain, or in quality of life were reported (Costa et al. 2007).   
A possible important therapeutic application of ∆9-THC might be the treatment of 
cancer pain. In fact, chronic cancer pain has a nociceptive component, which 
originates from inflammatory reactions around the sites of injury, and a neuropathic 
pain component, which results from damage to the nervous system. ∆9-THC has been 
tested with this purpose in some clinical trials, showing effectiveness as analgesic 
drug (Costa et al. 2007). 
Unfortunately the data collected so far are insufficient to support the introduction of 











































All reagents were purchased from SIGMA-ALDRICH® (Poole, UK), unless 
otherwise stated. 
Cannabidiol and tetrahydrocannabivarin were supplied by GW Pharmaceuticals 
(Porton Down, Wiltshire, UK) and SR144528 was obtained from Sanofi-Aventis 
(Montpellier, France).  
R-(+)-[2, 3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1, 2, 3-de]-1 ,4 
benzoxazin-6-yl]-1-naphthalenylmethanone (R-(+)-WIN55212), (–)-cis-3-[2-hydroxy 
4-(1,1-dimethylheptyl) phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55940), 
maprotiline hydrochloride and R-(+)-8-hydroxy-2-(di-npropylamino) tetralin (8-OH-
DPAT) were purchased from Tocris (Bristol, UK). 
For the binding experiments, [3H]CP55940 (160 Ci/mmol), [3H]8-OH-DPAT (180 
Ci/mmol)  and [35S]GTPγS (1250 Ci/mmol) were obtained from PerkinElmer Life 
Sciences Inc. (Boston, MA, USA), GTPγS, adenosine deaminase and Roche Protease 
Inhibitor Cocktail from Roche Diagnostic (Indianapolis, IN, USA). 
 






Binding experiments are based on the incubation of a sample containing the receptor 
of interest and a labelled ligand for this receptor in controlled time, temperature and 
pH conditions. 
During the incubation, part of the ligand X is able to bind the receptor R, resulting in 
the complex RX formation (Figure 7). 
 
                    R + X       RX 
Figure 7. The formation of the Complex RX is determined by an equilibrium reaction between the 
receptor R and the compound X. 
 37
The incubation is followed by filtration and washing which allow the separation of the 
complex RX from the unbound ligand X. The radioactivity of the complex RX is then 
quantified by a scintillation liquid. From the elaboration of the radioactivity data is 
possible to obtain specific parameters (i.e. Ki, Bmax, …). 
The ligand can be an agonist or antagonist at the receptor in question and must be 
labelled with a radioisotope at high specific activity (usually 3H or 125I) to ensure a 
sensitive assay.  
The incubation time is one of the key factors for the reaction, a competitive or 
displacement binding assay is carried out when the equilibrium of the complex RX is 
reached. Conversely, the incubation time is variable in the kinetic studies where other 
parameters are considered (i.e. half time of the RX dissociation). In addition, 
radioligands may also bind to other sites, as well as the receptor of interest. The 
binding to the receptor of interest is called specific binding, whereas the binding to the 
other sites is called non-specific binding (Figure 8).  
Non-specific binding is usually (but not necessarily) proportional to the concentration 
of radioligand (within the range it is used). Non-specific binding is detected by 
measuring radioligand binding in the presence of a saturating concentration of an 
unlabeled drug that binds to the receptors.  
                          
Figure 8. The graph represents a competitive binding assay. The top of the curve is a plateau at a value 
equal to radioligand binding in the absence of the competing unlabeled drug. The bottom of the curve 
is a plateau equal to non-specific binding (NS). The concentration of unlabeled drug that produces 
radioligand binding half way between the upper and lower plateaus is called the IC50 (inhibitory 
concentration 50%) or EC50 (effective concentration 50%). 
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COMPETITIVE OR DISPLACEMENT BINDING ASSAY 
 
Competitive binding experiments measure the binding of a single concentration of 
labeled ligand in the presence of various concentrations of unlabeled ligand. 
In a competitive binding assay, both the radioligand and the unlabelled compound can 
compete for the orthosteric site of the receptor, which is the effective site responsible 
of the receptor activation. In this case, the unlabelled ligand will produce 100% of 
displacement of the unlabelled compound (Figure 9A). Competition binding 
experiments allow the calculation of the Ki, which is the equilibrium dissociation 
constant and is a measure of the affinity of the unlabeled ligand for the receptor in 
question (Cheng, Prusoff 1973). By definition, the Ki is the concentration of the 
competing ligand that will bind to half the binding sites at equilibrium, in the absence 
of radioligand or other competitors. A ligand binding with a Ki of 1 nM or less is 
generally considered to have high affinity for its receptor whereas ligands binding 
with Ki of 1 μM have low affinity. 
However the unlabelled compound can bind to the allosteric binding site, which is a 
regulatory receptor binding site. In this case, the displacement of the radioligand from 
its receptor will be incomplete and it is possible to observe different effects (Figure 
9B). In fact, the binding of the unlabelled compound to the allosteric site can decrease 
or increase the binding of the radioligand to the orthosteric site (Figure 9B). 
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Figure 9. A) Increasing concentrations of compound X displaces [3H]X from specific binding sites of 
tissues or cells. B) Compounds which do not bind directly to the orthosteric site can produce a partial 
displacement of [3H]X (shown in black symbols), or even enhance binding of [3H]X to the orthosteric 




The assays were carried out with 0.7 nM of [3H]CP55940 or [3H]8-OH-DPAT and 
Tris-binding buffer (50 mM Tris–HCl, 50 mM Tris–base, 0.1% BSA, pH 7.4) in a  
total assay volume of 500 μL. Binding was initiated by the addition of transfected 
hCB2-CHO cells (50 μg proteins per well or 31250 whole cells per well), mouse 
whole brain membranes (33.3 μg of proteins per well) or rat brainstem membranes 
(500 µg protein per well). All assays were performed at 37°C for 60 min before 
termination by the addition of ice-cold Tris-binding buffer and vacuum filtration 
using a 24-well sampling manifold (Brandel Cell Harvester) and Brandel GF/B filters 
that had been soaked in wash buffer at 4°C for at least 24 h (Brandel Inc, 
Gaithersburg, MD, USA). Each reaction well was washed six times with a 1.2 mL 
aliquot of Tris-binding buffer. The filters were oven dried for 60 min and then placed 
in 5 mL of scintillation fluid (Ultima Gold XR, PerkinElmer). Radioactivity was 
quantified by a liquid scintillation counter (Tri-Carb 2800TR, Perkin Elmer). Specific 
binding was defined as the difference between the binding that occurred in the 
presence and absence of 1 μM unlabelled CP55940 or 8-OH-DPAT. The vehicle 
concentration in all assay wells being 0.1% DMSO.  
 
 
DISSOCIATION KINETIC ASSAY 
 
Allosteric modulation is classically defined as the binding of a ligand to a site which 
is topographically distinct from the orthosteric site. Binding to the allosteric site of the 
receptor can induce a conformational change of the receptor that can enhance or 
decrease the affinity of ligands for the orthosteric site. Similarly the conformational 
change can modify the efficacy of the response produced by the orthosteric ligand. 
The dissociation kinetics assay measures the rate at which a single concentration of 
radioligand dissociates from the orthosteric site of the receptor. A dissociation rate 
constant which deviates to that of a control performed in the presence of an unlabelled 
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ligand is indicative of allosteric modulation (Motulsky, Mahan 1984). Allosteric 
modulators have been found for many GPCRs, such as muscarinic acetylcholine 
receptors, dopamine D2 receptors and metabotropic glutamate receptors (reviewed in 
(Gao, Jacobson 2006). An allosteric site has also been discovered on the CB1 receptor 
(Price et al. 2005). 
 
Method-procedure 
Dissociation kinetic assays were performed with the 5-HT1A receptor agonist [3H]8-
OH-DPAT (0.7 nM) and Tris-binding buffer, total assay volume 500 µl. We used the 
“isotopic dilution” method to measure the dissociation rate constant for [3H]8-OH 
DPAT from brain stem membranes (Price et al. 2005, Christopoulos 2001). [3H]8-
OH-DPAT (0.7 nM) was incubated with rat brain stem membranes (500 µg protein 
per well) for 60 min at 25°C. Dissociation was initiated by the addition of 1 µM 
unlabeled ligand in the presence and absence of test compounds. Dissociation times of 
0.5 to 120 min at 25°C were used. To determine the nonspecific binding, experiments 
were also performed in the presence of a 1 µM concentration of the unlabeled ligand. 
Binding was terminated by addition of ice-cold wash buffer (50 mM Tris-HCl, 50 
mM Tris-base, and 0.1% BSA) followed by vacuum filtration method.  
 
 
[35S]GTPγS BINDING ASSAY 
 
The [35S]GTPγS binding assay is a functional assay which measures the levels of G 
protein-coupled receptor (GPCR) activation. The principle of this assay exploits the 
physiology of GPCRs which normally occurs upon activation of the receptor by a 
ligand (Figure 10). 
 41
Figure 10. All GPCRs are similar in structure, consisting of a single peptide containing seven 
hydrophobic α-helices separated by hydrophillic regions which form intracellular and extracellular 
loops. When an extracellular ligand binds to a GPCR it alters the conformation of domains of the seven 
transmembrane helix pocket, which consequently causes a change in conformation of the intracellular 
domains of the receptor. Receptors interact with G proteins through the COOH terminal and 
intracellular loops. G proteins are in a heterotrimeric complex with a Gα protein associated with a βγ 
complex. The conformational change in the receptor caused by agonist binding leads to a promotion of 
exchange of GDP bound in the Gα active site to GTP. The binding of GTP causes dissociation of the G 
protein heterotrimeric complex. The GTP bound α subunit and the βγ subunit then regulate the 
activities of intracellular effector molecules downstream.  
 
In the assay, [35S]GTPyS replaces endogenous GTP and binds to the Gα subunit 
following activation of the receptor to form a Gα-[35S]GTPγS species. Since the y-
thiophosphate bond is resistant to hydrolysis by the GTPase of Gα, G protein is 
prevented from reforming as a heterotrimer and thus [35S]GTPγS labelled Gα subunits 
accumulate and can be measured by counting the amount of 35S-label incorporated 
(Harrison, Traynor 2003). Because the Gα subunit remains associated with the 
membrane this is simply done by filtering the preparation, and counting the 
radioactivity retained on the filters. The assay is functional and can show if a 
compound is behaving as an agonist or antagonist. Moreover, [35S]GTPγS binding 
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assay can give a direct measure of potency (EC50), efficacy (Emax) and antagonist 
affinity (KB), for test compounds, by plotting sigmoidal dose-response curves 
(Harrison, Traynor 2003). 
                        
Figure 11. A hypothetical sigmoidal dose-response curve produced by Drug X in the [35S]GTPγS 




The Emax represents magnitude of the maximal response or in other words the 
maximal possible effect of a compound (Figure 11). The EC50 is the potency of a test 
compound and is given by the concentration that is required to produce 50% of the 
maximal response produced by the drug (Figure 11). Full agonists are drugs with high 
efficacy which will elicit the maximum response that is capable of the tissue in 
question even at low levels of receptor occupancy or with using low concentrations of 
the drug. Drugs with intermediate levels of efficacy may not elicit a full response 
even if all of the target receptors are occupied, these drugs are termed partial agonists 
(Figure 12). 
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Figure 12. An illustration of typical effects seen in response to the incubation of different types of 
ligand in the [35S]GTPγS binding assay. 
 
Inverse agonists behave in the opposite manner to agonists and are said to have 
negative efficacy, they are characterised by their ability to decrease levels of 
[35S]GTPγS binding below that of the basal levels. This is possible when the receptor 
is in a constitutively active state (“on” state) in the absence of any ligand (Figure 13). 
This aspect will be discussed in more detail in the second chapter. 
Neutral antagonists have affinity for the receptor but do not stimulate levels of 
[35S]GTPγS binding (Figure 12). 
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Figure 13. The two state model of receptor activation depicting how different ligands have different 
affinities for the two receptor states. 
 
              







































Antagonists can also be tested in the [35S]GTPγS assay. When antagonism is 
competitive in nature a parallel rightward shift of the plotted dose response curve is 
observed (Figure 14). If the plotted curve appears to hinge downwards, this could 
indicate that the antagonism is non competitive, possibly because the level of 
[35S]GTPγS binding being induced by the agonist is being modulated allosterically. 
Alternatively if an antagonist has inverse agonistic properties (Figure 12) at the 
concentration at which it is used as an antagonist then a downwards displacement may 
be observed (Thomas et al. 2007).  
 
Method-procedure 
Brain and brainstem membranes were thawed at room temperature, 500 μl of 
adenosine deaminase (ADA) added (0.75 units per ml), and then membranes were 
diluted up to 1.5 ml by adding binding buffer (Table 4) and incubated for 30 min in a 
30°C water bath.  
GDP (10 mM) was added to binding buffer (Table 4) in order to obtain a final 
concentration of 30 μM of GDP. Then, 350 μl of this solution was added into 24 wells 
of a 96 well plate, and 50 μl of cold GTPγS (final assay concentration 30 μM), 
vehicle control (0.1% (v/v) DMSO), or test compounds were added in duplicate into 
each well. 50 μl of 1 nM [35S]GTPγS was then added to each well to give a final assay 
concentration of 0.1 nM, followed by 10 μg (brain membranes), 100  μg (brainstem 
membranes) or 50 μg (cell membranes) proteins per well. Non-specific binding 
(NSB) was measured using 30 μM of cold GTPγS. The assay was incubated for 1 
hour at 30°C, and then filtered by rapid vacuum filtration using a 24-well sampling 
manifold, onto GF/B filters washed with ice-cold wash buffer (50 mM Tris-HCl, 50 
mM Tris-Base and 0.1% (w/v) BSA, pH 7.4). The filters were oven dried for 60 min, 
soaked in 5 ml scintillation fluid (Ultima Gold XR, PerkinElmer) and the amount of 










Binding buffer for brain and 
brain stem membranes 
Binding buffer for cell 
membranes 
Tris-HCl 50 mM 50 mM 
Tris-Base  50 mM 
NaCl   100 mM 100 mM 
MgCl2 3 mM 5 mM 
EGTA 0.2 mM  
EDTA  1 mM 
DTT  1 mM 
BSA (fatty acid free) 0.1% (w/v) 0.1% (w/v) 
 






Cells were cultivated in a sterile incubator (Galaxy S CO2 incubator, RS Biotech) at 
37°C in humidified air containing 5% CO2. All culture procedures were performed in 
a sterile laminar flood hood using instruments sterilised with 70% ethanol and 
plasticware supplied in sterile package, which were opened within the hood. 
 
Cell Lines 
CHO (Chinese Hamster Ovary) cells either untransfected or transfected with cDNA 
encoding human cannabinoid CB2 or CB1 receptors were maintained in Dulbecco’s 
modified Eagle’s medium nutrient mixture F-12 HAM, supplemented with 1 mM L-
glutamine, 10% fetal bovine serum and 0.6% penicillin–streptomycin for all cells 
together with G418 (400 mg·mL-1) for the hCB2- and  hCB1-CHO cells.  
 
Cell Maintenance 
Cells were grown in monolayer and passaged twice weekly when they reached a state 
of 80% confluence. In summary, media was discarded and dead cells were removed 
by washing once with 10 ml of PBS (Phosphate Buffered Saline). After removal of 
the PBS, cells were then dissociated from the flask by adding 5 ml of non enzymatic 
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cell dissociation fluid (Cell Dissociation Solution Non-enzymatic 1X). Cells were left 
to incubate at 37 °C for 2 minutes in the cell dissociation fluid, and then detached by 
tapping the side of the flask. The dissociation fluid containing the cells was then 
diluted with equal amount of medium and mixed well to obtain a homogeneous 
cellular suspension. For passage into a medium flask (75 cm2), 1 ml of resuspended 
cells (approximately 1.5 millions of cells) was added to 25 ml of media. For a large 
flask (175 cm2), 2 ml of resuspended cells were added to 50 ml of media. 
 
PTX-treatment 
Pertussis toxin (PTX) disrupt the function of Gi/o-coupled receptors (Howlett, Qualy 
& Khachatrian 1986), and can be used to implicate Gi/o-coupled receptors in agonist-
activated responses. 
The PTX stock powder was diluted with distilled water at the concentration of 100 
ng/μl. This stock solution was then diluted 1000X (100 ng/ml) in complete media. 
Cells grown in large flasks were washed once with 10 ml of PBS and incubated 
overnight with 20 ml of media containing PTX (100 ng/ml) at 37°C. Prior using the 





Since the present investigation focused on some small brain regions,  in order to 
obtain a high amount of proteins from the sample processing we decided to modify 
the commonly used method (“Old” Processing Method) in this laboratory. Therefore, 




All mice and rats were provided with free access to food and water and were in an 
environment with 12/12h light/dark cycle. MF1 mice or Lister Hooded rats were 





Brain and brain regions dissection 
Mice or rats were killed by CO2 exposure followed by rapid dislocation. The brain 
was then collected, washed rapidly in cold HEPES buffer (Table 5) and frozen down 
in dry ice. To isolate the different brain regions, the brain was washed in HEPES 
buffer, kept on a cold support and dissected with curved forceps (Micro-serrations 
forceps, MORIA MC31). The brain regions were then frozen down in dry ice. The 
tissues were moved to -80°C and stored for no more than 3 months. 
 
HEPES buffer Concentration (mM) g/500ml of DDW 
NaCl 130 3.7985 
KCl 5.4 0.2015 
CaCl2 1.8 0.1325 
MgCl2 1 0.1015 
HEPES 10 1.1915 
D-Glucose 25 2.252 
 
Table 5. HEPES buffer was prepared 10X without D-Glucose, pH 7.4, autoclaved and stored at 4°C for 
2-3 months. The day of the experiment, the buffer was diluted up to 1X and D-Glucose was added to 
the solution. 
DDW (double distilled water) 
 
 
“Old” Processing Method for brain 
The procedure was set up for 4 mouse brains,  
1. 4 brains were thawed on ice and placed in 2 tubes containing 5 ml of ice cold 
centrifugation buffer (Table 6). 
2. Brains were homogenised using a polytron homogeniser. 
3. The two tubes were centrifuged at RCF 1600 (rotor number 12158) for 10 minutes 
at 4°C. 
4. The resulting supernatant was saved on ice and the pellet was resuspended in 5 ml 
of centrifugation buffer. 
5. The two tubes with resuspended pellets were centrifuged as before in step 3. 
6. Again the supernatant was kept and combined with the supernatant from step 4. 
The large pellet consisting mostly of blood was discarded. 
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7. The two tubes of supernatant were centrifuged at RCF 28000 for 20 minutes at 
4°C. 
8. The resulting supernatant was discarded and the small pellet in each tube was 
resuspended in 20 ml of buffer A (Table 6). 
9. The 2 tubes were incubated in a water bath at 37°C for 10 minutes. 
10. The 2 tubes were then centrifuged at RCF 23000 for 20 min at 4°C. 
11. The supernatant was discarded and the pellet in each tube was resuspended in 20 
ml of buffer A again and incubated at room temperature for 40 minutes. 
12. The 2 tubes were centrifuged at RCF 11000 for 15 minutes, at 4°C. 
13. The supernatant was discarded and the combined pellets from both tubes were 
resuspended in a total volume of 2 ml of buffer B (Table 6). 
14. The membrane preparation was homogenised using a glass hand-held 
homogeniser. 
15. The concentration of proteins was determined using a BioRad protein assay kit. 
Brain membranes to be used for displacement binding assay the membranes were 
stored in 1 ml aliquots of 1 mg/ml.  
16. Aliquots of membranes were stored at –80°C. 
 
“New” Processing Method for brain and brainstem 
1. The brain and/or brainstem were thawed and homogenized on ice in processing 
buffer (Table 7) using a glass hand-held homogeniser (5 ml of processing 
buffer for 1 rat brain or 2 mouse brains, and 5ml of processing buffer for 3 rat 
brainstems).  
2. The samples were then transferred into 1.5 ml tubes and centrifuged at 10.000 
rpm for 15 min at 4°C. 
3. After centrifugation, the resulting supernatants were discarded and the pellets 
were frozen down to -80°C for at least 2 h (to enhance the breaking process of 
the membranes). 
4. The pellets were then thawed, resuspended in 300 μl/pellet of TME buffer 
(Table 7) and homogenized on ice using a hand motor mixer (VWR® pellet 
mixer).  
5. The resulting membranes were then collected and the protein concentration 
was assessed using a BioRad protein assay kit. 
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6. The membranes were diluted in TME buffer (Table 7) at different 
concentrations depending on the sample and the assay of interest (Table 8). 





Concentration (mM) g/500ml of DDW 
Tris HCl 2 0.16 
Tris Base 2 0.12 
EDTA 2 0.37 
MgCl2 5 0.24 
Sucrose 320 54.77 
 
Buffer A Concentration (mM) g/500ml of DDW 
Tris HCl 50 3.94 
Tris Base 50 3.03 
EDTA 2 0.37 
MgCl2 5 0.24 
NaCl 100 2.92 
   
Buffer B Concentration (mM) g/500ml of DDW 
Tris HCl 50 3.94 
Tris Base 50 3.03 
EDTA 1 0.19 
MgCl2 3 0.14 
NaCl 100 2.92 
 
Table 6. This Table summarizes all the buffers and their respective components used in the old 








Choi Lysis  
Buffer 
Concentration (mM) g/500ml of DDW 
Tris HCl 20 1.57 
EGTA 0.5 0.095 
EDTA 0.2 0.037 




Concentration  5ml of solution 
Choi Buffer  4825 μl 
Roche protease 
inhibitor cocktail 
1:40 v/v 125 μl 
PMSF 1 mM 50 μl 
   
TME 
Buffer 
Concentration (mM) g/500ml of DDW 
Tris HCl 50 3.94 
EDTA 1 0.19 
MgCl2 3 0.14 
 
Table 7. This Table summarizes all the buffers and their respective components used in the old 
processing method for brain. Choi lysis Buffer pH is 7.5, TME buffer pH is 7.4. 























[35S]GTPγS binding  10 30 10 
mouse/rat 
brain 
Displacement binding 1 1000 33.3 
rat brainstem [35S]GTPγS binding 10 300 100 




10 1500 500 
 






Unknown protein concentrations were determined by generating a standard curve 
using a set of standards of known protein concentrations, starting from a stock of 
concentration of 1.45 mg/ml bovine serum albumin (BSA) (Table 9). 
500 ml of reagent A (Bio-Rad Dc kit; Hercules, CA, USA) was added to each tube 
and vortexed, then 4 ml of reagent B (Bio-Rad Dc kit) added to each tube and 
vortexed. Tubes were incubated at room temperature for 15 min and absorbance read 
at 750 nm using a Novaspec III absorbance reader (Amersham Biosciences). 
The known protein amount of standards was plotted against their absorbance reading 
(nm) using Prism 5. Data were analyzed using a linear regression analyses and the 







 1 2 3 4 5 Unknown 
BSA (μl) 100 75 50 25 0 




0 25 50 75 100 80 
Protein 
amount (μg) 
145 107.50 72.50 36.25 0 X 
 
Table 9. Generation of protein standard curve and calculating an unknown protein concentration. 




CYCLIC AMP ASSAY 
 
The cyclic AMP (adenosine monophosphate) assay is a functional assay which 
measures the levels of the second messenger cyclic AMP. Cyclic AMP is synthesized 
from ATP (adenosine triphosphate) by the enzyme adenylyl cyclase located on the 
inner side of the plasma membrane. Adenylyl cyclase is activated by a range of 
signaling molecules through the activation of adenylyl cyclase stimulatory G (Gs) 
protein-coupled receptor and inhibited by agonists of adenylyl cyclase inhibitory G 
(Gi/o) protein-coupled receptor. 
Since cyclic AMP is a second messenger the receptor-signaling is more amplified and 
consequently, assays based on cyclic AMP detection are more sensitive than 
[35S]GTPγS binding assay (Pertwee 1999). 
In this investigation the cyclic AMP assays were first carried out with a kit based on 
radioactive cyclic AMP detection and purchased by GE Healthcare (Amersham cyclic 
AMP [3H] assay kit). The production of this kit was interrupted in September 2009 
and the cyclic AMP assays were then carried out with a kit based on luminescence 
technology and purchased by DiscoveRx (HitHunter cyclic AMP assay kit). 
These experiments were performed in adherent native CHO (Chinese Hamster Ovary) 
cells or CHO cells overexpressing human CB1 receptor (hCB1-CHO cells) or human 
CB2 receptor (hCB2-CHO cells).  
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Importantly, since cannabinoids receptors are preferentially coupled to Gi/o proteins, 
to detect a response upon activation of these receptors is essential that the basal levels 
of cyclic AMP in the cells are high. For this purpose, cells were treated with forskolin 
(SIGMA), a direct activator of adenilate cyclase, which is able to increase the 
intracellular cyclic AMP levels.  
 
Amersham cyclic AMP [3H] assay kit 
The assay is based on the competition between unlabelled cyclic AMP (produced by 
the cells) and a fixed quantity of the tritium labeled cyclic AMP for binding to a 
protein which has a high specificity and affinity for cyclic AMP. The amount of 
labeled protein-cyclic AMP complex formed is inversely proportional to the amount 
of the unlabelled cyclic AMP present in the assay sample. Measurement of the 
protein-bound radioactivity enables the amount of unlabelled cyclic AMP in the 
sample to be calculated. 
Cells were grown in large flasks (175 cm2) for 3-4 days and collected the day of the 
experiment by washing once with 10 ml of cold PBS and detached using 10 ml non-
enzymatic cell dissociation solution. Cells were then collected and centrifuged at 1200 
rpm (revolutions per minute) for 5 min.  
After centrifugation, cells were resuspended (2 X 106 cells/ml) in assay buffer 
containing PBS (calcium and magnesium free), 1% BSA (bovine serum albumin) and 
10 mM of rolipram (SIGMA), a phosphodiesterase inhibitor which blocks the 
hydrolysis of cyclic AMP. Experiments were carried out in 1.5 ml tubes containing 
250 μl of resuspended cells, 190 μl of assay buffer and 50 μl of the cannabinoid under 
investigation and incubated for 30 min in a water bath at 37°C. In antagonism studies, 
the antagonist was pre-incubated with cells and buffer first for ten minutes before the 
addition of the cannabinoid. In this case only 140 μl of buffer was used to account for 
the extra 50 μl of antagonist. 
A further 30 min incubation was carried out with 10 μl of forskolin (10 μM for native 
CHO and hCB2-CHO cells, or 5 μM for hCB1-CHO cells) in a total volume of 500 
μL. The reaction was terminated by the addition of 500 μl HCl (0.1 M) and incubated 
for 15 min at room temperature in order to break the cellular membranes. The cellular 
lysate was then centrifuged at 14000 rpm for 5 minutes to remove cell debris. 200 μl 
of the supernatant was removed and 11 μl of NaOH (1 M) was added to bring the pH 
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to 8-9. 50 μl of each sample and cyclic AMP standards were then transferred to 1.5 ml 
tubes, and 50 μl of [3H] cyclic AMP and 100 μl of binding proteins were added. The 
tubes were then vortexed and incubated on ice for 2 hours. After incubation, 100 μl of 
charcoal solution (supplied with the kit) was added to each tube, followed by vortex 
and centrifugation at 14000 rpm for 5 min at 4°C. Finally, 200 μl of the supernatant 
was removed and 3 ml of scintillation liquid (Ultima Gold XR, PerkinElmer) was 
added. The samples radioactivity was measured using a liquid scintillation counter 
and the data were expressed as percentage of inhibition of cyclic AMP production. 
 
HitHunter cyclic AMP assay kit 
This assay is based on enzyme fragment complementation (EFC) technology which 
uses two fragments of E. coli β-galactosidase (β-gal): a large protein fragment 
(enzyme acceptor, EA) and a small peptide fragment (enzyme donor, ED). Separately, 
these fragments are inactive, but in solution they rapidly complement (recombine) to 
form active β-gal enzyme. 
In this assay, cyclic AMP from cell lysates and ED-labeled cyclic AMP (ED-cyclic 
AMP) compete for antibody binding sites. Unbound ED-cyclic AMP is free to 
complement EA to form active enzyme, which subsequently produces a luminescent 
signal. The amount of signal produced is proportional to the amount of cyclic AMP in 
the cell lysate. 
Cells were detached using cell dissociation buffer, counted and seeded at 2 x 104 cells 
per well in 100 μl of complete medium onto white 96-well plates with clear bottom, 
and incubated at 37°C and 5% CO2 for approximately 24 hours before running the 
experiment. In some experiments hCB2 CHO cells were preincubated with 10 mM of 
AM630 for up to 24 hours and then subjected to intense washing, 6 times for 10 min 
each, with complete medium (Mancini et al. 2009). The assays and the drug dilutions 
were performed in a 1:1 mixture of DMEM and Ham's F12 medium without phenol 
red (D-MEM ⁄ F-12 Media), containing 10 µM of rolipram and forskolin. Before 
running the assay, the medium was discarded and cells were washed once with D-
MEM⁄F-12 Media. Then, cells were treated with the assigned drugs (30 μl per well) 
and incubated for 30 min at 37°C and 5% CO2. Finally, cyclic AMP standards and the 
appropriate mixture of kit components were added (as described by the manufacturer, 
DiscoveRx). Plates were incubated overnight at room temperature in the dark. 
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Chemiluminescent signals were detected on a Synergy HT Multi-Mode Microplate 
Reader (BioTek, Winooski, VT, USA). Data were expressed as percentage of 





Values are expressed as mean and variability as standard error mean (SEM) or as 95% 
confidence limits (CLs). 
The concentration of the compounds under investigation that produced a 50% 
displacement of radioligand from specific binding sites (IC50) and the corresponding 
Ki values were calculated using GraphPad Prism 5 (GraphPad Software Inc., San 
Diego, CA). EC50 and Emax values were calculated by non-linear regression analysis 
using the equation for a sigmoid concentration-response curve in GraphPad Prism 5. 
The apparent dissociation constant (KB) values for antagonists were calculated by 
Schild analysis in GraphPad Prism 5, constraining Schild and Hill slope equal to 1. 
Therefore, KB values were calculated only from data obtained in experiments of 
antagonism in which the rightward shift in the agonist dose-response curve was 
indicated by (2 + 2) dose parallel line analysis to be statistically significant and not to 













Pharmacological properties of the 
phytocannabinoid  
∆9-tetrahydrocannabivarin  























∆9-Tetrahydrocannabivarin (∆9-THCV or THCV) is the n-propyl analogue of ∆9-
tetrahydrocannabinol (∆9-THC). The discovery of this phytocannabinoid was made in 
1970 by Edward Gill (Gill, Paton & Pertwee 1970), who detected it in the tincture of 
cannabis BPC (British Pharmaceutical Codex), then a licensed medicine in UK.  
 
 
       




Molecular Mass 286.41 g/mol 




Figure 15. ∆9-THCV chemical structure and data.  
CAS (Chemical Abstracts Service) registry numbers are unique numerical identifiers for chemical 
elements, compounds, polymers, biological sequences, mixtures and alloys. 
SMILES (simplified molecular input line entry specification) is a specification for unambiguously 
describing the structure of chemical molecules using short ASCII strings. 
 
Differently from other phytocannabinoids, the biosynthesis of n-propyl 
phytocannabinoids (or their analogues) has been suggested to use a different precursor 
than olivetol, namely 4-carboxy-5-propylresorcinol ((Russo 2007); see general 
introduction). ∆9-THCV is found in large amounts in Cannabis indica, where in some 
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varieties it can reach a very high percentage of the total cannabinoid content (e.g. 
48.23 percent in the Afghanistan strain and 53.69 percent in the South Africa strain) 
(Turner, Hadley & Ps 1973).  
∆9-THCV is metabolized by human hepatocytes to 11-nor-∆9-tetrahydrocannabivarin-
9-carbocilic acid (THCV-COOH). Since this metabolite is excreted through urines, 
the content of THCV-COOH in urine specimens has been proposed as a marker to 
distinguish the ingestion of Marijuana versus Marinol® (ElSohly et al. 1999). 
Recently, a double-blind placebo-controlled trial, conducted with 117 patients, failed 
in the detection of THCV-COOH content in the urines of 50% of the patients smoking 
cannabis, suggesting that THCV may not be a sensitive enough measure to detect 
recent marijuana use. However, the different content of ∆9-THCV in cannabis 
varieties has been suggested as a possible explanation for the lack of THCV detection 
(Levin et al. 2010). 
 
 
Pharmacological properties of the phytocannabinoid ∆9- tetrahydrocannabivarin  
 
Preliminary pharmacological studies showed that ∆9-THCV shares the ability of ∆9-
THC to induce catalepsy in the mouse ring test, and that it can induce ∆9-THC-like 
effects in humans, although with a potency four or five times less than that exerted by 
∆9-THC (Gill, Paton & Pertwee 1970, Merkus 1971). These results were later 
confirmed with synthetic ∆9-THCV (O-4394), which has been shown to produce not 
only cataleptic behaviour in the ring test, but also antinociception in the tail-flick test, 
confirming the THC-like effects exerted by ∆9-THCV (Pertwee et al. 2007). Like ∆9-
THCV extracted from cannabis (e∆9-THCV), O-4394 exhibited less potency than ∆9-
THC in these bioassays. Moreover, the anti-nociceptive effect of O-4394 was 
attenuated by the selective CB1 receptor antagonist/inverse agonist, SR141716A, 
suggesting ∆9-THCV to be an agonist at CB1 receptors (Pertwee et al. 2007). This 
finding was supported by displacement binding experiments on mouse whole brain 
membranes, where CB1 receptors are higher expressed than CB2 receptors. In these 
assays, both e∆9-THCV and O-4394 were able to displace the non-selective 
cannabinoid receptor agonist, [3H]CP55940, from specific binding sites, with Ki 
values of 75.4 nM and 46.6 nM, respectively (Thomas et al. 2005, Pertwee et al. 
2007).  
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While these results show that ∆9-THCV acts as agonist at CB1 receptors in vivo, there 
is also evidence that it can behave as antagonist at these receptors both in vivo and in 
vitro. Thus, the administration of O-4394 to mice at doses below those at which it 
produces signs of CB1 receptor agonism, showed the ability of this compound to 
block ∆9-THC-induced anti-nociceptive and hypothermia effects, which are thought to 
be CB1 receptor mediated (Pertwee et al. 2007). Besides, ∆9-THCV has recently been 
shown to suppress food intake and weight gain in mice (Riedel et al. 2009), an effect 
shared by the selective CB1 receptor antagonists, SR141716A and AM251.  
In vitro, both O-4394 and e∆9-THCV have been found to antagonize CB1 receptor 
agonists in a surmounTable manner. In detail, both O-4394 and e∆9-THCV 
antagonize CP55940-induced stimulation of [35S]GTPγS binding to mouse whole 
brain membranes with mean apparent KB values (82 and 93nM, respectively) that do 
not deviate significantly from their Ki values for displacement of [3H]CP55940 from 
these membranes, suggesting that the antagonism is at CB1 receptors (Thomas et al. 
2005, Pertwee et al. 2007). Moreover, ∆9-THCV showed antagonism also in 
experiments with the mouse vas deferens, a tissue in which cannabinoid receptor 
agonists are thought to inhibit electrically-evoked contractions by acting on 
prejunctional neuronal CB1 receptors to inhibit contractile transmitter release 
(Pertwee 2008).  
Conversely from in vivo data, ∆9-THCV (O-4394) when tested alone in the 
[35S]GTPγS binding assay on mouse whole brain membranes, did not produce any 
detecTable activity (Pertwee et al. 2007). One possible explanation of the apparent 
discrepancy between the in vitro and in vivo data could be that ∆9-THCV is 
metabolized in vivo to a compound with higher efficacy as a cannabinoid receptor 
agonist (Pertwee 2008). Given the structural similarities between ∆9-THC and ∆9-
THCV, this hypothesis is supported by two findings: 
1. ∆9-THC exhibits less potency in vivo as a CB1 receptor agonist than its 11-
hydroxy metabolite (Pertwee 2008).  
2. ∆9-THCV can be metabolized to a 11-hydroxy metabolite (Pertwee 2008).  
Additional in vitro evidence that ∆9-THCV can block the activation of neuronal CB1 
receptors comes from experiments with murine cerebellar slices, in which ∆9-THCV 
has been shown to block CB1-mediated inhibition of GABA release from basket-cell 
interneurons caused by R-(+)-WIN55212 (Ma et al. 2008). The same group has also 
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demonstrated the ability of ∆9-THCV to antagonize R-(+)-WIN55212 in both 
cerebellum and piriform cortex membranes (pA2 values of 7,62 and 7.44, 
respectively) (Dennis, Whalley & Stephens 2008). 
Interestingly, based on the results observed for ∆9-THCV at CB1 receptors, “GW 
Pharaceuticals” started, in 2007, a phase 1 clinical trial on ∆9-THCV as a potential 
drug for treatment of obesity and related metabolic disorders 
(http://www.gwpharm.com/Metabolic%20Disorders.aspx). 
Regarding the pharmacology of ∆9-THCV on CB2 receptors, only few experiments 
have been conducted so far. Specifically, displacement binding assays performed in 
CHO (Chinese Hamster Ovary) cells transfected with human CB2 receptor (hCB2-
CHO cells) have shown the ability of ∆9-THCV to displace quite potently 
[3H]CP55940 from specific binding sites, with a Ki value of 62.8 nM. Moreover, in 
the same cell membranes, ∆9-THCV has been shown to antagonize the non-selective 
cannabinoid receptor agonist, CP55940, in a surmounTable manner, with a KB value 
of 10.1 nM (Thomas et al. 2005). Further investigations are required to better 
understand the pharmacology of ∆9-THCV at CB2 receptors. 
 
 
AIMS OF THE PROJECT 
 
The present work was directed at the pharmacological characterization of ∆9-THCV at 
cannabinoid receptors.  
From the few data reported in literature it emerges that there are some controversial in 
vitro and in vivo results regarding the pharmacology of ∆9-THCV at CB1 receptors, in 
particular for its agonistic properties. With the aim of further characterizing ∆9-
THCV, the present investigation focused on the in vitro pharmacology of this 
phytocannabinoid at CB1 receptors by using several assays both in mouse whole brain 
membranes and in CHO cells overexpressing human CB1 receptors (hCB1-CHO 
cells). 
It was also of our interest to investigate the pharmacology of ∆9-THCV at CB2 
receptors. Specifically, the few data present in the literature prompted us to perform 






1) Pharmacological properties of ∆9-tetrahydrocannabivarin at CB1 
receptors 
 
∆9-THCV displaces [3H]CP55940 at CB1 receptors 
 
With the aim of investigating the affinity of ∆9-THCV for CB1 receptors, 
displacement binding assays on mouse whole brain membranes, which naturally 
express these receptors, were first carried out. In addition, as already introduced in the 
Material and Methods section, a new sample processing method had been set up in 
order to obtain a higher amount of proteins. Hence, with the further aim of validating 
this new sample processing method, displacement binding experiments on mouse 
whole brain membranes were performed in parallel with the old and new sample 
processing protocols. The radioligand  [3H]CP55940 was used to occupy CB1 receptor 
binding sites and the displacement was quantified as a percentage of specific binding 
produced in the presence of 1 μM of the unlabelled ligand CP55940.  
 
 
Table 10. The Table reports the mean parameters resulting from the displacement binding assay in  
mouse whole brain membranes using the two different processing protocols. The labelled and the 
unlabelled compounds were [3H]CP55940 and ∆9-THCV, respectively. The 95% of Confidence Limits 






 Old protocol New protocol 
Specific Binding 71.5% (±0.3%) 58.3% (±5.9%) 
Emax 97.6% (95-100.3%) 96.7% (91-102.5%) 
EC50 40.9 nM (32.8-50.9 nM) 41 nM (25.7-65.4 nM) 

















Figure 16. Displacement of [3H]CP55940 by ∆9-THCV on mouse whole brain membranes with (A) old 
protocol (n=4) and (B) new protocol (n=4). Each symbol represents the mean percentage displacement 
± SEM.  
 
As previously published in this laboratory (Thomas, 2005), ∆9-THCV fully displaced 
[3H]CP55940 in mouse whole brain membranes (Figure 16, Table 10), with a 
moderately strong affinity versus [3H]CP55940 binding sites, as shown by Ki values 
in the namolar range (Table 10). Moreover, no differences were observed between the 
membranes obtained with the two different processing protocols (Table 10), 
validating the new assay method. 
Since the brain expresses not only CB1 receptors but also CB2 receptors, and CP55940 
is a non-selective cannabinoid receptor ligand, experiments of displacement binding 














































































Figure 17. Displacement of [3H]CP55940 by ∆9-THCV from specific binding sites on hCB1-CHO cells 
(n=4). Each symbol represents the mean percentage displacement ± SEM. 
 
As shown in Figure 17, ∆9-THCV fully displaced [3H]CP55940  from specific binding 
sites in hCB1-CHO cell membranes with a Ki of 9.5 nM (95% CL 6.1 and 14.8 nM). 
and an Emax of  87.7% (95% CL 82.8 and 92.5%). 
 
∆9-THCV does not stimulate [35S]GTPγS binding at CB1 receptors 
 
As previously published in this laboratory, ∆9-THCV does not stimulate [35S]GTPγS 
binding in mouse whole brain membranes (Thomas et al. 2005). However, as above 
mentioned, a new sample processing protocol had been set up. Hence, in order to 
further confirm the activity of ∆9-THCV in mouse whole brain membranes, 
















































Figure 18. The effect of ∆9-THCV on [35S]GTPγS binding to whole brain membranes obtained from 
MF1 mice (n=8). Each symbol represents the mean percentage change in binding ± SEM. None of the 
concentrations of ∆9-THCV tested were significantly different from zero (one sample t-test analyses).  
 
As shown in Figure 18, ∆9-THCV did not display any stimulation on [35S]GTPγS 
binding to mouse whole brain membranes, confirming data already published in 
literature (Thomas et al. 2005).  
However, since the brain expresses different types of GPCRs (G protein-coupled 
receptors), with the aim of establishing the specific activity of ∆9-THCV at CB1 
receptors, we carried out experiments using the [35S]GTPγS binding assay in 

















































Figure 19. The effect of ∆9-THCV on [35S]GTPγS binding to hCB1-CHO cell membranes (n=4). None 
of the concentrations of ∆9-THCV tested are significantly different from zero (one sample t-test 
analyses). 
 
We found that ∆9-THCV did not stimulate [35S]GTPγS binding in hCB1-CHO cell 
membranes (Figure 19). In addition, ∆9-THCV at concentrations of 10 µM showed a 
slight, although not statistically significant inverse agonism in these membranes. 
 
∆9-THCV antagonizes CP55940 in the [35S]GTPγS binding assay 
 
Further experiments were carried out aimed at investigating the potential antagonistic 
properties of ∆9-THCV at CB1 receptors. As previously published by this group, ∆9-
THCV has been shown to antagonize the non-selective cannabinoid receptor agonists, 
CP55940 and WIN55212, in both mouse brain membranes and vas deferens, with KB 
values in the nanomolar range (Thomas et al. 2005). To further confirm these results, 
∆9-THCV was tested at 1 μM as antagonist of CP55940 in mouse whole brain 











































Figure 20. The effect of 1 μM ∆9-THCV on the mean log concentration-response curve of CP55940 
for stimulation of [35S]GTPγS binding to mouse whole brain membranes. Each symbol represents the 
mean percentage change in binding of [35S]GTPγS to mouse whole brain membranes ± SEM (n=8). 
The right-ward shift produced by ∆9-THCV in the log concentration-response curve of CP55940 did 
not deviate significantly from parallelism (P>0.20) (2+2 dose parallel line analysis). 
 
The ability of CP55940 to stimulate [35S]GTPγS binding to mouse brain membranes 
was attenuated by ∆9-THCV (Figure 20), which at 1 μM produced a significant 
dextral shift in the log concentration-response curve of this cannabinoid receptor 
agonist that did not deviate significantly from parallelism. The mean apparent KB 
value for this antagonism was 22.4 nM (95% CL 16.4 and 34.2 nM), which is very 
similar to the Ki value obtained from [3H]CP55940 displacement binding assay in the 
same membranes (Table 10). 
With the aim of elucidating whether the antagonism observed was CB1 receptor-
mediated, ∆9-THCV was then tested at 1 μM against CP55940 in the [35S]GTPγS 
binding assay using hCB1-CHO cell membranes. 
The first set of these experiments showed that CP55940-induced stimulation of 
[35S]GTPγS binding to hCB1-CHO cell membranes was significantly antagonized by 
∆9-THCV at 1 μM (Figure 21A). However, ∆9-THCV at this concentration appeared 
to produce inverse agonism as displayed by a downward shift in the log 
concentration-response curve of CP55940. Subtracting the inverse agonism, a 



























significant rightward shift in the log concentration-response curve of CP55940 was 
still apparent (Figure 21B). Importantly, the mean apparent KB value calculated for 
the rightward shift (Table 11) did not differ significantly from the mean Ki value of 
∆9-THCV for displacement of [3H]CP55940 from hCB1-CHO cell membranes (Table 
10). 
As shown in Figure 21C and E, ∆9-THCV at these concentrations was still able to 
antagonize CP55940-induced stimulation of [35S]GTPγS binding to hCB1-CHO cell 
membranes. Again, ∆9-THCV appeared to produce both a rightward and a downward 
shift in the log concentration-response curve of the agonist. Importantly, after 
compensating for the downward shift (Figure 21D and F), it was found that the mean 
apparent KB values did not differ significantly between the different concentrations of 
∆9-THCV tested, as indicated by an overlap in the 95% confidence limits (Table 11). 
Besides, none of the mean apparent KB values differed significantly from the mean Ki 
value of ∆9-THCV for displacement of [3H]CP55940 from both brain and hCB1-CHO 
cell membranes (Figure 16 and 17). Since the rightward shift did not deviate 
significantly from parallelism for all the concentrations of ∆9-THCV tested, it is likely 
that ∆9-THCV is a competitive antagonist at CB1 receptors. 
Interestingly, ∆9-THCV at the concentrations of 1 μM and 100 nM displayed an 
increase in the Emax of the log concentration-response curve of the agonist tested 
































































































                              
 
 
Figure 21. The effects of different concentrations of ∆9-THCV (A, C and E) on the mean log 
concentration-response curve of CP55940 for stimulation of [35S]GTPγS binding to hCB1-CHO cell 
membranes. The effect of different concentrations of ∆9-THCV (B, D and F) on the mean log 
concentration-response curve of CP55940 for stimulation of [35S]GTPγS binding after subtraction of 
the mean inhibitory effect induced by each concentration of ∆9-THCV in the presence of the lowest 
concentration of CP55940. Each symbol represents the mean percentage change in binding of 
[35S]GTPγS to hCB1-CHO cell membranes ± SEM (n=4). The rightward shift produced by all 
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concentrations of ∆9-THCV tested in the log concentration-response curve of CP55940 do not deviate 
significantly from parallelism (P>0.05 for B and P>0.2 for D and F). 
 
Table 11. The mean apparent KB values of ∆9-THCV for antagonism of CP55940-induced stimulation 
of [35S]GTPγS binding to hCB1-CHO cell membranes. 
1Calculated after the subtraction of the mean inhibitory effect induced by each concentration of ∆9-
THCV in the presence of the lowest concentration of CP55940. 
CLs, confidence limits. 
 
∆9-THCV is an inverse agonist at hCB1 receptors in the cyclic AMP assay  
 
As ∆9-THCV displayed signs of inverse agonism when tested as an antagonist of 
CP55940 in the [35S]GTPγS binding to hCB1-CHO cell membranes, it was of our 
interest to investigate this phytocannabinoid in a more sensitive assay, the cyclic 
AMP test (Pertwee 1999). We found that, unlike CP55940 (Figure 22B), ∆9-THCV 
yielded an increase on forskolin-induced cyclic AMP production when tested using 
hCB1-CHO cells, thus behaving as an inverse agonist at CB1 receptors (Figure 22A).  
As shown in Figure 23A, the ability of ∆9-THCV to enhance forskolin-induced 
stimulation of cyclic AMP production was not observed in hCB1-CHO cells when 
these had been preincubated overnight with pertussis toxin (PTX) in a manner 
expected to eliminate Gi/o -mediated signalling (Bonhaus et al. 1998, Glass, Felder 
1997, Coutts et al. 2001). In contrast, the effect of CP55940 on cyclic AMP 
production switched from an inhibitory to a stimulatory effect in response to such 
preincubation to pertussis toxin (Figure 23B), presumably reflecting the reported 
ability of CB1 receptors to activate Gs proteins in the absence of functional Gi/o 




Antagonist concentration Mean apparent KB (95% CLs) Mean apparent KB (95% CLs)1 n 
       ∆9-THCV 1 μM                  3.5 nM (1.8 and 6.9 nM)  19.6 nM (8.3 and 46.6 nM) 4 
∆9-THCV 100 nM      2 nM (0.9 and 4.8 nM) 67.6 nM (11.8 and 386.7 nM) 4 
















Figure 22. The effect of ∆9-THCV (A) and CP55940 (B) on forskolin-induced stimulation of cyclic 
AMP production in CHO cells transfected with hCB1 receptor. The mean Emax and EC50 values of ∆9-
THCV (A), with 95% CLs shown in brackets, were -38.9% (50.1 and 27.7%) and 3.6 nM (0.3 and 35 
nM), respectively. The correspondent values of CP55940 (B) were 72.7% (62.6 and 82.9%) and 11.2 














Figure 23. The effect of ∆9-THCV (A) and CP55940 (B) on forskolin-induced stimulation of cyclic 
AMP production in hCB1-CHO cells preincubated overnight with pertussis toxin (PTX 100 ng/ml). The 
mean Emax value of ∆9-THCV (7 %) in A did not differ significantly from zero (one sample t-test 
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analyses). The mean Emax and EC50 values of CP55940 (B), with 95% CLs shown in brackets, were -
66.2% (-79.3 and -53.2%) and 6.5 nM (1.4 and 30 nM), respectively. The assays were performed using 
a kit purchased by GE Healthcare. 
When cyclic AMP assays were performed in untransfected CHO cells, neither ∆9-
THCV nor CP55940 produced any detecTable effect on forskolin-stimulated cyclic 















Figure 24. The effect of ∆9-THCV (A) and CP55940 (B) on forskolin-induced stimulation of cyclic 
AMP production in untransfected CHO cells. None of the concentrations of ∆9-THCV and CP55940 
tested differ significantly from zero (one sample t-test analyses). The assays were performed using a kit 
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2) Pharmacological properties of ∆9-tetrahydrocannabivarin at CB2 
receptors 
 
∆9-THCV displaces [3H]CP55940 at CB2 receptors 
 
In order to assess the affinity of ∆9-THCV at CB2 receptors, experiments of 
displacement binding were carried out in CHO cells transfected with human CB2 
receptors (hCB2-CHO cells), using ∆9-THCV at concentrations from 1 up to 10000 
nM. The displacement was quantified as a percentage of specific binding produced in 















Figure 25. Displacement of [3H]CP55940 by ∆9-THCV (A) and CP55940 (B) from specific binding 
sites on hCB2-CHO cells (n=8). Each symbol represents the mean percentage displacement ± SEM. 
 
∆9-THCV was able to completely displace [3H]CP55940 from CB2 receptor binding 
sites (Figure 25A), as shown by its Emax of 102.3 % (95% CL 97.5 and 107.1%). The 
mean Ki value resulting from this displacement was 225.1 nM (95% CL 170.4 and 
297.5 nM), which is 3.6 times higher than the mean Ki value reported previously in 
literature using the same method (Thomas et al. 2005).  
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In order to better understand the reason underlying this difference, we then carried out 
experiments looking at [3H]CP55940 displacement in hCB2-CHO cells using the 
cannabinoid agonist, CP55940, as the cold ligand (Figure 25B). CP55940 was able to 
fully displace [3H]CP55940 with Emax and Ki values of 103.4% (95% CL 95.5 and 
108.4%) and 13.4 nM (95% CL 10.1 and 17.8 nM), respectively. Importantly, the 
mean Ki value displayed by CP55940 was still above the Ki value reported in 
literature (Schire, 1996). The high expression of hCB2 receptors in these cells (215 
pmol/mg) could explain the reason of such high Ki values. In fact, one likely effect of 
a large receptor concentration is to reduce the potency with which a tritiated ligand is 
displaced from its specific binding sites by an unlabelled compound (Kenakin 1997). 
In light of this, we then performed experiments of displacement binding, using the 
same conditions as above, in CHO cells expressing lower amount of human CB2 














Figure 26. Displacement of [3H]CP55940 by ∆9-THCV  (A) and CP55940 (B) from specific binding 
sites on CHO cells expressing lower amount of human CB2 receptors (n=8). Each symbol represents the 
mean percentage displacement ± SEM. Mean Ki values, with 95% confidence limits shown in brackets, 
were (A) 51.6 nM (42 and 63.4 nM) for displacement with ∆9-THCV and (B) 5.3 nM (3.6 and 7.8 nM) 
for displacement with CP55940.  
 
Both ∆9-THCV and CP55940 were able to fully displace [3H]CP55940 from CB2 
receptor binding sites, as the Emax values obtained were 106.3% (95% CL 102.4 and 
110.1%) and 102.1% (95% CL 96 and 108.3%), respectively (Figure 26). The Ki 
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values displayed by both these compounds were in line to those reported in literature 
(Thomas et al. 2005, Shire et al. 1996), confirming our hypothesis. 
∆9-THCV behaves as CB2 receptor partial agonist 
 
The high affinity exerted by ∆9-THCV at CB2 receptors prompted us to investigate the 
effect of this phytocannabinoid on [35S]GTPγS binding to hCB2-CHO cell 
membranes. The experiment was carried out in parallel with the non-selective 














Figure 27. The effect of (A) ∆9-THCV (n=8) and (B) CP55940 (n=4) on [35S]GTPγS binding to hCB2-
CHO cells. Each symbol represents the mean percentage change in [35S]GTPγS binding ± SEM. The 
mean EC50 and Emax values of these cannabinoids are listed in Table 12. 
 
As shown in Figure 27, both ∆9-THCV and CP55940 were able to stimulate 
[35S]GTPγS binding to membranes obtained from hCB2-CHO cells. In particular, the 
efficacy of ∆9-THCV in stimulating [35S]GTPγS binding was lower compared to that 


























































Table 12. The mean Emax values ± SEM and the mean EC50 values, with 95% confidence limits (CLs) 
are in brackets for the efficacy of tested cannabinoids in hCB2-CHO cells. 
1cAMP assay kit based on radioactive reagents and purchased by GE Healthcare. 
2cAMP assay kit based on luminescence reaction, patented and purchased by DiscoverX. 
 
To confirm these data, we investigated whether ∆9-THCV was able to inhibit 
forskolin-induced stimulation of cyclic AMP production in hCB2-CHO cells. Again, 














Figure 28. The effect of (A) ∆9-THCV  (n=8) and (B) CP55940 (n=4) on forskolin-induced cyclic 
AMP production in hCB2-CHO cells. Symbols represent mean values ± SEM. The mean EC50 and Emax 
Cannabinoid Assay Emax %   stimulation above basal 
EC50   
(95% confidence limits) 
∆9-THCV [35S]GTPγS binding 26.3 ± 2.8 66.6 nM (14.3 and 311 nM) 
CP55940 [35S]GTPγS binding 44.6 ± 2.3 0.8 nM (0.3 and 2.1 nM) 
∆9-THCV Cyclic AMP1 40 ± 3.9 38.1 nM (11.7 and 124 nM) 
CP55940 Cyclic AMP1 54.7 ± 2.5 6.8 nM (3.5 and 13.8 nM) 
∆9-THCV Cyclic AMP2 39 ± 4.2 23.1 nM (4.9 and 109 nM) 
CP55940 Cyclic AMP2 87.7 ± 2.4 1.9 nM (1.2 and 2.9 nM) 
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values of these cannabinoids are listed in Table 12. The experiments were performed with a kit 
purchased by GE Healthcare. 
 
As shown in Figure 28A, we found that ∆9-THCV at concentrations in the nanomolar 
range can indeed induce such inhibition in this bioassay, with an EC50 very similar 
and not significantly different to that reported in the [35S]GTPγS binding assay (Table 
12). However, the Emax showed by ∆9-THCV in the cyclic AMP assay was 
approximately 10% higher compare to that shown in stimulating [35S]GTPγS binding 
(Table 12) 
Differences between the two assays were indeed found for CP55940 (Table 12). In 
fact, although this full agonist showed an inhibition of forskolin-induced cyclic AMP 
production in hCB2-CHO cells (Figure 28B), CP55940 displayed an higher efficacy 
but a lower affinity versus CB2 receptors in this bioassay (Table 12). The different 
Emax obtained between the [35S]GTPγS binding and cyclic AMP assay could be due 
by the higher sensitivity displayed by cyclic AMP assay (Pertwee 1999). 
Importantly, the cyclic AMP analyses were conducted with a kit purchased by GE 
Healthcare and based on radioactive reagents. However, the sudden interruption in 
the supply of this kit production, forced us to move and try different technologies 
based on cyclic AMP detection. Among those ones available, we chose a kit patented 
and purchased by DiscoverX, based on luminescence technology. We then 
investigated the activity of ∆9-THCV and CP55940 on forskolin-induced cyclic AMP 





























Figure 29. The effect of (A) ∆9-THCV (n=8) and (B) CP55940 (n=4) on forskolin-induced cyclic 
AMP production in hCB2-CHO cells. Symbols represent mean values ± SEM. The mean EC50 and Emax 
values of these cannabinoids are listed in Table 12. The experiments were performed with a kit 
purchased by DiscoverX. 
 
As shown in Figure 29, we found that both ∆9-THCV and CP55940 were indeed able 
to inhibit the production of cyclic AMP induced by forskolin. The EC50 displayed by 
these compounds were very similar and not significantly different compared to those 
found in the [35S]GTPγS binding assay (Table 12).  
Differences were instead found in the efficacy yielded by these compounds, which 
were significantly greater than those displayed in [35S]GTPγS binding assay (Table 
12). 
Summarizing, in relation to the efficacy window displayed by the full agonist, 
CP55940, in all of these assays, the log concentration-response curves displayed by 
∆9-THCV suggest it to be a partial agonist at hCB2 receptors. 
 
∆9-THCV activity at CB2 receptors: further evidences  
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In order to establish whether ∆9-THCV was acting at CB2 receptors, we first carried 
out experiments of antagonism using a CB2-selective antagonist/inverse agonist, 
AM630, on cyclic AMP assay.  
Thus, ∆9-THCV in the concentration range of 0.1 to 10000 nM was antagonized by 
AM630 at the concentration of 100 nM in hCB2-CHO cells. 
As already reported previously (Ross et al. 1999), we found that AM630 exerted a 
marked inverse agonism at CB2 receptors, masking the antagonistic properties of this 
compound (Figure 30). Thus, the lack of a CB2 receptor neutral antagonist (which will 
be the subject of the Chapter 2) prompted us to explore other strategies to assess the 
selective activity of ∆9-THCV at CB2 receptors.  
Firstly, as shown in Figure 31, we established that at concentrations of 0.1 nM to 10 
μM, neither ∆9-THCV nor CP55940 affected forskolin stimulated cyclic AMP 
production in hCB2–CHO cells when these had been preincubated overnight with 
pertussis toxin in a manner expected to eliminate Gi/o signalling (Bonhaus et al. 1998, 
Glass, Felder 1997, Coutts et al. 2001). 
Secondly, we tested the effects of these two compounds in the cyclic AMP assay in 
untransfected CHO cells. As previously shown (Figure 24), we found that none of the 
















































Figure 30. The effect of 100 nM of AM630 on the mean log concentration-response curve of ∆9-
THCV in forskolin-induced stimulation of cyclic AMP production in hCB2-CHO cells. Symbols 
















Figure 31. The effect of ∆9-THCV (A) and CP55940 (B) on forskolin-induced stimulation of cyclic 
AMP production in hCB2-CHO cells preincubated overnight with pertussis toxin (PTX 100 ng/ml). 
Symbols represent mean values ± SEM. None of the doses tested for both ∆9-THCV and CP55940 are 











































































Pharmacological properties of ∆9-tetrahydrocannabivarin at CB1 
receptors 
 
Results from our in vitro experiments show that ∆9-THCV exhibits a strong affinity 
and antagonism at CB1 receptors.  
We first confirmed previous data (Thomas et al. 2005) in which ∆9-THCV displaced 
[3H]CP55940 from specific binding sites on membranes prepared from brain tissue 
(Figure 16). We found that the mean Ki value displayed by ∆9-THCV (31.5 nM) was 
two times lower than the one reported previously (Thomas et al. 2005) in the same 
membranes (75.4 nM). It is not possible that ∆9-THCV has more affinity for CB1 
receptors because the method used to process the brain tissues was different. In fact, 
no differences in the Ki values were found when the tissues were processed with the 
same protocol reported in Thomas et al. (2005) (Table 10). However, one possible 
explanation could be the purity of ∆9-THCV which might be slightly different 
compared to the past (Thomas et al. 2005). 
We also confirmed that ∆9-THCV does not affect [35S]GTPγS binding to mouse brain 
membranes (Figure 18), but instead it behaves as a reasonably potent antagonist 
versus the CB1/CB2 cannabinoid receptor selective ligand, CP55940 (Figure 20). In 
particular, ∆9-THCV displayed an antagonism at CB1 receptors which is competitive 
in nature, as shown by a significant dextral shift in the log concentration-response 
curve of CP55940 that did not deviate significantly from parallelism. Interestingly, 
the KB value displayed by ∆9-THCV for its antagonism of CP55940 (22.4 nM) was 
approximately four times lower than that previously found in this laboratory (93 nM) 
(Thomas et al. 2005). Again, the purity of ∆9-THCV might explain the difference in 
KB values.  
Importantly, the mean KB value showed by ∆9-THCV did not differ significantly from 
the mean Ki value for displacement of [3H]CP55940 to mouse brain membranes, 
suggesting that ∆9-THCV is acting at CB1 receptors. In fact, there is little evidence for 
the presence of a significant population of CB2 receptors in healthy brain tissue 
(Howlett et al. 2002). 
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Further support to this hypothesis comes from results obtained in CHO cells 
transfected with human CB1 receptors. First we found that ∆9-THCV was indeed able 
to displace [3H]CP55940 from specific binding sites on membranes prepared from 
hCB1-CHO cells (Figure 19). The Ki value displayed by ∆9-THCV (9.5 nM) was 3.3 
times lower than the reported Ki value found in mouse brain tissue (31.5 nM). It is 
likely that ∆9-THCV has more affinity for the human form of the CB1 receptor 
compared to the mouse one, and/or the expression of different receptor populations in 
the brain tissue might influence the binding of ∆9-THCV to CB1 receptors.  
As in mouse brain membranes, ∆9-THCV did not affect [35S]GTPγS binding on hCB1-
CHO cells at any of the concentrations tested (Figure 19). However, when this 
phytocannabinoid was tested  as antagonist of CP55940, it was found that, in addition 
to a right-ward shift, the log concentration-response curve of CP55940 showed a 
down-ward shift (approximately 20%) at all the concentrations of ∆9-THCV tested 
(Figure 21). The ability of ∆9-THCV to inhibit [35S]GTPγS binding when tested as 
antagonist of CP55940 is not surprisingly. Previous data reported a similar effect for 
the CB2 receptor antagonist, SR144528 (Thomas et al. 2007). In this paper it was 
found that the inverse efficacy exerted by SR144528 on [35S]GTPγS was higher when 
the compound was tested as an antagonist of CP55940 than by itself (Thomas et al. 
2007). The authors suggested that CP55940, being an agonist and according to the 
two-state model, would be expected to shift the equilibrium of the receptors from R to 
R* and so increase the number of receptors in the constitutive R* active state. Thus, it 
may be possible that ∆9-THCV did not affect the GTPγS by itself because the 
amounts of CB1 receptors in the constitutively active state were not sufficient. 
Importantly, when the component of ∆9-THCV -induced antagonism that seemed to 
arise from its ability to inhibit [35S]GTPγS binding to hCB1-CHO cell membranes was 
excluded, significant right-ward shifts in the log concentration-response curves of 
CP55940 were still apparent (Figure 21). Furthermore, the mean KB values calculated 
from these dextral shifts (Table 11) at all the concentrations of ∆9-THCV tested, did 
not differ significantly from the mean KB values obtained for the antagonism of 
CP55940 to mouse brain membranes, further supporting the hypothesis that ∆9-THCV 
is a CB1 receptor antagonist. In addition, the 2+2 analyses showed that the antagonism 
exerted by ∆9-THCV on CP55490 to hCB1-CHO cell membranes was not 
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significantly different from parallelism (Table 11), suggesting it to be competitive in 
nature.  
The cyclic AMP assay provided further information about the activity of ∆9-THCV at 
CB1 receptors. In contrast to the data obtained using the [35S]GTPγS binding assay, 
we found that ∆9-THCV by itself affected forskolin-induced stimulation of cyclic 
AMP production in hCB1-CHO cells, producing signs of inverse agonism (Figure 22). 
No ∆9-THCV-induced inverse agonism was observed in either untransfected CHO 
cells or in hCB1-CHO cells that had been preincubated with pertussis toxin, 
suggesting that this effect was indeed CB1 receptor mediated (Figure 23, 24). It is 
possible that ∆9-THCV behaved as inverse agonist in the cyclic AMP assay because 
CB1 receptor signalling is amplified in this assay compared to [35S]GTPγS binding 
assay (Pertwee 1999). Furthermore, it should be considered that the [35S]GTPγS 
binding assay is performed with an excess of GDP reagent, with the aim to decrease 
the basal activity of the receptor and increase the receptor responsiveness. However, 
this approach can affect the amount of R* (constitutively active receptors) and 
consequently influence the response of slight inverse agonists, such as ∆9-THCV. 
Whether ∆9-THCV can induce inverse agonism in vivo remains to be investigated. 
There is already evidence, however, that it can behave in vivo as a CB1 receptor 
antagonist. Thus, ∆9-THCV has been reported to suppress food intake and weight gain 
in mice (Riedel et al. 2009) and to attenuate several in vivo effects of ∆9-THC, 
including ∆9-THC-induced antinociception in the tail flick test and catalepsy in the 
ring test (Pertwee et al. 2007). 
 
Pharmacological properties of ∆9-tetrahydrocannabivarin at CB2 
receptors 
 
Results from our in vitro experiments indicate that ∆9-THCV exhibits significant 
potency and efficacy as a cannabinoid CB2 receptor agonist. Thus, ∆9-THCV shared 
the ability of the established CB1/CB2 receptor agonist, CP55940, both to inhibit 
forskolin-induced stimulation of cyclic AMP production by hCB2-CHO cells and to 
stimulate [35S]GTPγS binding to membranes obtained from these cells (Table 12). In 
addition, neither ∆9-THCV nor CP55940 inhibited cyclic AMP production either in 
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untransfected CHO cells or in hCB2-CHO cells that had been preincubated overnight 
with pertussis toxin in order to eliminate Gi/o mediated signalling (Figure 24, 31). 
In contrast to our results, it was previously found in this laboratory that ∆9-THCV 
opposes CP55940-induced stimulation of [35S]GTPγS binding to membranes derived  
from hCB2-CHO cells (Thomas et al. 2005) and that by itself ∆9-THCV does not 
behave as a CB2 receptor agonist in this bioassay (Thomas and Pertwee, unpublished). 
However, the CB2 receptor density determined by [3H]CP55940 saturation binding 
was three times lower in the CHO cells used in these previous experiments 
([3H]CP55940 Bmax = 72.57 pmol mg-1) than in the cells used in the present 
investigation (Methods). Hence, ∆9-THCV is most likely a hCB2 receptor partial 
agonist since, as predicted by classical drug receptor theory for an agonist of this kind 
(Kenakin 2001, Kenakin 1997), the efficacy that ∆9-THCV displays at hCB2 receptor 
appears to be greatly influenced by the expression levels of these receptors. Thus, ∆9-
THCV seems to undergo conversion from an apparent neutral hCB2 receptor 
antagonist (Thomas et al. 2005) to an apparent hCB2 receptor agonist in the 
[35S]GTPγS binding assay when the expression level of these receptors is increased 
(Figure 27). Moreover, the Emax displayed by ∆9-THCV for the activation of hCB2 
receptors both in the [35S]GTPγS binding (Figure 27) and cyclic AMP assays (Figure 
28, 29) is less than that of the full agonist, CP55940, further supporting that ∆9-THCV 
is a partial agonist at CB2 receptors. 
Importantly, the mean EC50 values of ∆9-THCV for inhibition of cyclic AMP 
production (Figure 29) and for stimulation of [35S]GTPγS binding (Figure 27) to 
hCB2-CHO cells were significantly less than its mean apparent Ki value (225 nM) for 
displacement of [3H]CP55940 from specific binding sites in the same cell membranes 
(Figure 25). However, this is because the mean apparent Ki value we obtained in 
hCB2-CHO cells, which express high levels of hCB2 receptors (Methods), was 
significantly above the true Ki value of ∆9-THCV for CB2 receptors. In fact, one 
likely effect of a large receptor population is to reduce the potency with which a 
tritiated ligand is displaced from its specific binding sites by an unlabelled compound 
(Kenakin 1997). Thus, when ∆9-THCV was tested in the displacement binding assay 
in CHO cells expressing lower amounts of hCB2 receptors, it displayed a Ki value of 
51.6 nM (Figure 26), which is in line and not significantly different to the EC50 values 
found in the above mentioned assays, thus confirming our hypothesis. 
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The ability of ∆9-THCV to activate CB2 receptors has also been tested in membranes 
obtained from mouse spleen, a tissue that is thought to express CB1 as well as CB2 
receptors (Pertwee 1997). The experiments were performed by a colleague in my 
present laboratory. It has been found that ∆9-THCV can indeed stimulate [35S]GTPγS 
binding to these membranes (Bolognini et al. 2010). Its EC50 and Emax values, with 
95% CLs shown in parentheses, were 69 nM (2.6 and 1804 nM) and 23% (3.8 and 
42%), respectively (n=6). Moreover, when experiments of [35S]GTPγS binding were 
performed in CB2-/- mice spleen membranes, ∆9-THCV did not show any effect 
(Bolognini et al. 2010), confirming the ability of this phytocannabinoid to selectively 
activate CB2 receptors in this tissue.  
Having obtained evidence that ∆9-THCV can activate naturally expressed mouse CB2 
receptors in vitro, we went on to investigate its ability to activate mouse CB2 
receptors in vivo. We began collaborations with Dr. Barbara Costa (University of 
Milano-Bicocca) and Dr. Sabatino Maione (University of Naples) directed at 
determining whether ∆9-THCV shares the ability of established selective CB2 receptor 
agonists (Guindon, Hohmann 2008) to ameliorate signs of inflammation and thermal 
hyperalgesia induced in rats or mice by intraplantar injection of λ-carrageenan or 
formalin. The data presented were recently published in a peer reviewed journal 
(Bolognini et al. 2010). 
Lambda carrageenan (λ-carrageenan) is a mucopolysaccharide extracted by the red 
alga, Chondrus crispus. The subcutaneous injection of this substance causes swelling 
and pain. In experiments conducted by Dr. Barbara Costa, 20 μl of λ-carrageenan 
(2%w/v in saline) were injected in the paw of C57/black mice with successive 
evaluation of the oedematous effects and thermal hyperalgesia, which were measured 
by a plethysmometer and a plantar test, respectively. At 2 hours after λ-carrageenan 
administration, it was found that pretreatment with ∆9-THCV at 0.3 mg/kg 
significantly reverted the λ-carrageenan-induced oedema effect (Figure 32A). 
Moreover, ∆9-THCV, at the doses of 0.3 and 1 mg/kg, was also found efficacious in 
reducing the thermal hyperalgesia induced by the injection of λ-carrageenan (Figure 
32B).  
Because λ-carrageenan-induced oedema and thermal hyperalgesia remained at a high 
level throughout an observation period of 24 h (Figure 33), the anti-inflammatory and 
anti-nociceptive responses elicited by ∆9-THCV at 0.3 mg/kg were investigated at 
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additional time points. It was found that the anti-oedema effect of ∆9-THCV was still 
present and unreduced at 3 and 4 h after λ-carrageenan administration, slightly 
reduced but still present at 6 h after λ-carrageenan, and absent at 24 h after λ-
carrageenan (Figure 33A). Similarly, the anti-hyperalgesic effect of ∆9-THCV 
decreased progressively over this same observation period and was no longer 
detecTable 24 h after λ-carrageenan administration (Figure 33B). The anti-
inflammatory and anti–hyperalgesic properties of ∆9-THCV were also tested at 
different time points within a 4 day time period. In detail, ∆9-THCV was administered 
at 0.3mg/kg, 30 min after λ-carrageenan injection, and then again once daily over the 
next 3 days. As shown in Figure 34, ∆9-THCV significantly diminished oedema and 
thermal hyperalgesia after its first injection, and these anti-oedema and anti-
hyperalgesic effects of ∆9-THCV remained undiminished after each of its subsequent 
injections.  
The possible target/s underlying the anti-oedema and anti-nociceptive effects of ∆9-
THCV were also investigated in the λ-carrageenan model by administration of the 
CB1 receptor antagonist, rimonabant, or the CB2 receptor antagonist, SR144528. 
These compounds were administered 15 min before ∆9-THCV (0.3 mg/kg), and 
evaluations of oedema and thermal hypersensitivity were made at 2 and 3 h after λ-
carrageenan, respectively. Figure 35A shows that only SR144528 was able to reverse 
the anti-oedema effect of ∆9-THCV, suggesting that this phytocannabinoid induced its 
anti-inflammatory effect primarily through activation of the CB2 receptor. However, 
rimonabant elicited a partial, although not statistically significant, reversal of ∆9-
THCV -induced anti-hyperalgesia, whereas SR144528, at doses that have been found 
to block the effect of an established CB2 receptor agonist in this assay (Guindon and 
Hohmann, 2008), produced no sign of any such reversal (Figure 35B). Importantly, 
the doses of rimonabant (0.5 mg/kg) and SR144528 (1 mg/kg) used in these 
experiments did not affect λ-carrageenan-induced paw oedema or thermal 
hypersensitivity when administered alone (data not shown). These data suggest that 
∆9-THCV is able to decrease signs of inflammation through the activation of CB2 
receptors, since the ability of this phytocannabinoid to reverse λ-carrageenan-induced 
oedema effect was antagonized by the CB2 receptor antagonist, SR144528. 
Conversely, the ∆9-THCV -mediated anti-hyperalgesic effects show a more 
complicated panorama, since neither CB1 nor CB2 receptors seem to be involved in 
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this effect. In order to clarify this aspect, ∆9-THCV was then tested in the formalin 
test assay, which is a model to measure the anti-nociceptive response of an established 
compound. In particular, the formalin test is characterized by two phases, which are 
separated by a transient quiescent period (Guindon, Hohmann 2008). The two phases 
are: 
1. Early phase (0-7 min), which involves acute activation of chemo, thermo and 
mechano-sensitive fibers (C- and A-delta fibers). 
2. Second phase (15-60 min), which is a prolonged phase of tonic pain and involves 
an inflammatory reaction in peripheral tissue, the development of CNS 
sensitization and additionally involves activation of primary afferent nociceptors.  
∆9-THCV was found to display dose-dependent activity against formalin-induced 
nociceptive behaviour (Figure 36). In detail, 30 μl of formalin (1.25% in saline) was 
injected subcutaneously into the hind paw of the mice. It was found that the 
intraperitoneal (i.p.) injection of ∆9-THCV reduced pain behaviour in both phases of 
the formalin test at a dose of 5 mg/kg (Figure 36A), which is in contrast with previous 
findings with established CB2 receptors agonists, as reported in several investigations 
to suppress the second phase but not the first phase of formalin-induced nocifensive 
behaviour (Guindon, Hohmann 2008, Whiteside, Lee & Valenzano 2007). However, 
∆9-THCV affected only the second phase when administered at the dose of 1 mg/kg 
(Figure 36A). The ameliorating effect of the higher dose of ∆9-THCV (5 mg/kg) on 
the first and second phases of the formalin response (Figure 36B) and of the lower 
dose of ∆9-THCV (1 mg/kg) on the second phase (Figure 36C) was attenuated by 
pretreatment with both rimonabant (0.5 mg/kg) and SR144528 (1 mg/kg). As for the 
λ-carrageenan test, the doses of rimonabant and SR144528 used in these experiments 
did not affect formalin-induced pain behaviour when administered alone (data not 
shown). The data obtained from the formalin test suggest that ∆9-THCV produces its 
anti-nociceptive effect by activating both CB1 and CB2 receptors. It is noteworthy 
therefore that ∆9-THCV has been found to behave in vivo, though not in vitro (Figure 
18, 19), as a CB1 receptor agonist at doses above those at which it produces signs of 
CB1 receptor blockade (Pertwee et al. 2007). Combined CB1 and CB2 receptor 
activation provides a possible explanation why ∆9-THCV-induced suppression of λ-
carrageenan-induced hyperalgesia is not antagonized by SR144528 at a dose at which 
this CB2-selective antagonist does antagonize λ-carrageenan-induced oedema. It 
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might also explain why the highest dose of ∆9-THCV tested was able to suppress both 
phases of formalin-induced pain behaviour. In fact, there is evidence that, in contrast 
to CB2-selective agonists, established mixed CB1/CB2 receptor agonists such as ∆9-
THC and CP55940 have the ability to suppress both phases of the formalin test 
(Pertwee 2001). Why the relatively low doses of ∆9-THCV would activate CB1 
receptors in addition to CB2 receptors remains to be established, one possible 
explanation being that it is a consequence of λ-carrageenan- and/or formalin-induced 
upregulation of the CB1 receptor in pain pathways, there already being evidence that 
such upregulation does occur in primary afferent neurons in at least one rodent model 
of inflammatory pain (Amaya et al. 2006). 
In conclusion, ∆9-THCV has the ability to activate human CB2 receptors in vitro, 
acting as partial agonist, and mouse CB2 receptors both in vitro and in vivo. 
Concerning CB1 receptors, it seems that ∆9-THCV is able to activate these receptors 
at high doses only in vivo (Pertwee et al. 2007) and not in vitro, where instead it 
exerts inverse agonistic properties (Figure 22). As already mentioned (see 
introduction) it is likely that ∆9-THCV is metabolized in vivo to a more potent 
compound with agonistic properties at CB1 receptors. On the other hand, it is clear 
that ∆9-THCV acts as a CB1 receptor antagonist both in vitro (Figure 20, 21) and in 
vivo (Pertwee et al. 2007, Riedel et al. 2009), at doses below those at which it behaves 
as an agonist in vivo. The antagonistic properties of ∆9-THCV at CB1 receptors make 
this phytocannabinoid an interesting drug for such diseases (e.g. chronic liver disease 
and stroke) in which there is evidence that symptoms can be ameliorated by a 
combination of CB2 receptor activation and CB1 receptor blockade (Mallat et al. 2007, 






































Figure 32. Effect of ∆9-THCV, administered i.p. 30 min before λ-carrageenan (2%, 20 mL 
intraplantar), on (A) oedema evaluated 2 h after λ-carrageenan, and (B) thermal hypersensitivity, 
evaluated 3 h after λ-carrageenan. The basal hind paw withdrawal latency displayed by vehicle-treated 
mice was 10 ± 0.45 s. Data represent mean values ± SEM (n = 9). °°P < 0.01, °°°P < 0.001 versus mice 






























































Figure 33. Effect of ∆9-THCV (0.3 mg·kg-1 i.p.), administered 30 min before λ-carrageenan (2%, 20 
mL intraplantar), on (A) oedema and (B) thermal hypersensitivity evaluated at different times after λ-
carrageenan. Data represent mean values ± SEM (n = 5). ***P < 0.001 versus mice treated with 




















































































Figure 34. Effect of ∆9-THCV (0.3 mg·kg-1 i.p.), administered after λ-carrageenan once daily for 4 
days, on (A) oedema and (B) thermal hypersensitivity. Data represent mean ± SEM (n = 6–8). °°°P < 
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Figure 35. Effect of rimonabant (RIM; 0.5 mg·kg-1 i.p.) and SR144528 (1 mg·kg-1 i.p.) on (A) anti-
oedema and (B) antinociceptive effects evoked by ∆9-THCV (0.3 mg·kg-1 i.p.). Antagonists were 
administered 15 min before ∆9-THCV, and behavioural evaluations were made 2 h (oedema) and 3 h 
(thermal hypersensitivity), after λ-carrageenan. Data represent mean values ± SEM (n = 8–10). °°P < 
0.01, °°°P < 0.001 versus mice treated with vehicle/ λ-carrageenan. $$$P < 0.001 versus mice treated 
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Figure 36. Effect on nociceptive behaviour evoked by formalin (1.25%, 30 mL s.c.) of ∆9-THCV when 
administered at different doses by itself (A) or at 5 mg·kg-1 (B) or 1 mg·kg-1 (C) in combination with 
SR144528 (1 mg·kg-1 i.p.) or rimonabant (0.5 mg·kg-1 i.p.). ∆9-THCV was administered 
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represent mean values ± SEM (n = 8). °P < 0.05 versus vehicle. *Nociceptive responses to formalin 
that were significantly greater after SR144528 + ∆9-THCV or rimonabant + ∆9-THCV than after ∆9-














































CHAPTER TWO        
 
 
Pharmacology of  
∆9-tetrahydrocannabivarin        


























A receptor antagonist is a ligand that is able to block or dampen the agonist-mediated 
biological responses. Antagonists are important pharmacological tools to evaluate the 
selective activity of a ligand to a particular receptor, and they can find application 
both in vitro and in vivo. As shown in Table 13, antagonists can be classified into two 
main classes (Vauquelin et al. 2002): 
1) SurmounTable antagonists. These ligands are competitive in nature since they 
reversibly bind the same binding site (orthosteric) of the endogenous ligand or 
agonist. Pharmacologically, surmounTable antagonists produce parallel rightward 
shift of agonist dose-response curves with no alteration of the maximal response 
(Figure 37A). Considering the receptor two–state model (see material methods, Figure 
13), a seven transmembrane receptor can be found in an inactive state (R) and an 
active state (R*). Consequently, surmounTable antagonists can be divided in 3 
different subclasses: 
A) Neutral antagonists. These ligands can bind both the active and inactive state of 
the receptor without altering the equilibrium between these two forms. When tested 
by itself in functional assays, a neutral antagonist does not provoke any receptor 
response. 
B) Partial agonists are ligands that induce a response in a functional assay, but their 
maximum response is less than the one elicited by a full agonist. Although they are 
agonists, partial agonists can act as a competitive antagonist in the presence of a full 
agonist, as they compete with the full agonist for receptor occupancy, thereby 
producing a net decrease in the receptor activation as compared to that observed with 
the full agonist alone. 
C) Inverse agonists preferentially bind the inactivated form of the receptor, reducing 
the amount of active receptors and consequently the intrinsic activity. Depending of 
the percentage of constitutive active receptors in the system, they can act both as 
antagonist or inverse agonist (Seifert, Wenzel-Seifert 2002, Milligan 2003a). 
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2) InsurmounTable antagonists. These ligands produce a rightward shift on agonist 
dose-response curves with an additional decrease in the maximal response (Figure 
37B). In turn, insurmounTable antagonists can be divided in: 
A) Non-competitive. These ligands antagonize the activity of an agonist through an 
interaction with the allosteric binding site of the same receptor (allosteric antagonism) 
or binding to an other receptor (functional antagonism). 
B) Competitive. Similar to the sourmounTable antagonists, these ligands bind the 
ortosteric site of the receptor, so they compete with the agonist to bind the receptor. 
However these antagonists bind the receptor irreversibly or they dissociate to it very 
slowly, thus depressing the agonist-induced maximal response (Figure 37B). 
 
 
Table 13. Schematic representation of the potential mechanisms for surmounTable and 











































Figure 37. Theoretical agonist dose-response curves with increasing concentrations of surmounTable 
antagonist (A) or competitive insurmounTable antagonist (B).    
 
 
Antagonists at CB2 receptors 
 
So far, the only antagonists available for CB2 receptors are ligands with both 
antagonist and inverse agonist properties. In particular, the most noTable CB2-
selective antagonists/inverse agonists are SR144528 and AM630 (6-iodopravolidone) 
(Figure 38). Both these compounds bind with much higher affinity to CB2 receptors 
than to CB1 receptors, exhibit marked potency as CB2 antagonists and behave as 
inverse agonists at CB2 receptors (Pertwee RG, Tocris Bioscience Scientific review 
Series). As aforementioned, inverse agonists are defined as ligands which maximally 
stabilize the inactive R state and reduce basal GDP/GTP exchange. In this regard, 
SR144528 is referred as a full inverse agonist since it maximally reduces the 
exchange between GDP and GTP, whereas AM630 is a partial inverse agonist as less 
efficient in this regard than full inverse agonists (Seifert, Wenzel-Seifert 2002).  
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Figure 38. AM630 and SR144528 chemical structures. SR144528 is a pyrazole analogue, whereas 
AM630 is an aminoalkylindole analogue. 
 
In light of this, the receptor constitutive activity is an important parameter when 
antagonists/inverse antagonists are tested as antagonists of endogenous ligand or 
agonist. In fact, in the presence of constitutive active receptors in the system, 
antagonists/inverse agonists can determine a marked downward shift in the agonist 














Figure 39. The effect of an antagonist/inverse agonist in the agonist dose-response curve on a 
biological system characterized by receptor constitutive activity.   
 
The receptor constitutive activity is defined as the ability of a GPCR (G-protein 
coupled receptor) to adopt an active conformation in the absence of an agonist 
SR144528 























(Seifert, Wenzel-Seifert 2002). Constitutive activity has been reported in both native 
and cellular overexpressing systems (Seifert, Wenzel-Seifert 2002). In particular, 
constitutive activity can be produced in a recombinant system by increasing the level 
of receptors expressed on the cell membranes. The dependence of constitutive activity 
on receptor density [Ri] is given by: 
 
                                       [RaG]                 [Ri] 
                                       [Gtot]            [Ri] + (KG/L) 
 
Equation 1. This equation defines the relation between receptor density [Ri] and constitutive active 
receptors [RaG]. L is the allosteric constant describing the propensity of the receptor to spontaneously 
adopt the active state, and KG is the equilibrium dissociation constant for the activated receptor/G-
protein complex.  
 
It can be seen from equation 1 that a hyperbolic relationship is predicted between 
constitutive activity and receptor concentration (Kenakin 2006).  
Constitutive active CB2 receptors in our cell system (hCB2-CHO cells) are 
documented by results reported in chapter 1. In fact, when AM630 was tested as 
antagonist of ∆9-THCV on forskolin-induced cyclic AMP production in hCB2-CHO 
cells, a marked downward shift of ∆9-THCV dose-response curve was observed 
(Figure 30). Thus, AM630 inverse agonism suggests the presence of CB2 
constitutively active receptors in our cell line.  
Hence, the usage of antagonists/inverse agonists in our cell system does not represent 
a good tool for evaluating the selective activity of a ligand at CB2 receptors, 









AIMS OF THE PROJECT 
 
The key points of this project were: 
1. Eliminate the inverse agonism showed by AM630 in our cell line (hCB2-CHO 
cells). 
2. Evaluate the possibility that AM630 becomes a neutral antagonist at CB2 
receptors after abolishment of the receptor constitutive activity. 
3. Confirm the selective activity of ∆9-THCV at CB2 receptors using AM630 as 
selective CB2 receptor neutral antagonist. 
 


























AM630 is an antagonist/inverse agonist at hCB2 receptors 
 
In our initial experiments, we investigated whether ∆9-THCV -induced inhibition of 
forskolin-stimulated cyclic AMP production by hCB2-CHO cells was susceptible to 
antagonism by the established selective cannabinoid CB2 receptor antagonist/inverse 
agonist, AM630. As expected, (Ross et al. 1999), AM630 by itself produced marked 
signs of inverse agonism in the cyclic AMP assay performed in hCB2-CHO cells 
(Figure 41A). In light of this, the highest concentration of AM630 at which it didn’t 















Figure 40. The effect of 100 nM of AM630 on the mean log concentration-response curve of (A) ∆9-
THCV (n=3) and (B) CP55940 (n=4) on forskolin-induced stimulation of cyclic AMP production in 
CHO cells transfected with hCB2 receptors. Symbols represent the mean values ± SEM. Mean EC50 
values of CP55940 and ∆9-THCV in the absence of AM630, with 95 % confidence limits shown in 
brackets, were 5.3 nM (1.2 and 22.7 nM) and 72.7 nM (20.3 and 260.5 nM), respectively. The 
corresponding mean Emax values were 78.3 % (62.1 and 94.3 %) and 33.8 % (21.5 and 46.1 %), 
respectively. 
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As shown in Figure 40A and 30, at 100 nM, AM630 displayed a marked and 
significant downward shift in the log concentration-response curve of ∆9-THCV for 
inhibition of cyclic AMP production in hCB2-CHO cells. Similar results have also 
been obtained when AM630 was used to antagonize the established CB1/CB2 receptor 
full agonist, CP55940 (Figure 40B). 
 
Abolition of constitutive activity at hCB2 receptors  
 
In order to eliminate the inverse agonism of AM630, hCB2-CHO cells were 
preincubated for 24 hours with the antagonist /inverse agonist AM630. This protocol 
has been previously demonstrated to abolish the receptor constitutive activity 
(Mancini et al. 2009, Seifert, Wenzel-Seifert 2002, Milligan 2003b, Chanrion et al. 
2008). Experiments of cyclic AMP were then carried out in parallel both in 








































































































Figure 41. The effect of (A) AM630 (n=3-4), (B) CP55940 (n=6), and (C) ∆9-THCV (n=8) on 
forskolin-induced stimulation of cyclic AMP production in unpreincubated and AM630-preincubated 
hCB2-CHO cells. Symbols represent the mean values ± SEM.  
 
As reported above, AM630 by itself, at concentrations in the range of 0.25 nM to 25 
μM, enhanced the ability of forskolin to stimulate cyclic AMP production in 
unpreincubated hCB2-CHO cells (Figure 41A), with EC50 and Emax values reported in 
Table 14. Conversely, when cells were preincubated for 24 hours, AM630 was no 
longer able to stimulate forskolin-induced cyclic AMP production (Figure 41A). 
Different scenario has been shown by the full agonist CP55940, which was able to 
inhibit forskolin-induced cyclic AMP production in both unpreincubated and AM630-
preincubated hCB2-CHO cells (Figure 41B). This it did with EC50 and Emax values 
that did not differ significantly between the two experimental conditions (Table 14). 
Similarly, the ability of ∆9-THCV (Figure 41C) to inhibit forskolin-induced cyclic 
AMP production was maintained in cells preincubated with AM630 (Figure 41C). 
However, ∆9-THCV displayed a significant higher efficacy in absence of 
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  Unpreincubated hCB2-CHO cells AM630-preincubated hCB2-CHO cells 
Compound EC50 (95% CLs) Emax (95% CLs) EC50 (95% CLs) Emax (95% CLs) 
AM630 239,1 nM  (65 and 879.1) 
-116.4 % 
(-142.6 and -90.3) ND ND 
CP55940 11.2 nM  (7 and 17.7) 
93.4 %  
(85.9 and 100.9) 
11.9 nM  
(8.6 and 16.6) 
100.9 % 
(94.5 and 107.2) 
∆9-THCV 123.3 nM  (37.7 and 403.6) 
123.3 %  
(32.1 and 54.3) 
298 nM 
(182 and 488) 
84.5 %  
(76 and 92.9) 
 
Table 14. EC50 and Emax values of AM630 (n = 3), CP55940 (n = 6) and ∆
9-THCV (n = 8) for 
inhibition of forskolin-induced stimulation of cyclic AMP production in unpreincubated and AM630-
preincubated hCB2-CHO cells.  
ND, non determined indicates that the drug had not effect on the assay. 
CLs, confidence limits. 
 
AM630 becomes an apparent neutral antagonist in AM630-preincubated hCB2-CHO 
cells   
 
The results obtained in AM630-preincubated hCB2-CHO cells raised the possibility 
that AM630 might behave as neutral antagonist in absence of constitutively active 
CB2 receptors. Then, to investigate this possibility, we carried out experiments of 
cyclic AMP to establish whether AM630 could still antagonize the CB1/CB2 receptor 
full agonist, CP55940, in hCB2-CHO cells preincubated with AM630.  
We found that AM630, at concentrations in the range of 0.1 μM up to 25 μM, did not 
display any downward shift on CP55940-induced inhibition of cyclic AMP 
production (n= 2-4). In detail, at 0.1 and 1 μM, AM630 did not display any downward 
and/or rightward shift in the log concentration-response curve of CP55940 (Figure 
42A and B). At 10 μM, AM630 displayed a slight antagonism on CP55940 dose-
response curve (Figure 42C), with a rightward shift not significantly different from 1. 
Again, no downward shift has been shown by AM630 at this concentration. At 25 
μM, AM630 displayed a significant antagonism on CP55940-induced inhibition of 
cyclic AMP production (Figure 42D). This it did with a mean apparent KB value of 
5.2 μM that was significantly higher than its apparent Ki value for displacement of 
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[3H]CP55940 from hCB2-CHO cells (Ross et al. 1999). Importantly, no downward 
shift was observed in the log concentration-response curve of CP55940, suggesting 
AM630 to be a neutral antagonist in absence of constitutively active CB2 receptors 
(Figure 42D). In addition, as this rightward shift did not deviate significantly from 
parallelism, it is likely that AM630, in these experimental conditions, behaves as a 
competitive antagonist at hCB2 receptors. 
In AM630-preincubated hCB2-CHO cells (Figure 42E), at 25 μM, AM630 
antagonized also ∆9-THCV-induced inhibition of cyclic AMP production. The mean 
apparent KB value for this antagonism was 2.1 μM, which did not differ significantly 
from the mean KB value for the antagonism of CP55940 by AM630. Again, this 





























































































































Figure 42. The effect of 0.1, 1, 10 and 25 μM of AM630 on the mean log concentration-response curve 
of (A, B, C, D) CP55940 (n=2-4) and (E) ∆9-THCV (n=4) on forskolin-induced stimulation of cyclic 
AMP production in hCB2-CHO cells preincubated with AM630. Symbols represent the mean values ± 
SEM. The mean apparent KB values of AM630 for its antagonism of CP55940 (D) and ∆9-THCV (E), 
with 95% confidence limits shown in brackets, were 5.2 μM (2.9 and 9.2 μM) and 2.1 μM (1.1 and 
4.1 μM), respectively. The rightward shift produced by AM630 in the mean lo concentration-response 
curve of both CP55940 (D) and ∆9-THCV (E) did not deviate significantly from parallelism ( p > 0.20). 
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AM630 antagonizes WIN55212-2 in AM630-preincubated hCB2-CHO cells   
 
The reason why AM630 displayed low affinity as both CP55940- and ∆9-THCV-
antagonist, in AM630-preincubated cells, is to be further investigated. One possible 
explanation is that AM630, unlike CP55940, is an aminoalkylindole. It could be 
possible that CP55940 and AM630 bind to hCB2 receptors using different binding 
pockets.  
With this in mind, we went on to investigate whether AM630 could antagonize more 
potently the CB1/CB2 receptor full agonist and amynoalkylindole analogue, 
WIN55212-2. We then carried out experiments of cyclic AMP using AM630-














Figure 43. The effect of 25 μM AM630 on the mean log concentration-response curve of  WIN55212-
2 (n = 4) on forskolin-induced stimulation of cyclic AMP production in hCB2-CHO cells preincubated 
with AM630. Symbols represent the mean values ± SEM. The mean apparent KB value, with 95 % 
confidence limits shown in brackets, was 6.9 μM (3.3 and 12.8 μM). The rightward shift produced by 
AM630 in the mean log concentration-response curve of WIN55212-2 did not deviate significantly 
from parallelism (p > 0.20). 
 
As shown in Figure 43, at 25 μM, AM630 was indeed able to antagonize WIN55212-
2 with a mean apparent KB value of 6.9 μM which was not significantly different 
from the one displayed to antagonize both CP55940 and ∆9-THCV. Again, no 

































downward shift was displayed by AM630 in the log concentration-response curve of 
WIN55212-2 (Figure 43). This result suggests that AM630 could interact and bind the 
same CB2 receptor binding pocket of CP55940. 
Taken together, these findings support the hypothesis that AM630 is a neutral 
antagonist at CB2 receptors in absence of constitutively active receptors, albeit with 
much less affinity for CB2 receptors in these experimental conditions than in 
unpreincubated hCB2-CHO cells (Ross et al. 1999). 
 
AM630-preincubation at different time points    
 
A long exposure of cells to an inverse agonist could create alterations in receptor 
signalling. In order to rule this out, we carried out experiments of cyclic AMP assays 
in which hCB2-CHO cells were preincubated with AM630 at different time points and 
treated thereafter with AM630. 
 
 Unpreincubated hCB2-CHO cells AM630-preincubated hCB2-CHO cells 
Preincubation 
time (hours) 
EC50 (95% CLs) Emax (95% CLs) EC50 (95% CLs) Emax (95% CLs) 
0.5 
80.3 nM  
(17.8 and 359.4) 
-174.1% 
(-207 and -141.5) 
137.6 nM  
(6.42 and 2950) 
-41.5% 
(-58.3 and -24.8) 
1 
101.7 nM  
(46.9 and 220.6) 
-195.7 % 
(-215.3 and -176.2) 
16.9 nM  
(1.9 and 153.1) 
-36.2% 
(-44.3 and -28.1) 
2 
224.5 nM  
(98.7 and 510.6) 
-212.7 %  
(-242.4 and -183) 
60.1 nM 
(3.3 and 1102) 
-26.4 % 
(-37.3 and -15.5) 
6 
156.8 nM  
(42.4 and 580.4) 
-246.7 %  
(-293.7 and -199.6) 
ND ND 
12 
157.2 nM  
(100.9 and 245) 
-336.2 %  
(-359.2 and -313.3) 
ND ND 
 
Table 15. EC50 and Emax values of AM630 (n = 2-4), for inhibition of forskolin-induced stimulation of 
cyclic AMP production in hCB2-CHO cells preincubated at different time points with vehicle 
(unpreincubated) or AM630.  
ND, non determined indicates that the drug had not effect on the assay. 
CLs, confidence limits. 
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As shown in Table 15, following 0.5, 1 and 2 hours of preincubation, AM630 
displayed a slight inverse agonism by enhancing the ability of forskolin to stimulate 
cyclic AMP production. At 6 hours, AM630 was no longer able to alter forskolin-
induced cyclic AMP production (Table 15), suggesting this experimental to be 
sufficient to abolish the CB2 receptor constitutive activity. Similar results were 
obtained after 12 hours of incubation with AM630 (Table 15).  
In order to investigate whether AM630 could antagonize more potently the non 
selective CB2 receptor agonist, CP55940, experiments of cyclic AMP assay were 












    
 
Figure 44. The effect of 25 μM AM630 on the mean log concentration-response curve of  CP55940 (n 
= 4) on forskolin-induced stimulation of cyclic AMP production in hCB2-CHO cells preincubated for 6 
hours with AM630. Symbols represent the mean values ± SEM. The mean apparent KB value, with 95 
% confidence limits shown in brackets, was 2.6 μM (1.2 and 5.5 μM).  
 
As shown in Figure 44, 25 μM AM630 was not more effective as antagonist of 
CP55940 to hCB2-CHO cells preincubated with AM630 for 6 hours than after 24 
hours of preincubation (Figure 42B). Moreover, AM630 displayed a slight but 
significant inverse agonism in the log concentration-response curve of CP55940 
(Figure 44). These results suggested that a preincubation time less than 24 hours is not 
enough to abolish completely the constitutively active CB2 receptors. In light of this, 
we carried on preincubating hCB2-CHO cells with AM630 for 24hours. 




































Displacement binding assays in AM630-preincubated hCB2-CHO cell membranes 
 
The high KB values obtained with AM630 in absence of constitutively active CB2 
receptors prompted us to investigate whether the affinity of AM630 for hCB2 
receptors could negatively have been affected by the 24 hours pretreatment. 
Specifically, [3H]CP55940 displacement binding assays both in unpreincubated and 
AM630-preincubated cell membranes have been performed. AM630 has been tested 
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Figure 45. Displacement of [3H]CP55940 by CP55940 (A), AM630 (B), and ∆9-THCV (C) from 
specific binding sites in membranes from AM630-preincubated or unpreincubated hCB2-CHO cells 
(n=4-8). Each symbol represents the mean percentage displacement ± SEM.  
 
As shown in Figure 45A, CP55940 displaced [3H]CP55940 from specific binding 
sites with mean IC50 values not significantly different between unpreincubated and 
AM630-preincubated hCB2-CHO cell membranes (Table 16). Conversely, the 
potency displayed by both AM630 and ∆9-THCV (Figure 45B and C) in displacing 
[3H]CP55940 was approximately two times lower in AM630-preincubated hCB2-
CHO cell membranes compared to unpreincubated hCB2CHO cell membranes (Table 
16). However, such a difference did not justify the high KB values obtained for 
AM630 on cyclic AMP assay (Figure 42 and 43).  
 
  IC50 nM (95% CLs) 
Compound hCB2-CHO cells AM630-preincubated hCB2-CHO cells 
CP55940 15.6 nM  (11.7 and 20.8 nM) 
19.6 nM  
(14.7 and 26.1 nM) 
AM630 165.5 nM  (124.2 amd 220.5 nM) 
317.4 nM  
(225.6 and 446.7 nM) 
∆9-THCV 261.8 nM  (198.1 and 345.9 nM) 
437.2 nM  
(387.3 and 493.6 nM) 
 
Table 16. IC50 values of CP55940, AM630 and ∆9-THCV for displacement of [3H]CP55940 from 
specific binding sites on unpreincubated (n = 4) or AM630-preincubated hCB2-CHO cell membranes 
(n=4 or 8).  
 
[35S]GTPγS binding assays in AM630-preincubated hCB2-CHO cell membranes 
 
Since displacement binding assays were performed using hCB2-CHO cell membranes 
and cyclic AMP assays using intact cells, it is likely that the pretreatment with 
AM630 decreased the receptor constitutive activity only on the cell surface. In light of 
this, experiments of [35S]GTPγS binding in both unpreincubated and AM630-
















Figure 46. The effect of AM630 on [35S]GTPγS binding to unpreincubated or AM630-preincubated 
hCB2-CHO cell membranes (n=4). Each symbol represents the mean percentage change in [35S]GTPγS 
binding ± SEM. The mean EC50 values of AM630 in unpreincubated and AM630-preincubated hCB2-
CHO cells, with 95% confidence limits shown in brackets, were 675.5 nM (402.8 and 1133 nM) and 
669.6 nM (386.7 and 1159 nM), respectively. The corresponding Emax values were -49.7 % (-56 and -
43 %) and -61.9 % (-70.3 and -53.5 %), respectively. 
 
We found that AM630, in both experimental conditions (Figure 46), produced a 
concentration-related inhibition of [35S]GTPγS binding, thus behaving in both cases as 
inverse agonist. This it did with EC50 and Emax values very similar in both 
unpreincubated and AM630-pretreated cell membranes (Figure 46). 
 
Displacement binding assays in AM630-preincubated whole hCB2-CHO cells 
 
Results from [35S]GTPγS binding assays raised the possibility that a preincubation 
time of 24 hours with AM630 could affect exclusively the constitutively active CB2 
receptors on the cell surface. We therefore carried out some additional experiments 
directed at testing this hypothesis. Displacement binding experiments with AM630 













































Figure 47. Displacement of [3H]CP55940 by AM630 (A) and CP55940 (B) from specific binding sites 
on unpreincubated and AM630-preincubated whole hCB2-CHO cells (n = 4). Each symbol represents 
the mean percentage displacement ± SEM. Mean IC50 values of AM630 in unpreincubated and 
AM630-preincubated whole hCB2-CHO cells, with 95% confidence limits shown in brackets, were 
73.6 nM (45.9 and 118.1 nM) and 41.5 nM (29.4 and 58.5 nM), respectively. The corresponding IC50 
values for CP55940 were 6.8 nM (5.1 and 9.1 nM) and 6.6 nM (4.7 and 9.4 nM). 
 
As shown in Figure 47, both these compounds were able to displace [3H]CP55940 
from specific binding sites with mean IC50 values not significantly different between 
















































































AM630 is a well-known selective CB2 receptor antagonist/inverse agonist (Ross et al. 
1999) that, based on the “two state model”, is able to bind preferentially to the 
inactive form of the receptor (R), reducing the amount of the active receptors (R*) 
and consequently their intrinsic activity (Seifert, Wenzel-Seifert 2002, Milligan 
2003a). 
In our initial experiments of cyclic AMP assays, using hCB2-CHO cells, we have 
confirmed the inverse agonism of AM630 (Figure 41A), suggesting the presence of 
constitutively active CB2 receptors in our cells.   
When we tested AM630 as potential CP55940- and ∆9-THCV-antagonist (Figure 40), 
we found that the inverse agonism was still present at 100 nM, the highest 
concentration at which AM630 did not show any detecTable effect by itself (Figure 
41A). 
These results were not surprisingly since, as we have already reported for the other 
selective CB2 receptor antagonist/inverse agonist, SR144528 (Thomas et al. 2007), 
some inverse agonists could become more potent in presence of agonists, i.e. 
CP55940 and ∆9-THCV, that shift the equilibrium from the inactive form of the 
receptor (R) to the active form (R*), causing a considerable increase of the 
constitutively active receptors (Thomas et al. 2007, Leff 1995).  
Then, in presence of constitutively active receptors, the antagonistic properties of 
some compounds could be masked by their inverse agonism.   
So far only antagonists/inverse agonists are available for CB2 receptors. Therefore, a 
strategy aimed to transform inverse agonists in neutral antagonists is fundamental. To 
this intention, it has been reported in literature that the receptor constitutive activity in 
a cell system can be decreased by inverse agonist long-term exposure (Mancini et al. 
2009, Seifert, Wenzel-Seifert 2002, Milligan 2003b, Chanrion et al. 2008, Rinaldi-
Carmona et al. 1998, Kenakin 2004). With this in mind, following their experimental 
conditions (Mancini et al. 2009), hCB2-CHO cells have been preincubated for 24 
hours with 10 μM AM630. We found that, as consequence of this long-term exposure, 
AM630 was no longer able to stimulate forskolin-induced cyclic AMP production 
(Figure 41). This is in agreement with data reported in literature (Mancini et al. 2009), 
showing that AM630 did not display any detecTable activity both in AM630-
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pretreated rat and human CB2-CHO cells. As expected, the non selective CB1/CB2 
receptor full agonist, CP55940, did not show any changes both in its potency and 
efficacy in AM630-pretreated cells compared to the unpretreated cells (Figure 41). 
Again, this result is in agreement with data already reported both in rat and human 
CB2-CHO cells (Mancini et al. 2009). Moreover, similar results were reported in 
Rinaldi-Carmona et al., (1998) where both the efficacy and potency of CP55940 dose-
response curve were unaltered in hCB1-CHO cells preincubated with the selective 
CB1 receptor antagonist/inverse agonist, SR141716A. 
Differently than CP55940 and as we expected, the CB2 receptor partial agonist, ∆9-
THCV, increased its efficacy in AM630-preincubated hCB2-CHO cells (Figure 41). 
This effect could be due to the fact that, the preincubation with an inverse agonist 
causes not only abolishment of the constitutively active receptors but also an increase 
in the number of receptors, in particular on the cell surface (Chanrion et al. 2008, 
Rinaldi-Carmona et al. 1998, Bouaboula et al. 1999, Bouaboula, Dussossoy & 
Casellas 1999). In support of this, Bouaboula et al (1999) reported an increase in the 
G protein pool after preincubating CHO cells overexpressing hCB2 receptors with the 
antagonist/inverse agonist, SR144528. Then, it is likely that, following AM630 long-
term exposure, the increase in ∆9-THCV maximal efficacy is a consequence of the 
highest levels of CB2 receptors and associated G proteins. This would also confirm 
our previous results (Bolognini et al., 2010), that ∆9-THCV behaves as a partial 
agonist at CB2 receptors (Newman-Tancredi et al. 2000, Kenakin 2001). 
In addition, in our experiments of cyclic AMP, AM630 was found to behave as an 
apparent neutral antagonist in absence of constitutively active CB2 receptors, since 
none of the concentrations tested displayed a downward shift in CP55940 dose-
response curve (Figure 42).  
Surprisingly, AM630 behaved as a reasonably weak competitive antagonist of 
CP55940, as indicated by the manner at which it antagonized the ability of this 
cannabinoid receptor agonist to inhibit forskolin-induced cyclic AMP production in 
AM630-preincubated hCB2-CHO cells (Figure 42). In detail, the KB value displayed 
by AM630 for this antagonism was 5.2 μM, which was approximately 100 times 
higher compared to the mean Ki or IC50 values of AM630 for its displacement of 
[3H]CP55940 from specific binding sites in unpreincubated hCB2-CHO cells (Ross, 
1999, Table 16). 
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AM630 was also able to antagonize, in the same experimental conditions, the CB2 
partial agonist, ∆9-THCV, in an apparent competitive manner (Figure 42) and with a 
KB value not significantly different to the one displayed for the antagonism of 
CP55940 (Figure 42).  
The reason of such a very low potency of AM630 as both CP55940- and ∆9-THCV-
antagonist, in AM630-preincubated cells, is not clear yet and needs further 
investigation. A reasonable explanation could reside in the fact that AM630, 
differently than CP55940 and ∆9-THCV, has an aminoalkylindole chemical structure. 
It could be possible that AM630, as already reported for the other aminoalkylindole 
WIN55212-2 (Reggio 1999), binds to hCB2 receptors using a binding pocket different 
than that used by CP55940 and/or ∆9-THCV. With the aim of ruling out this 
hypothesis we have investigated further the ability of AM630 (25 μM) to antagonize 
WIN55212-2 in AM630-preincubated hCB2-CHO cells (Figure 43). Unfortunately, 
our results did not confirm our hypothesis, showing that AM630 antagonizes 
WIN55212-2 with a rightward shift not significantly different than the one displayed 
for the antagonism of both CP55940 and ∆9-THCV (Figure 43).  This result suggests 
that CP55940, ∆9-THCV, AM630 and WIN55212-2 could interact with a common 
CB2 receptor binding pocket. It is also unlikely that AM630 effect is due to an 
interaction with different kind of GPCRs expressed in CHO cells, since in 
experiments of cyclic AMP performed in untransfected CHO cells, AM630 did not 
show any significant effect (data not shown). 
Next, with the aim of confirming the results observed in cyclic AMP assays, we have 
also performed [35S]GTPγS binding assays using membranes from both AM630-
preincubated and unpretreated hCB2-CHO cells. Surprisingly, we found that AM630 
behaved as an inverse agonist in both experimental conditions (Figure 46). A possible 
explanation of these apparent contradictory results could be that the [35S]GTPγS 
binding assay was performed in cell membranes, instead the cyclic AMP assay in 
intact cells. Several studies have reported the presence of functional intracellular 
GPCRs (Marrache et al. 2005, Gobeil et al. 2006, Zhu et al. 2006). In particular, 
Rozenfeld at al. (2008) have shown the presence of functional cannabinoid type 1 
(CB1) receptors in intracellular endosomal/lysosomal compartments where they are 
associated with the subunit Gαi. Similarly, it is likely that AM630 long-term exposure 
increases CB2 receptor density not only on the cell surface but also in the 
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endosomal/lysosomal compartments. If so, the inverse agonism displayed by AM630 
on AM630-preincubated hCB2-CHO cell membranes in [35S]GTPγS binding assay 
could be the result of CB2 intracellular active receptors. It is also likely that the 
pretreatment with AM630 decreases the CB2 receptor intrinsic activity only on the 
cell surface, maintaining unaltered possible intracellular constitutively active CB2 
receptors. Unfortunately we cannot rule out this hypothesis, since [35S]GTPγS binding 
assays in intact cells cannot be done because of the inability of the [35S]GTPγS 
reagent to cross cell membranes (Harrison, Traynor 2003). 
An alternative explanation of such a low potency of AM630 as antagonist, in AM630-
pretreated cells, could be that the affinity of this compound for CB2 receptors has 
been reduced by the pretreatment. To rule out this hypothesis, we have performed 
experiments of displacement binding in both unpreincubated and AM630-
preincubated hCB2-CHO cell membranes, using CP55940, AM630 and ∆9-THCV. 
We found that these compounds were able to displace [3H]CP55940 from specific 
binding sites in both unpreincubated and AM630-preincubated hCB2-CHO cell 
membranes with a potency ratio of 0.8, 0.52 and 0.6, respectively (Table 16). 
Specifically, in hCB2-CHO cells preincubated with AM630, CP55940 displayed a 
slight, although not statistically significant, lower affinity, while AM630 and ∆9-
THCV displayed two times lower affinity for displacement of [3H]CP55940 from 
specific binding sites. However, these data did not explain why, in cyclic AMP 
assays, AM630 displayed 100 times lower potency for antagonism of CP55940 in 
AM630-preincubated hCB2-CHO cells. Also, ∆9-THCV did not show any significant 
difference in the potency for inhibition of forskolin-induced cyclic AMP production 
in unpreincubated and AM630-preincubated hCB2 cells.  
The slight lower affinity displayed by CP55940, AM630 and ∆9-THCV in AM630-
preincubated hCB2-CHO cells, in displacement binding assays, could be explained by 
the increase of CB2 receptor density after the pretreatment (Chanrion et al. 2008, 
Rinaldi-Carmona et al. 1998, Bouaboula et al. 1999, Bouaboula, Dussossoy & 
Casellas 1999). In fact, one possible effect of a large receptor concentration is to 
reduce the potency with which a tritiated ligand is displaced from its specific binding 
sites by an unlabelled compound (Kenakin 1997, Bolognini et al. 2010).  
Conversely to the data obtained in cell membranes, experiments of displacement 
binding performed in intact hCB2-CHO cells showed that CP5540 and AM630 
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displaced [3H]CP55940 from specific binding sites with a similar potency both in 
unpreincubated and AM630-preincubated cells (Figure 47). At the moment we do not 
know why differences in the ligand affinity were displayed in membranes and not in 
intact hCB2-CHO cells in experiments of displacement binding.  It could be possible 
that the pretreatment with AM630 causes an increase of CB2 receptor expression in 
intracellular compartments more than on the cell surface.  
Taken together, these results suggest that AM630 does not change significantly its 
affinity for CB2 receptors after AM630 long-term exposure in displacement binding 
experiments. Hence, the reason why AM630 displayed a marked low affinity in 
experiments of cyclic AMP, after elimination of constitutively active CB2 receptors, 
warrants further investigations. It is possible that AM630 has two different affinities 
for the CB2 receptor, one for the inactive form (R) and one for the active form (R*). 
In particular, AM630 would have high affinity (nanomolar range) for the receptor 
inactive form (R), and this would explain its inverse agonist properties. On the other 
hand, AM630 would have only low affinity (micromolar range) for the receptor active 
form (R*), which would be responsible of the antagonism at CB2 receptors.  
Further investigations will now be directed at testing these hypotheses. In particular, 
in order to confirm the results obtained so far with AM630, further experiments will 
be performed with the other well-known CB2 receptor antagonist/inverse agonist, 
SR144528. 
Concluding, since neutral antagonist at CB2 receptors have not been discovered yet 
and that the receptor constitutive activity is a common property for cells 
overexpressing a particular receptor, the inverse agonist long-term exposure method 
could be a useful tool to decrease the receptor constitutive activity and consequently 
to transform an antagonist/inverse agonist into an apparent neutral antagonist. Thus, 
this protocol could find application in experiments of high throughput screening to 
test the selectivity of compounds at CB2 receptors. 
Regarding ∆9-THCV, these results further confirm our previous hypothesis that this 






CONCLUSIONS CHAPTER ONE AND TWO 
 
The main findings from chapter one and two are: 
• ∆9-THCV displayed high affinity for CB2 receptors (Ki of 225.1 nM) in 
experiments of displacement biding assay on hCB2-CHO cell membranes 
(Figure 25) 
• ∆9-THCV, compared to the CB1/CB2 receptor full agonist (CP55940),  
displayed partial agonism in experiments of [35S]GTPγS binding and cyclic 
AMP assays on hCB2-CHO cells (Table 12) 
• ∆9-THCV did not show any effect in experiments of cyclic AMP assay on 
untransfected- or PTX-treated hCB2-CHO cells, confirming the selective 
activity of ∆9-THCV at hCB2 receptors (Figure 24, 31). 
• ∆9-THCV displayed selective partial agonism in [35S]GTPγS binding 
experiments on wild type but not CB2-/- mouse spleen membranes, confirming 
the ability of ∆9-THCV to stimulate both human and mouse CB2 receptors 
(Bolognini et al. 2010). 
• ∆9-THCV displayed a significant higher efficacy in experiments of cyclic 
AMP assay on hCB2-CHO cells after AM630 long-term exposure (Figure 41). 
Hence, ∆9-THCV is still an agonist in absence of constitutively active CB2 
receptors. 
• ∆9-THCV was antagonized by the CB2 receptor selective antagonist/inverse 
agonist, AM630, in AM630-treated hCB2-CHO cells on cyclic AMP assays 
(Figure 42). 
• The partial agonism of ∆9-THCV at CB2 receptors has also been shown 
efficacious as anti-inflammatory and anti-hyperalgesic agent on in vivo models 
of λ−carrageenan-induced oedema and thermal hyperalgesia, and formalin-
induced nociception (Figure 18, 19, 20, 21, 22). However, these data suggest 
the involvement not only of CB2 receptors, but also of CB1 receptors. 
 
Thus, all these findings confirm ∆9-THCV to be a partial agonist at CB2 receptors and 
that this activity might be implicated in ∆9-THCV-mediated anti-inflammatory 
effects. Conversely, ∆9-THCV mediated anti-hyperalgesic effect seems to involve 
also CB1 receptors rather than only CB2 receptors. 
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In vitro, future directions will be addressed at investigating the ability of ∆9-THCV to 
interact and mediate pathways involved in inflammatory states. 
In vivo it will be important to establish more conclusively whether, as has been 
proposed for CB2 receptor agonists (Guindon, Hohmann 2008), ∆9-THCV has 
therapeutic potential both as an anti-inflammatory agent and for the relief of 





































CHAPTER THREE       
 
Pharmacological properties of the 
phytocannabinoid cannabidiol  

























Cannabidiol (CBD) is the main non-psychoactive cannabis constituent. This 
compound was first isolated in late 1930s, and was chemically characterized 30 years 
later (Mechoulam, Shvo 1963). The CBD molecule is chiral, and the plant cannabis 
contains only the levorotatory form ((-)-CBD) (Figure 48). 
Like most of the cannabis constituents, CBD is insoluble in water but soluble in 
organic solvents. At room temperature it is a colourless crystalline solid, and under 
acidic conditions it cyclizes to ∆9-THC. 
 
       




Molecular Mass 314.46 g/mol 




Figure 48. CBD chemical structure and data.  
CAS (Chemical Abstracts Service) registry numbers are unique numerical identifiers for chemical 
elements, compounds, polymers, biological sequences, mixtures and alloys. 
SMILES (simplified molecular input line entry specification) is a specification for unambiguously 
describing the structure of chemical molecules using short ASCII strings. 
 
Regarding the pharmacokinetics, CBD metabolism is similar to that of ∆9-THC, with 
primary oxidation of C9 to the hydroxy and carboxylic acid moieties, and side chain 
oxidation (Huestis 2005b). Like ∆9-THC, CBD is subjected to a significant first-pass 
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effect, which reduces considerably the amount of CBD and its metabolites in the 
circulatory system. Unlike ∆9-THC, a large proportion of CBD is excreted unchanged 
in the faeces (Huestis 2005b). Moreover, it has been proven that the co-administration 
of CBD and ∆9-THC does not significantly affect the clearance, volume of 
distribution, and terminal elimination half-lives of ∆9-THC metabolites (Huestis 
2005b). 
Research surrounding CBD has increased dramatically in the last decade due to its 
lack of central side effects. 
 
 
Pharmacology of CBD at cannabinoid receptors 
 
Preliminary experiments of [3H]CP55940 displacement binding assay conducted in 
specific tissues or cell transfected membranes, showed a low affinity (micromolar 
range) of CBD versus both CB1 and CB2 receptors (Pertwee 2008). These results 
explain the lack of central side effects by CBD. 
However, recent results show that CBD can interact with both cannabinoid receptors 
at reasonably low concentrations when tested as antagonist of both CB1 and CB2 
receptor agonists (Thomas et al. 2007). In detail, Pertwee’s group showed the ability 
of CBD to antagonize both the non-selective CB1/CB2 receptor agonists, CP55940 
and R-(+)-WIN55212-2, in the [35S]GTPγS binding assay using mouse whole brain 
membranes with mean KB values of 79 and 138 nM, respectively (Thomas et al. 
2007). However, it has been suggested that CBD-induced antagonism might be non-
competitive in nature, since CBD has been found to behave as inverse agonist in the 
same assay at concentrations as those which exerted antagonism.  
These findings are supported by previous reports:  
1. CBD at 10 μM antagonizes CP55940-induced stimulation of [35S]GTPγS binding 
to rat cerebellar membranes (Petitet et al. 1998). 
2. CBD antagonizes CP55940 and R-(+)-WIN55212-2 in the mouse isolated vas 
deferens assay with an apparent KB value in the nanomolar range (Pertwee 2008). 
3. CBD can block various responses to ∆9-THC in rabbits, rats, mice and human 
subjects (Pertwee 2008). 
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Similar results were obtained in cell membranes over-expressing human CB2 
receptors (hCB2-CHO cells), where CBD antagonized CP55940 in the [35S]GTPγS 
binding assay with a KB value of 65 nM, which is markedly less than its Ki value for 
displacing [3H]CP55940 in the same cells (Thomas et al. 2007). In mouse brain 
membranes, as well as in hCB2-CHO cell membranes, CBD administered by itself 
inhibits [35S]GTPγS binding (Thomas et al. 2007), suggesting that CBD antagonizes 
CP55940 at CB2 receptors in a non-competitive way (Pertwee 2008, Thomas et al. 
2007).  
Further investigations are needed to elucidate the mechanism by which CBD exerts its 
moderately potent antagonism at both CB1 and CB2 receptors, in spite of its low Ki 
values at these receptors. 
 
 
Pharmacology of CBD at non-CB1, non-CB2 receptors 
 
The low affinity exerted by CBD for CB1 and CB2 receptors in displacement binding 
assays prompted researchers to seek out and characterise CB1 and CB2-independent 
modes of action for this phytocannabinoid (Mechoulam et al. 2007). 
The first evidence that CBD can interact with sites different than cannabinoid 
receptors was offered by the observation that natural CBD is able to bind to and 
stimulate the type-1 vanilloid receptor (VR1) (Bisogno et al. 2001).  
CBD has also been shown to interact with the adenosine system. In fact, a study 
conducted by the Hillard group demonstrated the ability of CBD to enhance adenosine 
signalling through inhibition of its uptake (Carrier, Auchampach & Hillard 2006, 
Castillo et al. 2010). 
Recent evidences suggest CBD to be a positive allosteric modulator at a low 
micromolar concentration for both α1 and α1β glycine receptors (Ahrens et al. 2009). 
Moreover, at concentrations above 100 μM, CBD has been shown to directly activate 
both these receptors (Foadi et al. 2010).  
In addition, several papers have also showed that CBD is able to interact with the 
type-1A serotonin receptor, 5-HT1A. Russo et al. (2005) showed that, in CHO cells 
over-expressing human 5-HT1A receptors, CBD displaced the agonist [3H]8-OH-
DPAT in a dose-dependent manner, and in experiments of [35S]GTPγS binding and 
 126
cyclic AMP assays CBD could act as agonist at 5-HT1A receptors. However, CBD 
displayed these effects only at micromolar concentrations (Russo et al. 2005). In vivo, 
the interaction between CBD and 5-HT1A receptors has been demonstrated to be 
involved in several disease models. For example, these serotonergic receptors were 
shown to induce the neuroprotective effects of CBD in a middle-cerebral-artery 
occlusion (MCAO) model (Mishima et al. 2005). In particular, CBD treatment 
displayed a reduction in the MCAO-mediated infarct volume by boosting the cerebral 
blood flow. This effect was antagonized by WAY100135, a 5-HT1A receptor 
antagonist, suggesting that the neuroprotective effects of CBD in this model might be 
related to the increase in cerebral blood flow through the 5-HT1A receptor (Mishima et 
al. 2005).  
In two other papers, the involvement of 5-HT1A receptors has been proposed for both 
the anti-stress and anxiolytic-like effects of CBD. In fact, the 5-HT1A receptor 
antagonist, WAY100635, was able to reverse both of these effects (Campos, 
Guimaraes 2008, Resstel et al. 2009). 
Supporting data about the interaction of these serotonin receptors and CBD come 
from a hepatic encephalopathy (HE) model, bile-duct ligation (BDL). This is a 
common model of chronic liver disease in rodents which exacerbates cerebral 
inflammation, mimicking human HE. CBD treatment was shown to ameliorate 
cognitive and motor dysfunctions, and moderated neuroinflammation in a BDL mouse 
model. These effects were reversed by the 5-HT1A receptor antagonist, WAY100635, 
suggesting the involvement of these receptors in CBD-mediated HE symptoms 
amelioration (Magen et al. 2010). 
In addition, in a recent presentation at the International Cannabinoid Research Society 
(ICRS), the Parker group suggested that 5-HT1A receptors might be involved in the 
anti-emetic and anti-nausea effects of CBD (Rock et al. 2009, Parker et al. 2010). This 






Serotonin neurons originate from raphe nuclei, which are 7 different cerebral nuclei 
localized in the brainstem (Figure 49). In particular, raphe nuclei are distributed in the 
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midbrain (where the main nucleus is dorsal raphe nucleus), in pons and medulla. The 
nuclei localized in the midbrain project into the brain (forebrain and cerebellum), 
instead the nuclei localized in the medulla project to spinal cord and brainstem 
(Figure 49) (Kandel, Schwartz & Jessel 2000). 
 
             
Figure 49. Distribution and organization of 5-HT neurons. Dark circles indicate the origin of 
serotonergic neurons. 
 
Serotonergic receptors include 7 different receptor families, and a total number of 14 
structurally and pharmacologically distinct subtypes (Figure 50). The endogenous 
ligand for these receptors is the neurotransmitter serotonin (5-HT) (Hannon, Hoyer 
2008). 
5-HT1A receptors are GPCRs coupled to Gi/o that mediate inhibitory neurotransmission 
(Hannon, Hoyer 2008). These receptors are largely distributed throughout the brain, 
but are also present in the peripheral nervous system (PNS), especially in the gastro 
intestinal tract (Barnes, Sharp 1999). In the brain, 5-HT1A receptors are densely 
expressed in limbic brain area, notably hippocampus, lateral septum, cortical areas 
(particularly cingulated and entorhinal cortex), and also mesencephalic and medullary 
raphe nuclei. Extremely low 5-HT1A receptor levels are detected in the basal ganglia 
and cerebellum (Hannon, Hoyer 2008, Barnes, Sharp 1999, Lanfumey, Hamon 2000). 
At subcellular level, 5-HT1A receptors are localized in the soma and dendrites in raphe 
nuclei, where they act as autoreceptors to inhibit cell firing. In limbic area, especially 
in the hippocampus, 5-HT1A receptors are localized at postsynaptic level on non-5-HT 
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neurons (heteroreceptors) (Riad et al. 2000). The activation of 5-HT1A receptors 
mediates neuronal hyperpolarization, through G-protein coupled K+ channel (GIRK 
channels), with the consequent inhibition of cell firing and 5-HT release (5-HT1A 
autoreceptors) (Hannon, Hoyer 2008).  
 
          
 
Figure 50. Classification of 5-HT receptors. The G-protein coupled to 5-HT5B has not been defined yet. 
Phospholipase C (PLC). The picture was adapted from (Hoyer, Hannon & Martin 2002).  
 
5-HT1A receptors are involved in several physiological responses (Table 17) (Barnes, 
Sharp 1999). Some of these are controlled specifically by presynaptic or postsynaptic 
5-HT1A receptors. On the other hand, in some physiological states the involvement of 
these receptors is still controversial; for example it seems that presynaptic 5-HT1A 
receptors are more involved in the anxiolytic effect of serotonin, instead postsynaptic 
5-HT1A receptors has been proposed as a target for antidepressant treatment (Batool 
2008).      
                                
IONIC CHANNEL
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Level Target Response Mechanism 
Neurochemical 5-HT release Inhibition Presynaptic 
 Noradrenaline release Stimulation Postsynaptic 
 Acetylcholine release Stimulation Postsynaptic 
 Glutamate release Inhibition ? 
Neuroendocrine ACTH Stimulation Postsynaptic 
 Prolactin Stimulation Postsynaptic 
Behavioral 5-HT syndrome  Postsynaptic 
 Hypothermia  Pre/Postsynaptic 
 Hyperphagia  Presynaptic 
 Anxiolysis  Pre/Postsynaptic 
 Antidepressant  Pre/Postsynaptic 
 Sexual behavior Stimulation Pre/Postsynaptic 
 Discriminative stimulus  Pre/Postsynaptic 
 
Table 17. Summary of the functional physiological responses associated with activation of the brain 5-
HT1A receptors. Pre and postsynaptic refer to the 5-HT1A receptor localization. ACTH refers to the 
adrenocorticotropic hormone. Table adapted from (Barnes, Sharp 1999). 
 
 
5-HT1A receptors, CBD and nausea/emesis 
 
Nausea and vomiting are one of the most common side effects of chemotherapy. The 
cannabis-mediated anti-nausea and anti-emetic effects are widely known, although the 
exact mechanism it is still uncertain (Mechoulam, Parker & Gallily 2002). 
Interestingly, the observations that marijuana suppresses nausea more effectively than 
oral ∆9-THC (Grinspoon, Bakalar 1997) led a Canadian group to investigate the 
potential anti-emetic and anti-nausea properties of CBD. The Parker group conducted 
several experiments in mouse musk shrew (Suncus murinus), an animal model in 
which the injection of Lithium Chloride (LiCl) induces vomit (Parker et al. 2004). In 
this model, CBD produced a biphasic pharmacological profile, with lower doses (5-10 
mg/Kg) producing suppression and higher doses (40 mg/Kg) producing enhancement 
of LiCl-induced vomiting (Parker et al. 2004). Recently, the same group presented 
new data supporting the anti-emetic effect of CBD, in particular the efficacy of this 
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phytocannabinoid has been demonstrated in nicotine-, cisplatin- and LiCl-induced 
vomiting in shrews (Rock et al. 2009). Moreover the anti-nausea properties of CBD 
have been proved in conditioned gaping in rats, an in vivo model to induce nausea 
(Parker, Limebeer 2006, Rock et al. 2008). Interestingly, even in this model CBD 
displayed a typical bell-shaped pharmacological profile, where only low doses of 
CBD were effective (Rock et al. 2008).  The anti-emetic and anti-nausea effects of 
CBD, in these models, have been suggested to be mediated by its action at 
somatodendritic 5-HT1A autoreceptors located in the raphe nuclei (Rock et al. 2009, 
Parker et al. 2010). The role of 5-HT1A autoreceptors in nausea and emesis is 
supported by several evidences. It has been demonstrated that the 5-HT1A agonist, 8-
OH-DPAT, which reduces serotonin release, interfered with LiCl-induced conditioned 
gaping in rats (Parker et al. 2010). In addition, depletion of forebrain serotonin by 
lesion of median and dorsal raphe nuclei attenuated the effects of LiCl-induced 
conditioned gaping (Limebeer, Parker & Fletcher 2004). The proposed 5-HT1A 
receptors-mediated anti-nausea and anti-emetic effects of CBD are supported by the 
capacity of the 5-HT1A antagonist, WAY100135, to block these effects (Rock et al. 
2009). In addition, the intracranial delivery of the non-selective 5-HT1A antagonist, 
WAY 100635, to the dorsal raphe nuclei (DRN) has been shown to attenuate the anti-
nausea property of CBD, suggesting that this phytocannabinoid is acting through 















AIMS OF THE PROJECT 
 
The potential anti-nausea and anti–emetic properties of CBD prompted us to start 
collaboration with Professor Linda Parker (University of Guelph, Canada). In 
particular, we focused our attention on the possible interaction between CBD and 
somatodendritic 5-HT1A autoreceptors. As aforementioned, CBD, at very high 
concentrations (16 μM), was already found to be an agonist in CHO cells 
overespressing human 5-HT1A receptors (Russo et al. 2005). However, since CBD 
displayed anti-nausea and anti–emetic effect only at low concentrations (Parker et al. 
2004, Rock et al. 2008), we tested this phytocannabinoid in the concentration range of 
1 nM up to 10 μM. Moreover, in order to isolate somatodendritic 5-HT1A 
autoreceptors we chose the brainstem for our experiments. In fact, this brain region 
contains all the raphe nuclei and consequently it is rich of somatodendritic 5-HT1A 
autoreceptors.  
Thus, with the aim of investigating a possible interaction between CBD and 5-HT1A 
autoreceptors we carried out experiments of displacement and [35S]GTPγS binding 




















CBD does not displace [3H]8-OH-DPAT in rat brainstem membranes 
 
There is already evidence that CBD, albeit at the rather high concentration of 16 µM, 
can directly bind to and activate human 5-HT1A receptors that have been transfected 
into CHO cells (Russo et al. 2005). However, the ability of lower concentrations of 
this phytocannabinoid to activate 5-HT1A receptors in vitro, when they are expressed 
naturally at physiological levels in rat brainstem membranes, has not been 
investigated before. Accordingly, we sought for evidence that CBD can directly target 
5-HT1A receptors in rat brainstem when administered in vitro at concentrations 
ranging from 1 nM to 10 µM.  
First, in order to investigate the ability of CBD to bind 5-HT1A receptors, experiments 
of displacement binding were carried out in rat brainstem membranes. The 
radioligand [3H]8-OH-DPAT was used to occupy 5-HT1A receptor binding sites and 
the displacement was quantified as a percentage of specific binding produced in the 
presence of 1 μM of the unlabelled ligand 8-OH-DPAT. Experiments were conducted 































Figure 51. Effects of 8-OH-DPAT (A) and CBD (B) on specific binding of [3H]8-OH-DPAT to rat 
brainstem membranes (n=6). The IC50 and Emax values of 8-OH-DPAT for its displacement of [3H]8-
OH-DPAT, with 95% confidence limits shown in parentheses, were 9.6 nM (5.6 and 16.3 nM) and 
96.6% (86.8 and 106.5%), respectively. Symbols represent mean values ± SEM. 
 
As shown in Figure 51A, 8-OH-DPAT was able to fully displace [3H]8-OH-DPAT 
from specific binding sites in rat brainstem membranes. The mean IC50 value 
displayed by 8-OH-DPAT was very similar to the one reported in literature for 
displacement of [3H]8-OH-DPAT in rat raphe area membranes (Assie, Koek 2000). 
Conversely, CBD at concentrations up to 10 μM did not share the ability of 8-OH-
DPAT to induce such displacement (Figure 51B). These results suggested that CBD, 
in this range of concentrations, is not able to bind the orthosteric site of 5-HT1A 
receptors. 
 
CBD is not an agonist at 5-HT1A receptors 
 
Since 5-HT1A receptors signal through Gi/o proteins (see introduction chapter three), 
we also compared the ability of both 8-OH-DPAT and cannabidiol to stimulate 
[35S]GTPγS binding to rat brainstem membranes. 
 
 











































































Figure 52. Effects of (A) 8-OH-DPAT (n=5) and (B) CBD (n=4) on [35S]GTPγS binding to rat 
brainstem membranes. Mean EC50 and Emax values for 8-OH-DPAT, with 95% confidence limits shown 
in parentheses, were 13.4 nM (0.91 and 197 nM) and 29.6% (19.7 and 39.5%). None of the 
concentrations of CBD tested were significantly different from zero (one sample T-test analyses). 
Symbols represent mean values ± SEM. 
 
As shown in Figure 52A, 8-OH-DPAT, as expected, was able to stimulate the 
[35S]GTPγS binding to rat brainstem membranes, with an EC50 value of 13.4 nM, 
which was not significantly different to the one reported in [35S]GTPγS binding 
experiments in rat dorsal raphe nucleus (Rossi, Burke & Hensler 2008) or 
hippocampus membranes (Sprouse et al. 2004, Newman-Tancredi et al. 2009). 
Conversely, CBD, in the same experimental conditions, was unable to stimulate or 
inhibit the [35S]GTPγS binding at any of the concentrations tested (Figure 52B). 
Together with the displacement binding data, these results rule out the ability of CBD, 
in this range of concentrations, to directly bind to and activate 5-HT1A autoreceptors. 
 
8-OH-DPAT acts at 5-HT1A receptors in rat brainstem 
 
Although 8-OH-DPAT is a 5-HT1A receptor agonist, it has been reported that this 
ligand has moderate affinity also for 5-HT7 receptors (Sprouse et al. 2004, Adham et 
al. 1998). In addition, 5-HT7 receptors are expressed in the dorsal raphe nucleus, 
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although at low levels (Hannon, Hoyer 2008). Thus, in order to confirm that 8-OH-
DPAT-induced [35S]GTPγS binding stimulation was mediated by 5-HT1A receptors, 
we then tested the ability of the 5-HT1A receptor antagonist, WAY100635, to 
antagonize 8-OH-DPAT dose-response curve in experiments of [35S]GTPγS binding 














Figure 53. Effects of 8-OH-DPAT in the presence of DMSO (Vehicle; n=11) or 100 nM WAY100635 
(n=11) on [35S]GTPγS binding to rat brainstem membranes. Mean EC50 values for 8-OH-DPAT, with 
95% confidence limits shown in parentheses were 13.6 nM (2.7 and 68.8 nM), in the presence of 
vehicle and 1936 nM (240 and 15630 nM) in the presence of WAY100635. The rightward shift 
produced by WAY100635 in the log concentration-response curve of 8-OH-DPAT was significant and 
did not deviate statistically from parallelism (p > 0.2). The mean apparent KB value of WAY100635 for 
this antagonism, with 95%confidence limits shown in brackets, was 1 nM (0.24 and 4.1 nM). Symbols 
represent mean values ± SEM. 
 
We found that WAY100635 did antagonize the stimulatory effect of 8-OH-DPAT on 
[35S]GTPγS binding assay to rat brainstem membranes (Figure 53). The mean 
apparent KB value of WAY100635 for this antagonism was 1 nM, which was not 
significantly different to the mean KB value reported previously in this laboratory for 
antagonism of 8-OH-DPAT in mouse whole brain membranes (Cascio et al. 2010).  
These results confirmed that the agonism displayed by 8-OH-DPAT in rat brainstem 
membranes was mediated by 5-HT1A receptors.  
 

























CBD acts at 5-HT1A receptors in rat brainstem 
 
Having established that CBD per se had not activity on 5-HT1A receptors on rat 
brainstem membranes (Figure 52B) and that 8-OH-DPAT was acting selectively at 5-
HT1A receptors on the same membranes (Figure 53), it was of our interest to 
investigate whether CBD could behave as 5-HT1A receptor enhancer. This we did to 
explore the possibility that 5-HT1A receptor antagonist, WAY100635, reduces CBD-
induced suppression of LiCl-induced conditioned gaping in rats (Rock et al. 2009) 
because this cannabinoid augments activation of 5-HT1A receptors in the brainstem by 
endogenously released serotonin. With this in mind, we tested 10 μM CBD, the 
highest concentration at which it did not stimulate [35S]GTPγS binding on its own, as 















Figure 54. Effect of (A) 8-OH-DPAT on [35S]GTPγS binding to rat brainstem membranes in the 
presence of DMSO (Vehicle; n=4) or CBD (n=4). Effect of (B) 8-OH-DPAT on [35S]GTPγS binding to 
rat brainstem membranes in the presence of DMSO (Vehicle; n=4) or CBD (n=4) after subtraction of 
the mean inhibitory effect induced by 10 μM CBD in the presence of the lowest concentration of 8-
OH-DPAT. Mean Emax values for (A) 8-OH-DPAT, with 95% confidence limits shown in parentheses 
were 26.1% (16.4 and 35.9%) in the presence of vehicle and -0.1% (-6.9 and 6.6%) in the presence of 
10 µM CBD. Corresponding mean EC50 values for (A) 8-OH-DPAT were 20.8 nM (2 and 214 nM) in 
the presence of vehicle and 5.1 nM (0.52 and 51 nM) in the presence of 10 µM CBD. Symbols 
represent mean values ± SEM. 
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The ability of 8-OH-DPAT to stimulate [35S]GTPγS binding on rat brainstem 
membranes was attenuated by CBD (Figure 54), which at 10 μM produced a 
downward but not a rightward shift in the log concentration-response curve of 8-OH-
DPAT. Subtracting the inverse agonism, no antagonism was displayed by CBD on 8-
OH-DPAT dose-response curve, suggesting that CBD is not a competitive antagonist 
at 5-HT1A receptors.  
 
CBD, at 10 μM, is an inverse agonist at CB1 receptors  
 
Data previously reported in this laboratory showed that CBD, at 10 μM, was able to 
displace the non-selective CB1/CB2 receptor radioligand, [3H]CP55940, from specific 
binding sites in mouse whole brain membranes (Thomas et al. 2007). Moreover, 10 
μM CBD was shown to inhibit [35S]GTPγS binding in the same brain membranes. In 
order to confirm the ability of CBD to act at CB1 receptors we went on performing 
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Figure 55. Displacement of [3H]CP55940 by CP55940 (A) and CBD (B) from specific binding sites on 
hCB1-CHO cell membranes (n=4). The Emax values were (A) 103.4% and (B) 74.5%.  
(C) The effect of CBD on [35S]GTPγS binding assay to hCB1-CHO cell membranes (n=4). The 
[35S]GTPγS binding-inhibition induced by CBD, at 10 μM, was statistically different from zero (one 
sample t-test analyses). Each symbol represents the mean percentage displacement ± SEM. 
 *** p<0.0001. 
 
CBD, compared to CP55940 (Figure 55B), at 10 μM was able to partially, but not 
fully, displace [3H]CP55940 from specific binding sites on hCB1-CHO cell 
membranes (Figure 55A). In [35S]GTPγS binding assay, CBD displayed significant 
inverse agonism only at the concentration of 10 μM (Figure 55C).  
In order to confirm CB1 receptor-mediated CBD inverse agonism, we carried on 
















































Figure 56. The effect of CBD on forskolin-induced stimulation of cyclic AMP production in hCB1-
CHO cells (A) and untransfected CHO cells (B). The inhibition induced by 10 μM CBD (A) was 
statistically different from zero (one sample t-test analyses). *** p<0.0001. The assays were performed 
using a kit purchased by GE Healthcare. 
 
We found that in hCB1-CHO cells, CBD, at the concentration of 10 μM, displayed a 
significant increase on forskolin-induced cyclic AMP production (Figure 56A). 
Conversely, none of the concentrations of CBD tested affected forskolin-induced 
cyclic AMP production in untransfected CHO cells (Figure 56B). 
Taken together these results suggested that CBD at 10 μM is able to bind to and act at 
CB1 receptors. Thus, it is possible that the downward shift produced by CBD on 8-
OH-DPAT dose-response curve in rat brainstem membranes (Figure 54A) is the result 
of an interaction between CBD and CB1 receptors. 
 
CBD enhances 8-OH-DPAT dose-response curve  
 
Since the anti-emetic and anti-nausea effects of CBD were displayed only at very low 
concentrations, as a possible enhancement in 5-HT1A receptor signalling (see 
introduction), and that CBD at 10 μM inhibited 8-OH-DPAT dose-response curve 
(Figure 54A), we went on investigating whether CBD, in the concentration range of 
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1nM up to 1 μM, could enhance 8-OH-DPAT dose-response curve. We then 
performed [35S]GTPγS binding experiments testing CBD as potential allosteric 
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Figure 57. Effect of 8-OH-DPAT on [35S]GTPγS binding to rat brainstem membranes in the presence 
of DMSO (Vehicle) or different concentrations of CBD. Mean Emax values for 8-OH-DPAT in panels 
A, B, C, D and E with 95% confidence limits shown in parentheses were 32% (23.3 and 40.7%; n=9), 
31% (20.2 and 42%; n=10), 41.2% (30 and 52.4%; n=6), 34.7% (30.3 and 39.3; ,n=8) and 35.1% (26.6 
and 43.5%; n=8), respectively, in the presence of vehicle and 28.7% (19.1 and 38.3%; n=9), 62.3% 
(51.0 and 73.6%; n=10), 51.3% (39.3 and 63.3%; n=6), 45.3% (35.5 and 51%; n=6) and 34% (22.2 and 
45.8%; n=8), respectively, in the presence of 1 µM, 100 nM, 31.6 nM, 10 nM, or 1 nM CBD. 
Corresponding mean EC50 values for 8-OH-DPAT were 37.6 nM (7.6 and 185 nM), 10.1 nM (0.75 and 
137 nM), 37.5 nM (6.7 and 168 nM), 22 nM (9.5 and 50.9nM) and 11.2 nM (1.9 and 66.7 nM), 
respectively, in the presence of vehicle and 31.8 nM (3.2 and 317 nM), 19.7 nM (2.8 and 139 nM), 28.6 
nM (4.5 and 180 nM), 45.7 nM (14.1 and 149 nM) and 7.1 nM (0.4 and 126 nM), respectively, in the 
presence of 1 µM, 100 nM, 31.6 nM, 10 nM, or 1 nM CBD. Symbols represent mean values ± SEM. * 
p<0.1 (one sample t-test analyses). 
 
As shown in Figure 57A, C and E, CBD at the concentrations of 1 μM, 10 nM and 1 
nM did produce neither stimulation nor inhibition on log concentration-response 
curve of 8-OH-DPAT on [35S]GTPγS binding assay in rat brainstem membranes. 
Conversely, 100 nM and 31.6 nM CBD produced an upward shift in the log 
concentration-response curve of 8-OH-DPAT that resulted in an increase of the Emax 
but not EC50 of this 5-HT1A receptor-selective agonist (Figure 57B and C). In 
particular, 100 nM CBD produced a significant different upward shift at all the 
concentration of 8-OH-DPAT tested (p<0.1). 
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CBD is not a 5-HT1A receptor allosteric modulator 
 
The ability of 100 nM CBD to enhance the log concentration-response curve of 8-
OH-DPAT raised the possibility that this phytocannabinoid might target an allosteric 
site on the 5-HT1A receptor, there already being evidence for the presence of such a 
site on this receptor (Barrondo, Salles 2009). We therefore investigated the ability of a 
8-OH-DPAT-potentiating concentration of CBD, 100 nM, to alter the rate at which 


















Figure 58. The dissociation of [3H]8-OH-DPAT from binding sites in rat brainstem membranes in the 
presence of vehicle or 100 nM CBD. These mean dissociation rates with their 95% confidence limits 
shown in parentheses were 7.0 min (4.3 and 18.2) and 4.8 (3.5 and 8.1), respectively (n=3). Each 
symbol represents the mean percentage of specific binding S.E.M.  
 
These experiments showed that the mean dissociation rates of [3H]8-OH-DPAT in the  
presence of vehicle or of 100 nM CBD were not significantly different (Figure 58). 





































Anti-nausea and anti-emetic effects of cannabis are widely recognized (Mechoulam, 
Parker & Gallily 2002) and are an important alternative for treatment of nausea 
associated with chemotherapy. Thus, in the 80’s the synthetic Δ9-THC, dronabinol, 
and the synthetic Δ9-THC analogue, nabilone, have been licensed in several countries 
as drug for treatment of nausea and emesis associated with cancer therapy when first-
line treatments (standard therapy recommended for the initial treatment of a disease) 
were not effective (see general introduction). Nevertheless, the side effects mediated 
by these drugs caused a reduction in the usage of these agents as a medication in 
nausea and emesis (Costa et al. 2007). Thus, in the last decade the research on 
cannabis, for this and other disease states treatment, has been focused on the non-
psychoactive cannabis constituent, CBD (Mechoulam et al. 2007). Recent evidences 
have shown the efficacy of CBD as anti-nausea and anti–emetic agent in several in 
vivo models (see introduction), where this phytocannabinoid has shown a typical bell-
shaped pharmacological profile. In addition, the Parker group suggested a possible 
involvement of somatodendritic 5-HT1A autoreceptors in CBD-mediated anti-nausea 
and anti–emetic effects (Rock et al. 2009, Parker et al. 2010).  
Results from our in vitro experiments indicated and confirmed the presence of 5-HT1A 
receptors in rat brainstem membranes. This was supported by the ability of the 
selective 5-HT1A receptor agonist, 8-OH-DPAT, both to displace the radioligand 
[3H]8-OH-DPAT from specific sites (Figure 51A), and to stimulate [35S]GTPγS 
binding to rat brainstem membranes (Figure 52A). In addition 8-OH-DPAT-induced 
stimulation of [35S]GTPγS binding was antagonized by the 5-HT1A antagonist, 
WAY100635 (Figure 53), further confirming the presence of 5-HT1A receptors in rat 
brainstem membranes and the ability of 8-OH-DPAT to act on these receptors.  
When CBD was tested in the concentration range of 1 nM to 10 μM neither 
displacement of [3H]8-OH-DPAT from specific binding sites (Figure 51B) nor 
stimulation of [35S]GTPγS binding (Figure 52B) were observed in rat brainstem 
membranes. These results suggested that CBD is not able to bind directly to 5-HT1A 
autoreceptors in this concentration range. This partially supports data already 
published in literature, where the ability of CBD to directly bind to and activate 
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recombinant human 5-HT1A receptors was observed only at the high concentration of 
16 μM (Russo et al. 2005). 
Then, we assessed the possibility of CBD to indirectly activate the 5-HT1A 
autoreceptors. Nevertheless, at 10 μM, CBD behaved as a non-competitive antagonist 
of 8-OH-DPAT, as indicated by the downward shift displayed by this 
phytocannabinoid in 8-OH-DPAT dose-response curve for stimulation of [35S]GTPγS 
binding to rat brainstem membranes (Figure 54A). Moreover, when this downward 
shift was subtracted no rightward shift was displayed by CBD on 8-OH-DPAT dose-
response curve (Figure 54B), suggesting that this downward displacement accounts 
entirely for the antagonism of 8-OH-DPAT. Together with the previous results, this 
confirms that CBD is not able to bind to the orthosteric 5-HT1A receptor binding site. 
Importantly, these results confirm the in vivo data showing the ability of high CBD 
concentrations to enhance LiCl-induced vomiting (Parker et al. 2004). 
We then sought for the possible target underlying this CBD-mediated 5-HT1A receptor 
inhibition. Data previously published in our laboratory showed that CBD is an inverse 
agonist at 10 μM in mouse whole-brain membranes (Thomas et al. 2005). Thus, we 
found that CBD at the concentration of 10 μM is able both to displace [3H]CP55490 
from specific binding sites and inhibit [35S]GTPγS binding to hCB1-CHO cell 
membranes (Figure 55). The CBD-induced inverse agonism at CB1 receptors was 
indeed confirmed in experiments of cyclic AMP assays, where this phytocannabinoid 
displayed inhibition of forskolin-induced cyclic AMP production in hCB1- but not 
untransfected-CHO cells (Figure 56).   
Hence, the downward shift displayed by 10 μM CBD in 8-OH-DPAT dose-response 
curve in [35S]GTPγS binding to rat brainstem membranes could be mediated by CB1 
receptors. This would also explain why CBD on its own did not display any effect on 
[35S]GTPγS binding in rat brainstem membranes (Figure 52B). In fact, since the 
expression of CB1 receptors is low in this brain region (Howlett et al. 2002), it is 
possible that CBD displayed inverse agonism only in the presence of an agonist. In 
light of this, it is likely that a heterodimerization or cross-talk could occur between 5-
HT1A and CB1 receptors in brainstem. 5-HT1A receptors, in the brainstem, are 
localized at somatodendritic level (Riad et al. 2000). Conversely, CB1 receptors are 
well-known to be localized at the presynaptic terminals (Chevaleyre, Takahashi & 
Castillo 2006). However, several evidences showed the presence of CB1 receptors at 
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somatodendritic level in different brain regions, such as rat caudate putamen, rat 
nucleus accumbens, dorsal horn (Hohmann, Briley & Herkenham 1999, Rodriguez, 
Mackie & Pickel 2001, Pickel et al. 2004). In addition, a recent paper showed a 
somatodendritic distribution of CB1 receptors in the locus coeruleus, which is 
localized in the brain stem, suggesting a possible heterodimerization between CB1 and 
mu-opioid receptors (MOR) (Scavone, Mackie & Van Bockstaele 2010). Hence, 
although there are not evidences so far showing the presence of somatodendritic CB1 
receptors on 5-HT neurons in brainstem this cannot be ruled out, as well as a possible 
cross-talk between 5-HT1A and CB1 receptors in this brain region. Thus, it is likely 
that 8-OH-DPAT dose-response curve was inhibited by 10 μM CBD through an 
interaction between 5-HT1A and CB1 receptors.  
Having established that CBD, at the high concentration of 10 μM, was not able to 
enhance 8-OH-DPAT-mediated [35S]GTPγS binding stimulation, we moved on testing 
lower concentrations of CBD. Thus, as previously reported in vivo data show that low 
concentrations of CBD to be effective in the inhibition of LiCl-induced nausea and 
vomiting (Parker et al. 2004, Rock et al. 2008), we found that CBD, at the 
concentration of 100 nM, was able to enhance 8-OH-DPAT dose-response curve on 
[35S]GTPγS binding assays in rat brainstem membranes (Figure 57). In particular, 100 
nM CBD showed an enhancement of approximately 20% on 8-OH-DPAT-induced 
[35S]GTPγS binding stimulation (p<0.1). These results strengthen the in vivo data, 
suggesting that CBD might suppress LiCl-induced conditioned gaping in rats by 
somehow augmenting activation of 5-HT1A receptors in the brainstem produced by 
endogenously released 5-HT. Interestingly, CBD displayed a typical bell-shaped 
pharmacological profile as antagonist of 8-OH-DPAT in rat brain stem membranes. In 
fact, when CBD was tested at lower and higher concentrations than 100 nM in 
experiments of [35S]GTPγS binding assay, it did not show any effect on 8-OH-DPAT 
dose-response curve (Figure 57). Again, these results confirm data already reported in 
vivo, where CBD displayed a biphasic profile on LiCl-induced vomiting in musk 
shrew model (Parker et al. 2004). Moreover, this biphasic pharmacological profile 
displayed by CBD has also been reported in other apparent 5-HT1A receptors-
mediated effects on ischemic injury (Mishima et al. 2005), anxiety (Campos, 
Guimaraes 2008) and depression (Zanelati et al. 2010). 
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The possible mechanism underlying CBD-mediated 5-HT1A receptor potentiation is 
still under investigation. Preliminary results indicated that CBD is not an allosteric 
modulator at 5-HT1A receptors. In fact, the 8-OH-DPAT-potentiating concentration of 
CBD, 100 nM, did not alter the rate at which [3H]8-OH-DPAT dissociates from 
specific binding sites in rat brainstem membranes (Figure 58). Hence, this result 
strengthens the hypothesis that CBD is not interacting directly with 5-HT1A receptors, 
but its effect could be mediated through a possible cross-talk between these serotonin 
receptors and CB1 or other receptors. Thus, the implication of heterodimers between 
5-HT1A receptors and CB1 or other receptors cannot be ruled out. In fact, the ability of 
5-HT1A receptors to form homo- and heterodimers has been demonstrated in 
recombinant systems (Salim et al. 2002). In particular, 5-HT1A receptors formed 
heterodimers with several GPCRs, such as 5-HT1B and 5-HT1D, Endothelial 
Differentiation Gene (EDG) 1 and 3 receptors (Salim et al. 2002). On the other hand, 
CB1 receptors have been demonstrated to form heterodimers with: 
• Adenosin 2A (A2A) receptors (Carriba et al. 2007) 
• Mu-opioid receptors (MOR) (Rios, Gomes & Devi 2006) 
• Orexin-1 receptors (OX1) (Ellis et al. 2006) 
• Dopamine 2 (D2) receptors (Kearn et al. 2005) 
Differently from the concentration of 10 μM, CBD at 100 nM did not show any 
affinity for CB1 receptors. However, data previously reported in this laboratory 
showed that CBD has affinity for CB1 receptors in the nanomolar range when this 
phytocannabinoid is tested as antagonist of the non selective CB1/CB2 receptor 
agonists, CP55940 and WIN55212-2 (Thomas et al. 2007). Despite this, the possible 
implication of CB1 in CBD-induced 5-HT1A receptors potentiation is yet to be 
established and warrants further investigations. 
Thus, experiments are now in progress to further confirm data obtained so far and to 
better characterize the mechanism underlying CBD effects in brainstem. First of all, in 
order to confirm [35S]GTPγS binding assay data, 8-OH-DPAT-potentiating 
concentration of CBD, 100 nM, will be tested in association with 8-OH-DPAT in 
experiments of cyclic AMP assay in primary neuronal cultures derived from raphe 
nuclei.   
Moreover, with the aim of further confirming the selective activity of CBD at 
somatodendritic 5-HT1A autoreceptors in raphe nuclei, [35S]GTPγS binding 
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experiments will be performed in hippocampus, a cerebral region rich of postsynaptic 
5-HT1A heteroreceptors.  
An other possible experiment to uncover the involvement of other receptors in CBD-
mediated 5-HT1A receptors potentiation would come from functional assays (i.e. 
[35S]GTPγS binding and/or cyclic AMP assays) in cells overexpressing 5-HT1A 
receptors. The expression of these receptors is a system different from the brain 
should give us more information about the possible specific activity of CBD in the 





Data here reported confirm that the anti-nausea and anti-emetic effects of CBD are 
mediated by somatodendritic 5-HT1A receptors. Moreover, our results suggest that the 
effect of CBD at 5-HT1A receptors might also involve the interaction with other 
receptors.  
Thus, the lack of psychoactive effects and the efficacy showed by CBD to treat 
nausea and vomit, bring evidences that CBD might be a good candidate to treat these 
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